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Hypertension has been described as an important risk factor for cardiovascular 
morbidity and mortality, despite current treatments. Therefore an increased 
understanding of the mechanisms in the development of hypertension has become 
essential. This project involves the study of the vascular component of murine models 
of hypertension. Firstly the protective role of calcitonin gene-related peptide (CGRP)-
like peptide adrenomedullin (AM) was examined using transgenic mice for the AM 
receptor. Secondly transient receptor potential vanilloid 1 (TRPV1) was studied, 
activation of which is known to release the sensory neuropeptide CGRP.  
 
The angiotensin II (ATII) induced hypertension murine model is considered to mimic 
essential hypertension. Here, hypertension was induced in 3-4 month old mice (mixed 
gender) over 14 days following implantation of ATII-containing osmotic mini-pumps. 
Blood pressure was monitored before mini-pump implantation and until day 14 by either 
tail cuff plethysmography or telemetry. Post-hoc study analysis of vascular hypertrophy 
and vascular dysfunction biomarkers (e.g. VCAM-1 and endothelin) was performed. 
Studies in AM receptor transgenic mice revealed no effect on hypertension, but 
significant protection against aortic vascular remodelling. This indicates that 
adrenomedullin, like CGRP, is a protective peptide in the vasculature. Surprizingly, the 
TRPV1 KO mice were protected against hypertension and aortic remodelling, 
suggesting a lack of critical involvement of CGRP. 
 
To further understand the role of TRPV1, a second more chronic model was used. 
Obesity-induced hypertension was established in mice following high fat diet (HDF, 
35% fat), from 3-15 weeks.  Blood pressure and glucose tolerance were monitored 
during the last week of the study. Post-hoc study analyses revealed TRPV1 KO-HFD 




This PhD project provides evidence that i) up-regulation of the functional AM1 receptor, 
protects against vascular hypertrophy and inflammation despite no change in blood 
pressure. ii) The AM1 receptor mechanisms involved in inhibition of vascular smooth 
muscle cell proliferation. iii) Deletion of TRPV1 protected mice from the hypertension 
and vascular hypertrophy induced by ATII or high fat diet. iv) Deletion of TRPV1 is also 
associated with improving glucose tolerance. Collectively these results provide 
evidence of two distinct mechanisms involved in cardiovascular regulation, of relevance 
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CHAPTER ONE: INTRODUCTION 
 
1.1 Background  
Blood pressure is the pressure exerted by circulating blood on the vessel walls. 
Hypertension, is a chronic medical condition, also called arterial hypertension, and is 
the state at which the blood pressure is increased from the normal range (Chobanian et 
al., 2003). This causes extra pressure on the heart, in order that blood can circulate 
normally. Hypertension has been described as the leading cause of morbidity and 
mortality all over the world. This is mainly due to the development of secondary 
hypertension-linked diseases, for instance heart failure and renal dysfunction (Kearney 
et al., 2005). Therefore, understanding the mechanisms underpinning the development 
of hypertension has become critical. This is especially important as one report has 
indicated that more than 25% of  adults aged > 20 years old in the world were 
hypertensive in 2000, and this is predicted to increase to  29% by the year 2025 
(Kearney et al., 2005).  
 
This thesis contains a study of mechanisms involved in the development and 
maintenance of hypertension using two different murine models of hypertension; an 
angiotensin II (ATII)-induced hypertension model and an obesity-induced hypertension 
model. Firstly, this PhD project has involved the study of the CGRP-related peptide, 
adrenomedullin (AM). Secondly, this PhD project has concentrated on the role of the 
ion channel, transient receptor potential vanilloid 1, (TRPV1) which is believed to be 
primarily localized to the sensory nerves (Caterina et al., 1997). Activation of TRPV1 
can lead to release of calcitonin gene related peptide (CGRP) a potent vasodilator 
neuropeptide (Brain et al., 1985). This introduction will begin by discussing the current 
knowledge about the CGRP family (mainly AM and CGRP) and then focusing on 
TRPV1. Then, I will discuss the pathophysiology of hypertension, and mechanisms 
involved in its development. Finally, I will explain the main hypertensive models and the 
models used in my PhD. 
 
1.2 CGRP family 
The calcitonin-gene related peptide superfamily (CGRP family, also known as the 
calcitonin family) includes CGRP, AM, amylin (AMY) and intermedin (IMD). CGRP, 
  
24 
formed from the tissue-specific splicing of the primary transcript of the calcitonin/CGRP 
gene, is a 37 amino acid neuropeptide. It was the first of the non-calcitonin peptides 
discovered in 1982 (Bell and McDermott 1996; Brain and Grant, 2004). AM, a 52 amino 
acid peptide, is ubiquitously expressed.  It was first isolated in 1993 from human 
phaeochromocytoma cells (Kitamura et al., 1998). AMY, a 37-amino acid peptide, was 
first identified in 1986 as amyloid deposits from the pancreas from non-insulin-
dependent diabetics (Westermark et al., 1987). The latest peptide to be discovered is 
IMD, a 47 amino acid peptide, also known as adrenomedullin 2 (AM2). It was 
discovered by two different groups at the same time (Roh et al., 2004; Takei et al., 
2004a). CGRP, AM, IMD and AMY are grouped because they share similar structures 
(shown in Fig. 1.1), such as one 6-amino acid ring formed by the disulfide bond and an 
amidated C-terminal tyrosine residue (-CONH2), which is different from calcitonin which 
only has a 5-amino-acid ring. Both the disulfide bond and its amidated C-terminus are 
essential for the peptides‘ biological activity as they are essential for receptor binding 
and then cAMP generation (Eguchi et al., 1997). Removal of the first 15 amino acids for 




Figure 1.1 Sequence alignment for the calcitonin/intermedin family peptides from human and 
mouse. The two cysteine residues (in red), form a disulphide bond to create a ring and are shared 
by all family peptides. (h) Human; (m) mouse. 
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hAM H2N-YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY - CONH2 
mAM H2N-YRQSMN—QGSRSNGCRFGTCTFQKLAHQTYQLTDKDKDGMAPRNKISPQGY-CONH2 
hCGRP                                H2N-ACDTATCVTHRLAGLLSRSGGVVKNFVPTNVGSKAF-CONH2 
mCGRP                               H2N-SCNTATCVTHRLAGLLSRGGVVKDNFVPTNVGSEAF-CONH2 
hAMY                                  H2N-KCNTATCATQRLANFLVHSSNNFGAI LSSTNVGSNTY-CONH2 
mAMY                                 H2N-KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTY-CONH2 
hIMD                               H2N-VGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY-CONH2 




CGRP has two different isoforms, alpha CGRP (αCGRP) and beta CGRP (βCGRP), 
where they differ from each other by only three amino acids in both humans (Morris et 
al. 1984, Van Rossum et al., 1997) and mice (Rezaeian et al., 2009,). αCGRP is the 
main isoform of CGRP in the body (Smillie et al., 2011). 
 
CGRP is the most potent microvascular vasodilator identified to date (Brain and Grant., 
2004). There is evidence to suggest the involvement of CGRP in controlling blood 
pressure. The circulating levels of CGRP are decreased in patients with uncomplicated 
essential hypertension (Portaluppi et al., 1992). On the other hand, the lack of CGRP 
may also contribute the development of hypertension (Portaluppi et al., 1992). 
Additionally, it is suggested that CGRP plays a role in certain pathological and 
physiological events such as vasodilatation, cardioprotection, and neurogenic 
inflammation (Qi and Hay, 2010). First of all, injection of picomole doses of CGRP can 
cause vasodilation of resistance vessels in human skin (Brain et al., 1985). Moreover, it 
is suggested that CGRP can cause coronary artery dilation which would delay the start 
of myocardial ischemia in patients with chronic angina (Uren et al., 1993). More 
recently an in vitro study in isolated perfused hearts from α-CGRP knockout (KO) and 
wild type (WT) mice demonstrated the cardioprotective role of CGRP against 
ischemia/reperfusion injury (Huang et al., 2008).  
 
1.2.2 AM 
AM, a 52 amino acid peptide, is modified by amidation from an immature 53-amino acid 
precursor (shown in Fig 1.2). A second peptide product is known to be generated from 
the AM gene. This is the proadrenomedullin N-terminal 20 amino acid peptide (PAMP). 
Even though AM and PAMP are generated by the same precursor molecule, the 
PAMP/AM ratio depends on the tissue or organ (Garcia et al., 2006). It has been 
demonstrated in the human forearm that PAMP is 60 times less potent than AM in 
regulating blood flow (Wilkinson et al., 2001). Therefore, it is believed that PAMP is less 
important in regulating both the blood pressure and blood flow. In addition to sharing its 
sequence homology with CGRP (Brain and Grant, 2004), AM also shares some 
cardiovascular activities with CGRP, such as vasodilatation but with 3-30 times less 
potency than CGRP (Brain and Grant, 2004). Perhaps, the most important function of 
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AM is during foetal development. The AM gene is believed to be essential for survival 
as AM-/- (the null mutation of AM gene) mice fail to survive beyond embryonic E14.5 
(embryonic days 14.5). The reason for the fatalities was suggested to be linked with 
hydrops fetalis (a condition of accumulation of fluid or oedema in the fetus) and 
incomplete development of the heart and arterial vasculature (Caron and Smithies 
2001). 
 
AM is found in a range of tissues and cell types. Together with the potent vasodilatory 
activity of AM, AM also plays a protective role in the pathophysiology of cardiovascular 
diseases. Elevated plasma levels of AM are reported in a variety of cardiovascular 
disorders, including myocardial infarction, hypertension and atherosclerosis (Tsuruda et 
al., 2003; Nishikimi et al., 1995; Nagaya et al., 1999). In addition, secretion of AM was 
studied in isolated endothelial cells; vascular smooth muscle cells (VSMCs) and 
cardiomyocytes. It is suggested that production of AM is up-regulated by several factors, 
such as oxidative stress, angiotensin II (ATII), pro-inflammatory cytokines, hypoxia, 
hyperglycaemia and so on (Beltowski et al., 2004). AM can be produced as an 
immature glycine-extended form (comprising 85% of the total plasma AM) which is then 
converted to mature AM intracellularly by enzymatic amidation (Beltowski et al., 2004). 
Circulating AM is metabolised rapidly with an approximate half-life of 20 minutes. The 
lung is suggested to be the main site for peptide clearance of AM (Dupuis et al., 2005). 
More details about the cardiovascular function of AM will be discussed in section 1.6.2. 
 
1.2.3 IMD and AMY 
IMD (the AM2) is closely related to AM. There are two version of IMD. The first, a 53 
amino acid version, is produced from a pre-prohormone (Yang et al., 2005). The 
second, a 47 amino acid version, is generated from processing the first one (Roh et al., 
2004). However it is still difficult to confirm which version of these two is the major 
peptide. IMD is found in both peripheral tissues and the central nervous system (Bell 
and McDermott, 2008; Hong et al., 2012). 
 
It is suggested that IMD interacts with all three receptor activity-modifying protein 
(RAMP)/ calcitonin receptor-like receptor (CL) complexes (details about the receptor 
complexes will be discussed in section 1.4) and displays a distinct profile from both AM 
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and CGRP but generally with less potency (Bell and McDermott, 2008; Jolly et al., 
2009). Similar to the actions of AM and CGRP, IMD inhibits the progression of vascular 
hypertrophy and remodelling in terms of fibroblast and VSMC proliferation (Cai et al. 
2010; Bell and McDermott, 2008). Moreover as a vasodilator, it is also thought to have 
cardiovascular protective benefits such as hypotensive actions (Fujisawa et al. 2007).  
 
AMY, a 37-amino acid peptide, was first discovered in 1986 (Westermark et al., 1987). 
AMY shares some structural homology as well as biological activities with CGRP and 
AM, but it is suggested that its major physiological effect is to regulate glucose 
metabolism and energy balance (Trevaskis et al., 2010, Zhang et al., 2011, Roth 2013). 
For example, it was shown that mice lacking islet amylin exhibited increased insulin 
secretion and glucose tolerance (Gebre-Medhin et al., 1998).  
 
1.3 Distribution of CGRP and AM  
 
1.3.1 Distribution of CGRP 
The distribution of CGRP is not closely linked to AM, as CGRP is widely expressed in 
both the central and peripheral nervous system and is classically known as a 
neuropeptide. In peripheral systems, it is primarily located within sensory neurons such 
as small unmyelinated C-fibres and myelinated Aδ-fibres (Brain and Grant, 2004). As 
mentioned before, a classic mechanism to release sensory CGRP is mediated by 
TRPV1 receptor activation on sensory C and Aδ fibers. CGRP is co-localized with other 
peptides in these fibres, such as tachykinins, especially substance P and neurokinin A 
(Brain and Grant 2004). In relation to the CGRP isoforms, αCGRP is primarily 
expressed in neurons of the central nervous and peripheral system (Schutz et al., 
2004), while βCGRP was suggested to be primarily found in the gut, specifically, in the 
enteric nerves and pituitary gland (Petermann et al. 1987; Jonas et al. 1985). Recently 
both subtypes of CGRP were also reported in cultured human umbilical vein endothelial 
cells as determined by immunocytochemical analysis and mRNA expression (Luo et al., 
2008).  
 
CGRP is also widely expressed in the cardiovascular system and CGRP containing 
sensory neurons are embedded in most blood vessels. This CGRPergic network is 
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located at the junction of the adventia and the media and into the smooth muscle layer 
(Marshall 1992, Bell and McDermott 1996, Onuoha et al., 1998, Gulbenkian et al., 1993, 
Wimalawansa, 2001). Indeed a high density of CGRP immunoreactive fibres in the 
abdominal aorta and pial arterioles of the cat were identified (McCulloch et al., 1986) 
Such fibres have also been identified in the surrounding nervous and connective tissue 
of the myocardium and coronary vessels in the rat (Yoshizaki et al. 1987) and pig 
(Miyauchi et al. 1988). However, it is less densely invervated in the myocardium than 
the epicardium, endocardium or pericardium (Wimalawansa, 2001). In addition to the 
cardiovascular system, CGRP containing nerve fibres are also found in the 
gastrointestinal tract, lungs, thyroid gland (close to the C cells), human skin and splenic 
vein and sinusoids (Hagner et al., 2002a,b c). Moreover, non-neuronal sources of 
CGRP were also suggested recently to be present in human lymphocytes (Wang et al., 
2002), keratinocytes (Hou et al., 2011) and endothelial progenitor cells (Fang et al., 
2011). 
 
1.3.2 Distribution of AM 
Although AM is found circulating in humans (ranging from 1-10pM), levels are 
increased in some disease states as well as several physiological conditions (Brain and 
Grant, 2004). AM in plasma is specifically bound to factor H (Pio et al., 2001) making it 
difficult to determine the exact concentration in circulation. Circulating levels of AM 
were shown to be raised during pregnancy (Hata et al., 1997), in cardiovascular 
diseases such as hypertension (Hohno et al., 1996), and ischemic stoke (Hosomi et al., 
2004). Such increased levels are suggested to be linked to the disease severity 
(Richards et al., 1996; Wang et al., 1995).  
 
AM gene expression is widely expressed in most organs during both embryonic 
development as well as adulthood. Since AMs discovery it has been found in a range of 
tissues, such as the vasculature, heart, lung, kidney, adipose tissue, and macrophages. 
The expression of AM also can be stimulated by inflammatory cytokines such as TNFα 
and IL-1β (Brain and Grant, 2004). In addition, AM is also produced by fibroblasts, and 
cardiomyocytes (Sugo et al., 1994, Sugo et al., 1994a). It is primarily localised in the 
ventricles in the heart and aorta (Ichiki et al., 1994, Fukai et al., 2004, Yanagawa et al., 
2007). Moreover, immunohistochemical studies demonstrated that the AM peptide is 
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present in all three layers of vessel wall, an observation confirmed by cell culture of 
endothelial cells, VSMCs and adventitial fibroblasts (Ishihara et al., 1997; Uemura et al., 
2002; Jiang et al., 2004). Immunoreactivity for AM was detected in SMCs of intima and 
media of human atherosclerotic lesions (Marutsuka et al., 2003). The AM expression in 
coronary artery plaques was increased in patients with unstable angina when 
compared to those with stable angina (Ishikawa et al., 2004). This finding was 
supported by VSMC culture studies showing that AM production and secretion were 
increased by factors like ATII, endothelin-1 and aldosterone (Uemura et al., 2002, Sugo 
et al., 1995) which are presumably pro-atherogenic.  
 
1.4 The receptors 
The active receptors for CGRP and AM are G-protein-coupled (Figure 1.3), composed 
of calcitonin-receptor like receptor (CL) and one of the three available RAMP isoforms 
(McLatchie et al., 1998). CL, consisting of 461 amino acids, was cloned in 1993 and 
belongs to the seven transmembrane domain G-protein-coupled receptor (GPCR) 
family (Njuki, et al., 1993). Depending on its co-expression with different RAMPs, CL 
together with RAMP1 forms a CGRP receptor, which can also be activated by AM and 
in some cases by IMD. In contrast, CL associates with RAMP2 to produce the 
functional AM1 receptor that is activated by AM and in some cases by IMD as well. CL 
links with RAMP3 to produce the AM2 receptor which also can be activated by CGRP 
and by IMD albeit at a lower potency than AM (Brain and Grant 2004; Bell and 
McDermott, 2008). The CGRP receptor can be antagonized by the CGRP peptide 
fragment CGRP8–37 (Chiba et al., 1989) or by the non-peptide antagonist BIBN4096BS 
(Doods et al., 2000), while the AM1 receptor can be inhibted by AM22–52, a weak 
selective AM peptide receptor antagonist (Gardiner et al., 1999). Blocking activities 
induced by AM through the AM1 receptor can inhibit angiogenesis e.g. (reduce vessel 
number and impede tumour growth; Ishikawa et al., 2003). In terms of the binding of 
AM22-52 to the AM receptor, it was recently been revealed that Y52, G51 and I47 of 
AM22-52 are essential for the binding to the AM1 receptor (Watkins et al., 2013). 
Removing or substituting those amino acids will result in more than 100 times reduction 






Figure 1.2: Model of CGRP/AM receptors. CL is a G-protein-coupled 7-transmembrane 
receptor. The RAMP is a single transmembrane domain protein. The interaction of RAMP1 with 
CL forms a CGRP receptor, RAMP2 with CL to produce an AM receptor, while RAMP3 with 
CL forms a CGRP/AM receptor. 
 
CL belongs to the subfamily of GPCRs known as the ‗B‘ family (Kolakowski, 1994) 
which also includes the calcitonin receptor. CL is composed of a long N-terminus 
extracellular domain, three extracellular loops, seven transmembrane domains, three 
intracellular loops as well as an intracellular C-terminus (as shown in figure 1.3). CL is 
poorly expressed on the surface of cells and it does not bind to any known endogenous 
ligand (Sexton et al., 2009). The N-terminus is believed to be essential for mediating 
the binding between CL and RAMPs to form a functional receptor (Barwell et al., 2011,). 
It was reported that the extreme N-terminus of CL (residues 23-60) is not only is 
responsible for the selectivity of the interaction with either AM or CGRP (Koller et al., 
2002) but is also necessary for RAMP1 association as residue 41 in the N-terminus α-
helix of CL was shown to be essential for CGRP binding (Barwell et al., 2010). 
Moreover, CL regions (from transmembrane domain 1 to 5) are responsible for 
transporting RAMPs to the plasma membrane. In addition, Kuwasako et al. also 
demonstrated that the human CL third extracellular loop is essential for AM signaling 
(Kuwasako et al., 2012).  
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Each of the three RAMP isoforms (RAMP1, RAMP2, and RAMP3) is about ~160 amino 
acids, long. They share some common structures including an extended extracellular 
N-terminus (approximately 100 amino acid residues), a single membrane spanning 
domain, and a short intercellular C-terminus (approximately 100 amino acid residues). 
However, they share no more than 30% sequence identity and their tissue distributions 
are different (Mclatchie et al., 1998; Sexton et al., 2001, Spielman and Parameswaran 
2012). Studies have shown that the N-terminus of RAMP1 determines the expression 
of CGRP binding (Steiner et al., 2002). Similar conclusions have been drawn from 
studies on all RAMPs interactions with the CL, where the N-terminus of the RAMP is 
the chief determinant of receptor pharmacology (Mclatchie et al.,1998; Qi and Hay 
2010). RAMP1 can be found in many tissues such as heart, uterus, brain, bladder, 
pancreas and skeletal muscle while RAMP2 is expressed widely in many organs, such 
as lung, heart, placenta, skeletal muscle, spleen, liver as well as pancreas. RAMP3 is 
also widely distributed in humans but expression is at low levels in the rat (Chakravarty 
et al., 2000; Nagae et al., 2000). The relatively highest expression in rats was found in 
lung, spleen, spinal cord (Chakravarty et al., 2000) and kidney (Nagae et al., 2000). 
RAMP expression has also been studied in a range of cardiovascular conditions, such 
as heart failure in rats where increased levels with RAMP2 were detected but not 
RAMP1 or 3 (Totsune et al., 2000). Similar observations were made during myocardial 
ischemia in rats (Qi et al., 2003) and spontaneously hypertensive stroke-prone rats 
(Wang et al., 2003). The expression and functions of RAMPs have been reviewed in 
details by others (Kuwasako et al., 2004; Udawela et al., 2004, Spielman and 
Parameswaran 2012). RAMP2 plays an essential role in blood vessel development as 
homozygous KO of RAMP2 but not RAMP1 or RAMP3 is lethal. It was suggested that 
the lethal effect was due to the lack of abiligty of AM to act on the AM1 receptor to 
maintain the blood vessel barrier (Kadmiel et al., 2012). This indicates the important 
function of RAMP2, which can not be compensated byother RAMPs. RAMP2 
expression is not only observed in healthy conditions but also in some cardiovascular 
disease conditions. Nishikimi et al. have shown that increased gene expression of 
RAMP2 occurs in left ventricular hypertrophy and this is also observed even at a higher 




CL co-expressed with RAMP2 produces the AM-selective AM1 receptor, which does 
not recognize CGRP and CGRP(8-37) to any great extent (Muff et al., 2003). In addition, 
Kuwasako et al. have suggested that on the N-terminus, the third intercellular loop 
and/or transmembrane 6 within CL are essential for selective cell surface relocation of 
RAMP2 (Kuwasako et al., 2009). As soon as AM binds to AM1 receptors, these 
receptors are soon internalized which leads to lysosomal degradation. Human RAMP2 
is 26 amino acids longer than either RAMP1 or RAMP3, and human RAMP2 is unlike 
RAMP1 and 3 which possess 11 conserved amino acids in their N-terminus and 
transmembrane domains (McLatchie et al., 1998, Hay et al., 2006). Such distinct 
features of RAMP2 may account for its specific trafficking interaction with CL. Therefore, 
in the presence of RAMP2, the specificity of CL will change from RAMP1/CL to 
RAMP2/CL radically.  
 
In addition to the CL and RAMP components, immunoprecipitation studies have 
identified the requirement of an intracellular peripheral membrane protein, termed 
receptor component protein (RCP) for facilitating signal transduction by CGRP and AM 
(Prado et al., 2001). RCP is an intracellular peripheral membrane protein that 
associates with CL (as Figure 1.3). Indeed, CL/RAMPs complex requires RCP for 
intracellular signaling cascade. Evans et al. (2000) demonstrated that knockdown of 
RCP expression will decrease CGRP-mediated cAMP production without affecting 
binding to the CGRP receptor (Evans et al., 2000). More recently the role of RCP in 
regulating the function of CL/RAMP1 complex has been investigated further.  It has 
been demonstrated that RCP enables signal transduction of CL by interacting with the 
second intracellular cytoplasmic loops of CL (Egea and Dickerson 2012).  
 
1.5 Cellular signaling of CGRP and AM 
 
1.5.1 CGRP signaling  
CGRP is a very potent vasodilator, approximately 3-30 times more potent than AM. 
Several mechanisms have been suggested by which CGRP produces vascular 
relaxation (Brain and Grant 2004). The first one is an endothelium-independent 
pathway: via activating CGRP receptors on the smooth muscle cells. This leads to 
increased cAMP and PKA activities, which causes vascular relaxation. The second 
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pathway is an endothelium dependent pathway, by which CGRP interacts with 
receptors on the endothelial cells to stimulate the cAMP and PKA pathway. It leads to 
the production of nitric oxide (NO) by stimulation of endothelial NO synthase (Brain and 
Grant 2004). Furthermore, apart from the vasodilator effect, CGRP was also reported to 
inhibit rat ATII stimulated VSMC proliferation in an in vitro study by inhibiting ERK1/2 
activity (Qin et al., 2004). 
 
1.5.2 AM signaling  
As mentioned before, the actions of AM are mediated by the AM1 and AM2 receptors. 
Since the multifunctional AM was discovered, the molecular mechanisms of its action 
have been studied (Fig 1.4). AM dilates blood vessels via an endothelial-dependent 
and independent mechanism. Ishizaka et al., (1994) have shown that AM regulates 
vasodilatation by triggering cAMP accumulation and activating cyclic AMP-dependent 
protein kinase (protein kinase A, PKA) in smooth muscle cells (Ishizaka et al., 1994). In 
addition, Shimekake et al. suggested that the hypotensive effect of AM can be 
explained by two pathways: it increases the intracellular cAMP by acting on smooth 
muscle cells directly which leads to relaxation; and it increases intracellular Ca2+ level in 
bovine aortic endothelial cells, which leads to activation of NO synthase and NO 
release (Shimekake et al., 1995). Indeed, AM is more potent than CGRP at increasing 
the cAMP levels in rat vascular smooth muscle cells (Eguchi et al., 1994). The 
increased cAMP results in decreasing concentrations of Ca2+ and, in turn, induces SMC 
vasodilatation. Moreover, Nishimatsu et al. studied the NO-dependent relaxation in rat 
aorta and demonstrated that AM induces endothelial cell-dependent vasodilatation by 
activating Akt via a Ca2+/calmodulin-dependent pathway, an established stimulant of 
eNOS (Nishimatsu et al., 2001). Furthermore, AM+/- mice demonstrated ischemia-
induced renal damage to a greater extent than wildtype mice, whereas AM-
overexpressing mice showed lesser damage after ischemia (Nishimatsu et al., 2002). 
This effect was again dependent on the level of NO production. Thus, these studies 
suggest that AM is likely to regulate vascular tone and blood pressure and to protect 




Kim et al. have shown that AM carries out the protective and anti-apoptotic functions 
via the PI3K/Akt pathway which is a well known protective signaling mechanism (Kim et 
al., 2002). In a model of myocardial infarction, adenovirus-mediated gene delivery of 
AM has protected the myocardium against apoptosis, whereas this effect was 
abolished in mice containing dominant negative Akt (Yin et al., 2004). The mitogen-
activated protein kinase/extracellular signal regulated kinases (MAPK-ERK) is a well-
characterised stress-induced protective signaling pathway. The angiogenic effect of AM 
is mediated by activating Akt together with MAPK/ERK 1/2 in endothelial cells (Kim et 
al., 2003). Moreover, in a cardiac hypertrophic model using AM+/- mice subjected to 
aortic constriction (causing pressure overload) or ATII infusion, it was demonstrated 
that endogenous AM plays an essential role in protecting the heart from cardiac 
hypertrophy via suppressing ERK activation by inhibition of protein kinase C (PKC) and 
activation of protein kinase A (PKA, Niu et al., 2004).  
 
1.6 Cardiovascular function of CGRP and AM 
 
1.6.1 CGRP 
CGRP shares some vascular activities with AM. The most famous effect of CGRP is 
being a vasodilator. It has been suggested that CGRP selectively dilates different 
vascular beds, which include the cerebral, coronary and renal vasculature (Brain and 
Grant, 2004). However, following studies using CGRP KO mice and antagonists 
    




















    
    
   












Fig 1.3: Possible intracellular signal 
transduction mechanism for AM 
(three main pathways: cAMP 




demonstrate that CGRP does not play an important role in the physiological control of 
systemic blood pressure in normal individuals. Injection of the selective CGRP receptor 
antagonists BIBN4096BS or CGRP8-37 does not affect the resting heart rate or blood 
pressure in a range of species, including rats (Arulmani et al. 2004; Zeller et al. 2008) 
and humans (Olesen et al. 2004). The expression of CGRP together with its receptors 
are decreased, elevated or unchanged in different experimental models of hypertension 
(Deng and Li, 2005). In the past, using CGRP KO mice or a hypertensive rat model, 
several research groups have demonstrated a protective role of CGRP in hypertension 
(Gangula et al., 2000, Wimalawansa 1996, Wang et al., 1998). The protective effects of 
CGRP are believed to be related to its ability to cause vasodilaton and to increase 
blood flow. 
 
More recently, Li et al., by comparing two different hypertensive models, demonstrated 
that both plasma levels and mRNA levels of CGRP were decreased in spontaneously 
hypertensive rats (SHR) but increased in a model of 2 kidneys 1 clip (2K1C) 
hypertensive rats (Li et al., 2009). These results suggested that CGRP could play 
different roles in different circumstances. On the other hand, within our group, by using 
CGRP KO mice, we demonstrated that CGRP plays a protective role in the 
hypertension, vascular hypertrophy, vascular inflammation and remodeling induced by 
ATII (infusion of dose of 1.1mg/kg/day for 14 days, Smillie, 2012). 
 
As discussed before, one of the pathways by which CGRP is released is by activation 
of neuronal TRPV1 ion channels. Therefore, the activation of TRPV1 and subsequent 
release of CGRP has been investigated. Deng et al. have shown that CGRP synthesis 
and release following activation of TRPV1, played a protective role in hypertensive 
models of phenol-induced hypertension (Deng et al., 2004) and 2K1C hypertensive rats 
(Deng et al., 2003). More details about the cardiovascular function of TRPV1 will be 
discussed in a later section.  
 
1.6.2 AM 
AM is a known vasodilator. Animal experiments have been carried out in a range of 
species, such as rat, mouse, cat, sheep and rabbit (Khan et al., 1997; Cheng et al., 
1994; Hjelmqvist et al., 1997; Westphal et al., 2002), to show that AM can induce a 
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sustained, dose-dependant vasorelaxation and hypotension. It is also suggested that a 
bolus dose of AM acts in a functionally different manner to endogenous AM due to the 
fact that AM normally exists bound to factor-H (Pio et al., 2001, Gibbons et al., 2007). 
Therefore it is important to understand more about how endogenous AM contributes to 
maintain the vascular tone and blood pressure.  
 
As discussed before, expression of AM is increased in patients who have acute and 
chronic cardiovascular diseases (Ishimitsu et al., 1994, Tsuruda et al., 2003, Kato et al., 
1996, Oyar et al., 2011 and Suzuki et al., 2004). The link between hypertension and the 
plasma level of AM was shown to be positively related with renal failure and impaired 
renal function (Ishimitu et al., 1994; Kohno et al., 1996). In addition, elevated AM levels 
are also shown to be linked with cardiac and arterial hypertrophy (Morimoto et al., 
1999). AM induced a substantial decrease in blood pressure in a spontaneous 
hypertensive and Dahl salt-sensitive deoxycorticosterone acetate-salt (DOCA) rat 
model of hypertension (Chao et al., 1997; Zhang et al., 2000). All this evidence 
suggests that there is a relationship between increased blood pressure and AM release. 
Such increases are believed to be associated with multiple host protective functions 
and to be a predictor of future cardiovascular events (Nishida et al., 2008). However it 
has also been shown that circulating levels of AM stay high even in patients treated 
with effective doses of calcium channel blocker-based anti-hypertensive therapy 
(Kohno et al., 1996). This indicates that the role and regulation of AM in hypertension is 
complex. Thus, more studies need to be carried out to address the role and benefit of 
AM in the treatment of hypertension. 
 
As mentioned before, null mutation of the AM gene leads to embryonic lethal mice; 
therefore several research groups have focused on the AM+/- mice or AM-
overexpressing mice as models to study the AM gene. AM performs its cardioprotective 
effects directly, for example by reducing the ventricular remodeling after myocardial 
infarction by acting as an endogenous inhibitor of myocyte hypertrophy and fibroblast 
proliferation (Tsuruda et al., 1998, 1999). This finding has been supported by Niu et al. 
who had demonstrated that after aortic constriction or infusion of ATII in AM+/- mice, 
these mice showed increases in cardiomyocyte size and fibroblast proliferation 
compared to wild type controls (Niu et al., 2004). Moreover AM-overexpression in mice 
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caused a reduction in blood pressure (Shindo et al., 2000). In addition, Nishikimi et al. 
also carried out studies using cultured rat neonatal cardiac fibroblasts and 
demonstrated that AM played a protective role against fibrosis (Nishikimi et al., 
2005).Thus, these results suggest that endogenous AM has an essential role in 
cardiovascular protection. However, little is known about the involvement of its 
receptors regarding the protection of AM in other cardiovascular conditions, such as 
hypertension. 
 
In recent years, smooth muscle cell-specific RAMP2 overexpressing mice were 
generated using a transgene containing an α-actin promoter (details about the 
transgenic mice are available in the materials and methods section). Using these 
RAMP2 transgenic mice, our group had previously demonstrated that these mice 
exhibit no difference in basal or ATII-induced blood pressure despite a greater degree 
of hypotension is observed following infusion of AM peptide (Tam et al., 2006). This 
study implies that the AM1 receptor component RAMP2 may be involved in mediating 
blood pressure control under certain conditions. On the other hand, in an in vitro study, 
Kim et al. (2003) demonstrated that AM inhibits vascular endothelial growth factor 
(VEGF) induced by inflammatory cytokines. Furthermore, AM can induce expression of 
some cell surface adhesion molecules (Hagi-Pavli et al., 2004), such as vascular cell 
adhesion molecule 1 (VCAM-1), inter-cellular adhesion molecule (ICAM-1) and E-
selection. Therefore it seems that AM has both inhibitory and pro-inflammatory effects 
depending on different cell types and disease conditions.  
 
1.7 The Transient Receptor Potential Vanilloid receptor  
 
1.7.1 Discovery of TRPV1 
Chilli peppers are eaten on a daily basis all over the world and are one of the oldest 
cultivated crops in South America. They were first introduced to Europe in the sixteenth 
century (Perry et al., 2007). Capsaicin, (8-Methyl-N-vanillyl-trans-6-nonenamide, 
molecular formula: (CH3)2CHCH=CH(CH2)4CONHCH2C6H3-4-(OH)-3-(OCH3), Fig 1.4), 
the active ingredient of chilli pepper, was first extracted by Christian Friedrich Bucholz 
and its almost pure form was first isolated and named by Thresh in 1846. Despite its 
early discovery, the exact chemical structure of capsaicin was determined by Nelson in 
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1919; followed by the chemical synthesis 10 years later (Szallasi and Blumberg, 1999). 
Pure capsaicin is a colourless, odourless and a crystalline to waxy compound. 
Capsaicin causes a sensation of burning pain when it comes into contact with tissues. 
Additionally capsaicin can selectively activate sensory nerves, which will cause the 
release of neurotransmitters such as CGRP, substance P and neurokinin (NKA) 
(Rubino and Burnstock 1996, Brain 1997, Nagy et al., 2004) and these 
neurotransmitters are linked with cardiac performance and vascular tone. Despite the 
long history of capsaicin being used in traditional medicine, the capsaicin receptor was 
not cloned until 1997 from a rat and characterized in the laboratory of David Julius 
(Caterina and Julius, 1997). Capsaicin evokes these effects by selectively activating its 
receptor, now known to be transient receptor potential vanilloid 1 (TRPV1). TRPV1 is 
primarily localised to sensory neurons that transfers information into the central nervous 
system thus playing a role in the pain sensation (Caterina and Julius; 2001). 
 
 
Figure 1.4: The structure for capsaicin 
 
1.7.2 Structure of TRPV1 
The transient receptor potential (TRP) channels are a group of non-selective cation 
channels. The TRP family includes six subfamilies which are different from each other 
with respect to the amino acid sequences in their C and N termini. The subfamilies are 
TRPV (1 to 6), transient receptor potential melastatin (TRPM, 1 to 8 members), 
transient receptor potential canonical (TRPC, 1 to 7 members), transient receptor 
potential muclolipin (TRPML, 1 to 3 members), transient receptor potential polycycstin 
(TRPP, 1 to 3 members) and transient receptor potential ankyrin 1 (Nakagawa and 
Hiura, 2006). In a similar manner to other family members, the TRPV1 receptor is a 
non-selective cation channel; composed of six complete transmembranous domains, a 
short, pore region between the fifth and sixth domains and cytoplasmic C and N- 
Termini (Fig 1.5).  TRPV1 is featured with three ankyrin repeat domains at its N-
terminus, which is important for the TRPV1 channel to interact with cytosolic proteins, 
such as calmodulin (Tominiaga and Tominaga, 2005; Baylie and Brayden, 2011). 
TRPV1 also has a TRP-like domain (like others in the TRP protein family) in its C-
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terminus (Ferrer-Montiel, et al. 2004; Tominiaga and Tominaga, 2005). The TRPV1 
channel is suggested to form both homotetramers (just containing TRPV1 only) and 






1.7.3 TRPV1 Expression  
TRPV1 is expressed in a range of tissues, predominantly in small to medium size of 
primary sensory neurons such as myelinated Aδ and unmyelinated C fibres, their dorsal 
root ganglion (DRG), as well as the trigeminal ganglia (Caterina et al., 1997).  
Activating TRPV1 channels in these neurons results in cations influx (including calcium) 
into the peripheral terminus (Caterina et al., 1997). Studies on WT and TRPV1 KO mice 
indicated that TRPV1 is also highly expressed in the central nervous system (Mezey et 
al., 2000, Roberts et al., 2004). Indeed, TRPV1 has been proposed as a target for 
treatment not only of pain but also for other conditions such as anxiety (Starowicz et al., 
2008). However, neonatal capsaicin treatment did not eliminate TRPV1 mRNA in the 
central nervous system and the mechanism is still poorly understood. Even so, certain 
studies indicated that some of the TRPV1 expression in the brain must be form the 
Fig 1.5: Structure of the TRPV1 receptor and different binding sites for a range of stimuli 
(Ferrer-Montiel, et la., 2004; Tominiaga and Tominaga, 2005). 
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functional capsaicin receptor (Mezey et al., 2000). Many studies had shown significant 
levels of TRPV1 in the cortex, specific areas of the limbic system (hippocampus, 
amygdale) as well as thalamus (Holzer 2008) by using different methods. Despite these 
findings, the existence of TRPV1 in the brain is still controversial as recent study has 
demonstrated limited expression of TRPV1 in the brain using TRPV1 reporter mice (a 
line of mice containing certain genes which are under control of the TRPV1 promoter 
but can be expressed without interrupting TRPV1 coding region (Cavanaugh et al., 
2011). In addition, TRPV1-expressing fibres innervated blood vessels are found in all 
layers of viscera (e.g. rat urinary tract and gastrointestinal tract) as TRPV1 
immunopositive fibres were shown in the mucosa membrane as well as muscular layer 
(Avelino et al., 2002, Ward et al., 2003).  
 
Recent evidence has shown that TRPV1 is expressed in a range of non-neuronal tissue. 
TRPV1 protein was shown to be present in cultured human keratinocytes by 
immunohistochemistry. Its functionality was shown by capsaicin activation leading to 
Ca2+ influx in a subpopulation of these cells (Inous et al., 2002). TRPV1 is also 
expressed in vascular tissue, such as endothelium, and smooth muscle (Golech et al., 
2004; Kark, et al., 2008). TRPV1 has been found in vitro in cerebrovascular endothelial 
cells by reverse transcription-polymerase chain reaction (RT-PCR) and 
immunohistochemistry (Golech et al., 2004) and denervated rat mesenteric arteries by 
RT-PCR (Poblete et al., 2005). TRPV1 may also be expressed in vascular smooth 
muscle as mRNA for TRPV1 was found in rat pulmonary artery and aorta using RT-
PCR, followed by western blot to confirm presence of protein (Yang et al., 2006). 
Furthermore, Kark et al (2008) and colleagues revealed expression of TRPV1 in rat 
skeletal smooth muscle arterioles by immunohistochemistry (Kark, et al., 2008). In 
addition, functional TRPV1 has been found in other non-neuronal cells, such as human 
bladder urothelium (Lazzeri, M et al., 2004), rat pancreatic beta cells (Akiba et al., 
2004), marcophages (Chen et al., 2003). However, the physiological roles in these cells 
remains to be fully understood (Fernandes et al., 2012). 
 
1.7.4 Exogenous agonists of TRPV1 
TRPV1 receptors can be activated by certain exogenous stimuli, including chemical 
agonists/activators, such as acid (proton, pH<6 at room temperature; Jordt et al., 2000) 
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and noxious heat (>43ºC; Caterina et al., 1997). TRPV1 is gated open only when the 
extracellular pH is reduced to less than 6. In contrast, the range of pH 6-7 will increase 
the sensitization of TRPV1 to other stimuli like capsaicin and heat (Tominage et al., 
1998, Jordt et al., 2000). As a result, the temperature threshold for TRPV1 activation is 
lower in acidic environments, although the exact mechanism is not clear. However, it is 
known that activation of TRPV1 by its stimuli leads to a rapid rise in intracellular 
calcium level (Tominage et al., 1998). 
 
Capsaicin, the pungent vanilloid component of chilli peppers, is suggested to be 
responsible for the burning sensation of the spicy food (Caterina et al., 2000). 
Capsaicin is historically an agonist for TRPV1. At negative holding potentials, the 
activation of TRPV1 by capsaicin leads to the increase of the influx of cations (both 
calcium and sodium), and then leads to depolarization of the cell. Capsaicin and its 
related compounds are collectively named ‗vanilloids‘. TRPV1 can also be activated by 
these vanilloids, such as olvanil (the first synthetic capsaicin analogue) and the potent 
capsaicin analogue resiniferatoxin (RTX; Piper et al., 1999).  
 
1.7.5 Endogenous agonists of TRPV1 
Under physiological conditions, TRPV1 is unlikely to be triggered by heat or acid. 
Therefore, the existence of endogenous ligands which act on this receptor or via 
intracellular signaling has been suggested. These endogenous ligands and activators 
of TRPV1 are defined as endovanilloids (Di Marzo et al., 2001; van der Stelt and Di 
Marzo, 2004). There are three classes of lipids that have been proposed to act as 
endovanilloids. Firstly, the fatty acid amide arachidonoyl-ethanolamine, also known as 
anandamide and known as a cannabinoid receptor 1 (a G-protein-coupled receptor co-
expressing with TRPV1 receptor on sensory nerves) agonist, was the first identified 
endogenous activator of TRPV1 due to its chemical similarity to capsaicin (Smart et al., 
2000, Ralevic et al., 2002). Anandamide is biosynthesized by the phospholipase D  
mediated hydrolysis of arachidonoyl phosphatidyl-ethanolamine (NAPE, Wang et 
al.,2008a) and was shown to be able to activate human and rat TRPV1 (Bianchi et al., 
2006, Panlilio et al., 2009). Secondly, arachidonic acid is metabolized via the 
lipoxygenase pathway, producing a range of products including (S)-12-
(hydroperoxy)eicosatetraenoic acid (12-HPETE), (S)-15-(hydroperoxy)eicosatetraenoic 
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acid (15-HPETE) and leukotriene B4 (LTB4). 12-HPETE and LTB4 have both been 
shown to activate TRPV1 directly. The third class is the long-chain unsaturated fatty 
acid amides, such as N-arachidonoyl dopamine (NADA) and N-oleoyldopamine (OLDA, 
Huang et al., 2002, Chu et al., 2003).  NADA is similar to capsaicin in terms of potency 
as determined by different assays of TRPV1 activity (Huang et al., 2002). OLDA is a 
weak ligand for cannabinoid receptor 1, where it was suggested to be an endogenous 
agonists as it is similar to capsaicin in its chemical structure and activates TRPV1 (Chu 
et al., 2003).  
  
There are other products that have also been reported to activate TRPV1, such as 
bradykinin and nerve growth factor (NGF). Bradykinin and NGF are two potent 
endogenous factors produced during inflammation. The nonapeptide bradykinin has 
been shown to directly activate TRPV1 as well as sensitize the TRPV1 receptor 
(Burgess et al., 1989). NGF also has been demonstrated to sensitise TRPV1 to 
capsaicin (Chuang et al, 2001). Additionally, TRPV1 can be activated or sensitised by 
other inflammatory mediators such as prostaglandins (Huang et al., 2002). 
 
1.7.6  Activation/sensitization of the TRPV1 receptor 
As mentioned before, TRPV1 receptors can be activated directly by vanilloids, such as 
capsaicin and its analogues. In the rodent form of TRPV1, it is suggested that the two 
key residues, Arg-114 and Glu-761, in the intracellular N- and C- tails of TRPV1 provide 
important structural elements by forming a binding pocket to convey sensitivity to 
capsaicin and its analogues (Jung et al., 2002). In addition, Tyr-511 and Ser-512 
between the 2nd intracellular loop and 3rd transmembrane domain, and Tyr 550 at the 
fifth transmembrane domain have also been suggested to be the important sites where 
vanilloid ligands may interact with TRPV1 (Jordt and Julius 2002, Tominaga and 
Tominaga, 2005). RTX, the capsaicin analogue, was suggested to be much more 
(about thousand fold more) potent than capsaicin (Szolcsanyi et al., 1990). In addition, 
the presence of residue Met 547 at the 3rd transmembrane domain is required for the 
bringing of RTX to TRPV1 (Gavva et al., 2004). 
 
TRPV1 is thought to mediate the phenomenon of peripheral sensitization with a 
reduction in the threshold of activation. Acid (extracellular protons) can increase the 
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potency of heat or capsaicin by lowering the threshold for TRPV1 activation, as well as 
acting as direct agonists themselves (Tominaga et al., 1998). In vivo studies revealed 
that Glu 600 located within the putative extracellular domain is an important site for 
proton potentiation of TRPV1. In addition, Glu 648 is implicated in the direct activation 
of TRPV1 by protons (Jordt et al., 2000).  
 
As mentioned before, agents produced during inflammatory events can act to lower the 
activation threshold of TRPV1 to its chemical and physical stimuli. These agents 
include bradykinin, prostaglandins as well as others (reviewed by Szallasi et al., 2007). 
Bradykinin can stimulate protein kinase C (PKC) by promoting diacylglycerol formation 
as well as degrading phosphatidylinositol(4,5)-bisphosphate (PIP2) by facilitating 
phospholipase C activity (Chuanget al., 2001). Phosphorylation of TRPV1 by PKC is 
also mediated by prostaglandins. Indeed, PKC can phosphorylate the TRPV1 receptor 
directly (Numazaki et al., 2002) and then increase the probability of channel gating by 
heat, protons, as well as agonists such endovanilloids ((Premkumar and Ahern, 2000; 
Vellani et al., 2001; Di Marzo et al., 2002). Both Ser 502 and Ser 800 have been 
identified as responsible for the above actions (Numazaki et al., 2002). Moreover, 
prostaglandins, such as prostaglandin E2, enhance the sensitivity of primary sensory 
neurons to noxious stimuli, which is believed to involve the cAMP transduction cascade 
pathway (Szallasi and Blumberg, 1999). Lipoxygenase products, such as 12-HPETE 
and LTB4, are by-products of inflammation and are also able to sensitise TRPV1 via 
phospholipase C or PKC production (Suh and Oh 2005). The binding site for 
lipoxygenase products is suggested to be intracellular; therefore these products must 
be produced within the TRPV1 expressing cell or be transported into it (Van Der Stelt M 
and Di Marzo V., 2004).  They have been identified as primary endogenous activators of 
TRPV1 due to their structural similarity to capsaicin (Jung et al., 2002).  
 
1.7.7 Desensitisation of the TRPV1 receptor 
Capsaicin, an irritable compound, initiates neuronal excitation which is followed by a 
refractory rest state that occurs where the previously excited neurons become 
desensitised to a series of seemingly unrelated stimuli (Szallasi and Blumberg, 1999). 
This phenomenon is traditionally referred to as desensitisation (Szallasi et al., 2007). 
There are two states of desensitisation. The first phase is an acute phase where 
  
44 
repeated or prolonged capsaicin treatment can result in a decreased response to 
further capsaicin challenge. As discussed before, activation of the TRPV1 receptor by 
capsaicin results in calcium influx (Caterina et al., 1997). However the prolonged 
calcium influx may cause acute desensitisation by causing calcium cytotoxicity, 
producing the acute phase of desensitisation. This desensitisation has been shown to 
depend on a variety of factors, such as the concentration of capsaicin, duration of 
application, and the presence or absence of the extracellular calcium. Studies 
demonstrated that removal of extracellular calcium diminished the desensitisation to 
capsaicin (reviewed by Szallasi and Blumberg, 1999). However the desensitisation of 
TRPV1 is complicated because it is also dependent on the agonist used. In contrast to 
observations with capsaicin, desensitisation to olvanil (another TRPV1 agonist) is 
apparently not influenced by the removal of extracellular calcium (Liu and Simon, 1998). 
 
The second phase is a chronic phase where capsaicin application can reduce or 
eliminate responsiveness to other stimuli that range from noxious heat to mechanical 
pressure to endogenous or exogenous agents, often referred to as functional 
desensitisation (Bevan & Docherty 1993). High doses of capsaicin selectively destroy 
C- and Aδ sensory nerves, which will completely prevent nerve activation (Szallasi et 
al., 1995). The capsaicin desensitisation model has been widely used to study the 
effects of TRPV1, including studies focusing on the study of obesity and hypertension 
in mice (Gram et al. 2007).  
 
1.7.8 Cardiovascular function of TRPV1  
As discussed earlier, in the cardiovascular system TRPV1 is expressed in two areas; 
innervating perivascular nerves and non-neuronal tissues (such as vascular endothelial 
cells and smooth muscle cells). Wang et al (2006) using TRPV1KO mice, demonstrated 
that electrical field stimulation induced significantly more vasodilation in arteries from 
WT mice when compared with those from the TRPV1KO mice. The vasodilation was 
abolished by blocking CGRP release from the sensory nerves but not substance P; 
such an effect was not seen in the TRPV1KO mice (Wang et al. 2006). Thus activation 
of TRPV1 on peri-vascular sensory nerves leads to release of the potent vasodilatator, 
CGRP, and results in vasodilation in mesenteric artery. However, it is also suggested 
that TRPV1 in mesenteric peri-vascular sensory nerves contributes to myogenic 
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constriction, mediated by releasing substance P after activation of TRPV1 (Scotland et 
al., 2004). They proposed that increased intravascular pressure leads to the release of 
20-HETE from VSMC to activate the sensory nerve TRPV1 and then increase neuronal 
Ca2+ entry and cause the release of substance P, which then causes contraction of the 
smooth muscle.  
 
The function of TRPV1 in endothelial cells and smooth muscle cells is difficult to 
distinguish due to the presence of peri-vascular nerves. In a chronically denervated 
mesenteric vascular bed, TRPV1 activation by capsacin leads to endothelium-
dependent NO release resulting in vasodilation but such a vasorelaxing effect was not 
seen with anandamide (Poblete et al., 2005). The effect of releasing NO was abolished 
by applying the TRPV1 receptor antagonist, capsazepine, as well as endothelium 
removal or NO synthase inhibition (Poblete et al., 2005). This confirms the involvement 
of TRPV1 and endothelium-dependent NO release. Moreover, Kark et al. demonstrated 
the diverse vascular effects of TRPV1 in the arterial bed of the rat hind limb following 
TRPV1 activation (Kark et al., 2008). Activation of neuronal TRPV1 caused vasodilation 
and was proposed to be due to release of neurotransmitters (such as CGRP and 
substance P) or endothelial NO synthesis. In contrast, capsaicin also directly stimulated 
vascular smooth muscle TRPV1 in the isolated skeletal muscle arterioles and this led to 
vasoconstriction. This effect was not affected by endothelium removal (Kark et al., 
2008). Moreover, the presence of TRPV1 in the vasculature of skeletal muscles was 
demonstrated by immunohistochemistry and TRPV1 mRNA was also detected in both 
aorta and cultured VSMCs (Kark et al., 2008). Furthermore, Czikara et al. also 
demonstrated the presence of TRPV1 in isolated arteries and activation by capsaicin 
caused vasoconstriction (Czikora et al., 2012). This effect was absent in the TRPV1 KO 
mice. All these results suggest that the role of TRPV1 in the cardiovascular system is 
complex; therefore more research will be of benefit to understand the role of TRPV1 in 
regulating cardiovascular events.  
 
1.8 Cardiovascular Disease  
Cardiovascular diseases (CVDs) include diseases of the heart, blood vessels and 
vascular diseases of the brain, and are the leading causes of death and disability in 
developed as well as developing countries. In the 2011 report, the World Health 
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Organization (WHO) revealed that in 2008 CVDs were responsible for over 17.3 million 
deaths (31% of the total deaths) (Mendis et al., 2011). CVDs include high blood 
pressure (hypertension, diseases of aorta and arteries), coronary artery disease (e.g. 
heart attack), stroke, congenital heart disease, myocardial infarction and others. Out of 
the 17.3 million global deaths in 2008, myocardial infarctions were responsible for 7.3 
million and strokes were responsible for 6.2 million deaths. In the developed country of 
UK the CVD mortality rate in males is about 120-238 (age standardized, per 100,000) 
while it is 76-180 (age standardized, per 100,000) in females (Mendis et al., 2011). In 
the developing country of China the CVDs mortality rate in male is 239-362 (age 
standardized, per 100,000) while it is 181-281 (age standardized, per 100,000) in 
females (Mendis et al., 2011). Therefore, CVDs remain a huge challenge and burden to 
both developed and developing countries.  
 
There are many factors contributing to the development of CVDs. These include 
behavioural risk factors (such as tobacco smoking, physical inactivity and unhealthy 
diets) and other major risk factors (such as cancer, diabetes and chronic respiratory 
disease). Long-term exposure to behavioural risk factors results in raised blood sugar 
(diabetes), raised blood pressure (hypertension) and obesity, which contribute to the 
major risk factors for the CVDs. Among those, hypertension is the most common factor 
which is linked with other CVDs. More details about hypertension and its link with 
obesity will be discussed in the later sections.  
 
1.8.1 Hypertension  
Blood pressure (BP) varies between a minimum (diastolic pressure) and a maximum 
(systolic pressure) during each heartbeat. Systolic BP is the highest pressure in the 
arteries, achieved when the ventricles are contracting. Diastolic BP occurs when the 
ventricles are filled with blood. BP is summarized by systolic and diastolic BP, then it is 








BP classification Systolic blood pressure 
(mmHg) 
Diastolic blood pressure 
(mmHg) 
Normal < 120 < 80 
Prehypertension 120-139 Or/and 80-89 
Stage 1 hypertension 
(mild hypertension) 
140-159 Or/and 90-99 
Stage 2 hypertension 
(moderate/severe 
hypertension) 
≥160 Or/and ≥100 
Isolated systolic 
hypertension 
≥ 140 < 90 
 
Table 1.1: Classification of blood pressure in adults.   
 
Classification of hypertension can depend on ethnic origin, gender, age, geographic 
patterns and socioeconomic status (Oscar and Suzanne, 2000). As mentioned 
previously, hypertension is a common pathological condition and is the most essential 
risk factor for the increased cardiovascular morbidity and mortality. The British Heart 
Foundation reported in 2006 that 31% men and 28% women suffered from 
hypertension in England. Moreover, the newest data shows that globally the prevalence 
of hypertension in adults aged 25 and over was around 40% in 2008 (Mendis et al., 
2011). Indeed, hypertension is estimated to cause 7.5 million deaths, which is about 
12.8% of the total of all the annual deaths (WHO, 2010). It is suggested by the WHO 
that hypertensive patients should lower salt consumption, lower the fat content in their 
diet and increase physical activity in order to control and reduce their BP.  
 
Hypertension (persistently higher BP over 140/90 mmHg) is one of the main risk factors 
for many cardiovascular diseases, such as myocardial infarction, heart failure, and 
stroke (Chobanian et al. 2003). In addition, hypertension can also be a consequence of 
diseases such as obesity and type II diabetes mellitus (Chobanian et al. 2003). Indeed, 
obesity is a growing health problem for both developed and developing countries. It is 
believed that patients being overweight contribute to about 60% - 70% of hypertensive 
diseases (World Health Organisation 2003; Wofford & Hall 2004). Although progress 
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has been made into understanding the pathogenesis of hypertension leading to several 
different therapeutic approaches, the number of well controlled or treated patients 
remains low in the world (Franco et al., 2004). Therefore, further research into 
understand the pathophysiological dysfunction and the relation between obesity and 
hypertension in this area is necessary and essential in order to develop new therapies. 
 
1.8.2 The classification of hypertension 
Depending on the causes, hypertension can be classed as either essential (primary) or 
secondary hypertension. Secondary hypertension, which is much less common than 
essential hypertension, is caused as a result of another medical condition, such as 
endocrine disease, kidney disease, heart disease or tumors. Secondary hypertension 
affects approximately 5% of hypertensive patients and could also be a side effect of a 
medical treatment. Therefore, it is important to recognize this kind of hypertension 
because the underlying cause has to be treated. Most of the mechanisms linked with 
secondary hypertension are well understood. There are common and well recognized 
secondary causes, such as Cushing‘s syndrome, renal segmental hypoplasia, 
pregnancy or sleep disturbances (Magiakou et al., 2006; Babin et al., 2005; Podymow 
and August, 2007; Kario et al., 2009).  
 
By contrast, essential hypertension often has no identifiable cause and accounts for 90-
95% of all hypertensive patients. Even though it has been indicated that there is no 
direct cause of essential hypertension, a number of known factors lead to the increase 
of BP, including genetics, increased sympathetic nervous activity, increased renin 
secretion resulting in increased production of ATII, endothelial dysfunction and 
deficiencies of vasodilators such as nitric oxide and natriuretic peptides. Moreover, 
different lifestyles such as high alcohol intake, high salt intake, sedentary lifestyle, 
stress, low potassium intake and low calcium intake (Oscar and Suzanne., 2000) are 
other causes contributing to essential hypertension.  
 
The pathophysiology for developing essential hypertension has been researched 
extensively. One major risk factor is suggested to be sodium sensitivity as nearly one 
third of essential hypertension is responsive to sodium intake (Katori and Majima, 2006). 
When sodium intake exceeds the ability of excretion by the body, it results in an 
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increase in arterial pressure as the cardiac output increases. Indeed a modest 
reduction in salt intake has a significant and important effect on BP in patients with 
hypertension (He & MacGregor 2009). The lower the salt intake, the lower the blood 
pressure, suggesting a correlation between reduction of salt intake and the reduction of 
blood pressure, studied from the daily intake range of 3–12 grams/day (Brown et al., 
2009, He and MacGregor, 2009).  
 
Another major pathophysiologic mechanism includes the renin-angiotensin system 
(RAS - also termed renin-angiotensin-aldosterone system, RAAS). Inappropriately 
activated systemic or local tissue RAS contributes to the haemodynamic and metabolic 
abnormalities, which leads to endothelial dysfunction, hypertension and other 
cardiovascular diseases. Indeed, an overactive RAS leads to vasoconstriction and 
retention of sodium and water, and then leads to raised blood volume and, in turn, to 
hypertension (Manrique et al. 2009). More details about RAS will be discussed in 
section 1.8.5.1. 
 
Obesity is another main factor (growing to be the most important factor) as obesity is 
also the cause of insulin resistance, adult-onset diabetes mellitus, left ventricular 
hypertrophy and atherosclerotic disease. A weight in kilograms divided by square 
height in metres (body mass index; BMI) less than 25 kg/m2 is considered as normal 
while a BMI of 26 -28 kg/m2 increases the risk of elevated BP by 180% and the risk of 
insulin resistance by >1000%. Over 85 % of hypertensive patients have a body mass 
index greater than 25 (Aram et al., 2003). More details about obesity-induced 
hypertension will be discussed in section 1.8.5.4. 
 
1.8.3 The effects of untreated hypertension   
Undetected and uncontrolled hypertension leads to increased cardiovascular diseases, 
such as myocardial infarctions, stroke, kidney failure as well as blindness (Branca et al. 
2007). The risk of developing complications with hypertension is higher than with other 
cardiovascular risk factors. It is suggested that BP variability (both short-term - BP can 
change within 24 hours, and long-term - marked BP differences are detectable between 
different days) increases cardiovascular risks, organ damage, risk of coronary heart 
disease and cerebrovascular events (Grassi et al., 2012). The Blood Pressure 
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Association estimates that there are 16 million people in the UK with hypertension, of 
which 5.7 million are unaware that they have the condition (Blood Pressure Association 
2009). 
 
An analysis of over 1 million adults aged between 40-69 years, indicated that the risk of 
death from coronary heart disease is doubled when the systolic BP is increased every 
20mmHg or diastolic BP is increased every 10mmHg (British Heart Foundation 2008). It 
has been suggested that if the people who have hypertension in the UK could control 
their hypertension, the incidence of stroke would reduce by 28-44% while ischemic 
heart disease would reduce 20-35%. That would equate to a reduction of 42,800 stokes 
and 82,800 ischemic heart disease incidents (He & MacGregor 2003). Furthermore, 
direct and indirect costs detecting and treating patients with hypertension and related 
diseases are increasing every year. Recent figures from the British Heart Foundation 
suggested that 11% of the entire disease burden in developed countries is from 
hypertension. Therefore, treatments of hypertension become essential to decrease the 
morbidity and mortality of different critical cardiovascular events, as well as save 
treatment expenditure.  
 
1.8.4 Treatments for hypertension 
As mentioned ealier, lifestyle plays an important part in developing hypertension 
Therefore, lifestyle changes such as ensuring a low salt intake, low alcohol intake and 
stopping smoking, are strongly recommended before drug treatment is started. When 
blood pressure level becomes mild hypertension (see table 1.1), medication becomes 
necessary. To date, there are many kinds of antihypertensive drugs available. The 
most common medications (Table 1.2) are the thiazide diuretics, inhibitors for the RAS 
system (such as the angiotensin-converting enzyme inhibitors (ACE) and ATII receptor 
1 blockers (ARB)), the beta blockers and calcium channel blockers. The effectiveness 
and choice of treatments depends on both age and race (Baglioni et al. 2007, National 
Institute for Health and Clinical Excellence, 2011). In reality, the treatments are proven, 
however they do not work all the time especially for some drug-resistant hypertensive 
patients, as well as due to the complex nature of hypertension development. Therefore, 
a better understanding of the mechanisms underlying the onset and development of 




In the UK, the National Institute for Health and Clinical Excellence (NICE) published a 
report in 2011 that stated that the aim of treatment is to maintain BP at 140/90 mmHg 
for people aged under 80 years and at 150/90 mmHg for people aged over 80 years 
(NICE, 2011). Figure 1.5 summarises the current therapy decisions to determine the 





Drugs Examples Mechanism Advantages Disadvantages Application for 
hypertensive patients 
ACE inhibitors  
Captopril, 
Enalapril 
Block the conversion of 
angiotensin I to 
angiotensin II under the 
mediation of ACE. 
May have anti-obesity 
effects. Safe and 
potent. cause 
regression of left 
ventricular hypertrophy 
Renal failure, dry 
cough. 
Used with caution in 









Block the activity of 
angiotensin II AT1- 
receptors 
Potent, benefit 





increase the risk of 
heart attack.  
Used for the patients 
who are intolerant of 





Suggested via reduction 
of cardiac output and 
antagonism of peripheral 
adrenoreceptors.  
Reduce stroke in 
clinical trials, 
inexpensive; benefit 




Particularly use for 
patients with angina, 
cardiac arrhythmia, 
congestive heart failure, 
cardioprotection after 
myocardial infarction 






Work by blocking voltage-
gated calcium channels in 
cardiac muscle and blood 
vessels. 
Efficacious  Flushing, headache, 
ankle oedema 
Use for patients with 
atrial fibrillation or flutter 
in whom control of the 






absorption in distal 
convoluted tubule  
Reduce stroke and 
inexpensive 
Dehydration and 
impaired  glucose 
intolerance, 
thrombocytopenia 
Use for patient with mild 
heart failure 





Figure 1.6: Pharmacological treatment of hypertension.  Progression of treatment options based 
on a patients age and ethnicity, ARB=Angiotensin receptor blocker, used when the patient is 
intolerant to ACE inhibitors (NICE 2011). General treatment principles include offering people 
aged over 80 years the same antihypertensive drug treatment as people aged 55-80 years, 
offering people with isolated systolic hypertension the same treatment as people with both raised 






ACE inhibitor or ARB  Calcium-channel blocker  
(ACE inhibitor or ARB) + Calcium-channel blocker 
<55 years 
(ACE inhibitor or ARB) + Calcium-channel blocker 
+ Thiazide-type diuretic 
Resistant hypertension 
Add either of follows: Further diuretic therapy 









1.8.5 Mechanisms involved in hypertension 
As discussed previously, hypertension has been described as the leading cause of 
morbidity and mortality and is related to the development of co-morbidities. The 
mechanisms involved in the development of hypertension are multifaceted, ranging 
from renin-angiotensin system and other humoral contributors to neurogenic 
mechanisms. This section will focus on discussing constrictor systems in details, which 
are involved in the animal models that have been utilized in this thesis.  
 
1.8.5.1 Renin-angiotensin system (RAS) pathway 
RAS is a hormone system that has an important role in the maintenance of 
hemodynamic stability via regulation of extracellular fluid volume, sodium balance & 
cardiac and vascular trophic effects. Figure 1.7 illustrates the major components and 
function of the RAS. Renin is a circulating enzyme secreted from the granular cells 
(also called juxtaglomerular cells which synthesise, store and secrete renin) in the 
kidney under the stimulation of a decrease in arterial blood pressure or sodium chloride 
level. It helps to maintain extracellular volume and arterial vasoconstriction (Jan Danser, 
2012). Thus, it contributes to regulation of blood pressure. Renin regulates the RAS by 
cleaving angiotensinogen, produced by the liver, to create angiotensin I (ATI) which has 
no biological activity but exists solely as a stepwise product in the pathway to create 
ATII. To produce ATII, the ATI is further cleaved in the lung by the angiotensin-
converting enzyme (ACE) which can be found at the surface of endothelial cells all over 
the body but is mainly located in the lung capillaries and renal endothelium due to high 
density of capillary beds there (Jan Danser J 2012).  
 
ATII is a potent vasoconstrictor that increases peripheral vascular resistance, therein 
elevating arterial pressure. It also regulates aldosterone release and sodium re-
absorption, as well as inducing the expression of many substances, such as growth 
factors, cytokines, chemokines and adhesion molecules. All these are involved in cell 
growth/apoptosis, fibrosis and inflammation (Mezzano et al., 2001; Sadoshima 2000; 
Ruiz-Ortega et al., 2001; Higuchi et al., 2007, Savoia et al., 2011). Indeed, in the event 
of hypertension both ATII-stimulated hypertrophy and inflammation contribute to the 
vascular remodelling. Delva et al. (2002) demonstrated increased collagen I and III 
mRNA and enhanced collagen protein synthesis in cultured fibroblasts from essential 
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hypertensive patients (Delva et al., 2002). In addition, cardiomyocytes produce active 
transforming growth factor (TGF) under stimulation of ATII where TGF in turn induces 
interleukin 6 (IL-6) to promote collagen synthesis (Sarkar et al., 2004). Moreover, ATII 
mediates expression of pro-inflammatory molecules in the vessel wall. In VSMCs ATII 
induces production of vascular cell adhesion molecule 1 (VCAM-1), monocyte 
chemoattractant protein-1 (MCP-1) as well as interleukin 6 (Phillips & Kagiyama 2002), 
which contribute to the recruitment of mononuclear leukocytes into the vessel wall. All 
these effects of ATII are mediated, on the whole, via actions on two seven 
transmembrane G-protein-coupled receptors: ATII receptor 1 (AT1R) and ATII receptor 
2 (AT2R).  
 
The AT1R receptor, primarily expressed on the cardiovascular cells, such as VSMCs, 
has been shown to mediate most of the physiological and pathophysiological actions of 
ATII. For instance, the pro-inflammatory actions of ATII are mediated by activation of 
AT1R, which causes vasoconstriction, aldosterone synthesis and secretion, fibrosis, 
increased cardiac hypertrophy, vascular smooth muscle cell proliferation, recruition of 
proimflammatory cells and so on (Catt et al., 1984; Ruiz-Ortega et al., 2001). ATII acts 
on the AT1R to produce secondary messengers (such as MAPK and PKC) or activates 
proteins like Rho and Ras, which lead to different downstream pathways (Higuchi et al., 
2007). Knocking out the AT1R reduces levels of vascular oxidative stress, endothelial 
dysfunction and atherosclerosis (Wassmann et al., 2004). However, Kato et al. showed 
that the RAS-activated transgenic mice (a mouse model of persistent hypertension) 
displayed accelerated atherosclerosis and mortality but no change in term of kidney 
damage after receiving a bone marrow transplantation from an AT1R KO mouse (Kato 
et al., 2008).  
 
The AT2R, is expressed at low levels in a few organs (such as adrenal gland, ovary, 
brain and kidney) and is believed to be associated with the anti-proliferative, 
vasodilatory and pro-apoptotic action of ATII, which tends to counteract the effects of 
ATII by AT1R (D‘Amore et al., 2005, Savoia et al., 2011). Expression of AT2R has been 
found in the vascular wall of small resistance-size arteries from hypertensive diabetic 
patients when treated with ARBs. Moreover, a crosslink between AT1R and AT2R is 





Figure 1.7: Renin-angiotensin pathway and its pharmacological inhibition. Renin inhibitors, 
ACE inhibitors, and ARB modulate angiotensin activities and inflammatory processes. 
 
It is now noticeable that the RAS plays an essential role in the initiation and 
maintenance of the vascular inflammatory response which is associated with 
remodelling of resistance vessels as well as the development of organ damage (such 
as left ventricular hypertrophy, congestive heart failure, atherosclerosis, stroke, 
myocardial infarction) in hypertensive patients (McConnaughey et al., 1999). Therefore, 
inactivation of the RAS system, especially targeting the ATII pathway, becomes an 
























anti-hypertensive and anti-inflammatory effects (Ma et al., 2010). ACE inhibitors bind to 
ACE to limit the ACE-mediated generation of ATII and also to prevent breakdown of 
bradykinin (Imig, 2004). ACE has therefore been targeted for the treatment of 
conditions such as hypertension and heart failure. ARBs cause reduction of BP in 
patients with essential hypertension and left ventricular hypertrophy through blocking 
the AT1R (Dahlöf et al., 2002). ARBs can stimulate the ATII- AT2R pathway which then 
promotes the kinin/NO system. However they can also increase circulating levels of 
ATII (Csajka et al., 1997, Regoli et al., 2012). Therefore, ARBs are introduced for the 
treatment for hypertension for those who are intolerant of ACE inhibitor therapies.  
 
1.8.5.2  Endothelin pathway 
Endothelins (ET-1, ET-2 and ET-3) are expressed in humans. ET-1 is a 21 amino acid 
vasoconstrictor peptide produced in cardiomyocytes and aortic VSMCs, but mainly in 
endothelial cells. ET-2 is produced primarily by the kidney and intestine while ET-3 is 
mainly localised in the brain, the intestine, as well as kidney tubule cells (Khimji and 
Rockey., 2010). Here, we focus on ET-1 whose action in the vascular wall has been the 
best characterized and is suggested to be implicated in a wide range of diseases, such 
as cardiovascular diseases (including arterial hypertension) and type II diabetes. ET-1 
is released towards the basolateral side of the cells and then typically acts on SMCs. 
Therefore, normal tissue levels of ET-1 tend to be higher than the plasma levels (range 
1-10pmol/L, Haynes and Webb 1994).  
 
ET-1 exerts its action mainly through two major receptor subtypes namely endothelin A 
receptor (ETA) and endothelin B receptor (ETB). Both ETA and ETB receptors belong to 
the GPCR superfamily. In the vascular wall, ETA receptor is found mainly in smooth 
muscle cells, which mediates ET-1-induced vasoconstriction under physiological 
conditions (Huggins et al., 1993). For example, ETA receptor stimulation by ET-1 
induces vasoconstriction, production of reactive oxygen species (ROS) and 
inflammation of the vascular wall (Schneider et al. 2007). In contrast to this, the ETB 
receptor is found abundantly in endothelial cells and mediates vasodilatation by 
releasing NO (Huggins et al., 1993, Schneider et al. 2007). However both receptors 
have a wide distribution in many other cell types; for example, ETB receptors are also 
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found on macrophages and platelets (Dockrell et al., 1996). Also, both ETA and ETB are 
distributed in the kidney (Davenport et al., 1991).  
 
Generally ET-1 has been shown to be involved in the pathogenesis of a variety of 
diseases, such as congestive cardiac failure, coronary artery disease, essential 
hypertension, diabetes and metabolic syndrome (Khimji and Rockey 2010). ET-1 is 
shown to be correlated to several other inflammatory markers, such as transforming 
growth factor-beta, TNF, interleukins, insulin, noradrenaline, ATII and thrombin 
(Yanagisawa et al., 1988), which suggests an important role for ET-1 in chronic 
inflammation in the vascular wall. ET-1 not only can cause vasoconstrictor effects by 
vascular smooth muscle cellular constriction, but can also indirectly enhance the 
vasoconstrictor effects of other neurohumoral and endocrine factors, such as ATII and 
transforming growth factor beta-1 (TGFβ1), which potentiate the progression of 
essential hypertension (Lariviere and Lebel 2003). In addition, in an in vitro model, ET-1 
induces conversion of angiotensin to ATII and stimulates the adrenal synthesis of 
epinephrine and aldsterone (Kaddoura et al., 1996). These results suggest that there 
may be crosslinking mechanisms between ET-1 and RAS, which suggests that ET-1 
may contribute to the multisystem complications of hypertension.  
 
ET-1 is suggested to be involved with the development of obesity which has strong 
links to type 2 diabetes. PreproET-1 mRNA expression and subsequent ET-1 release is 
mediated by thrombin via activation of PKC and mobilization of intracellular calcium 
(Emori et al., 1992). Circulating levels of ET-1 are raised in obese people with 
metabolic syndrome (Ferri et al., 1997). In addition, it has been shown that adipose 
tissue produces ET-1 and expresses both ETA and ETB receptors. Interestingly, such 
expression of ETA receptors and release of ET-1 in adipose tissue is markedly elevated 
in obesity (Eriksson et al., 2009; van Harmelen et al., 2008). Moreover, incubation of 
adipocytes with ET-1 results in increased lipolysis via the ETA receptor pathway 
resulting in increased free fatty acid release (Eriksson et al., 2009). Furthermore, a 
recent study in humans demonstrated an increased forearm vasoconstrictor response 
to exogenous ET-1 in overweight and obese adults when compared with normal weight 
adults (Weil et al., 2011). A selective ETA receptor antagonist (BQ123) displayed a 
significant vasodilator effect in overweight/ obese adults but not in normal weight adults 
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(Weil et al., 2011). These results suggest that being overweight or obese is associated 
with increased sensitivity to ET-1 mediated vasoconstriction, which contributes to the 
development of endothelial dysfunction. Finally, compared with WT mice, mice with 
endothelial cell-selective ET-1 overexpression (selectively overexpressing human 
preproET-1 in the endothelium), cross-bred with apolipoprotein E gene deleted 
(apoE−/−) mice exhibited significantly enlarged atherosclerotic lesion size following a 
high fat diet (Simeone et al., 2011). These results suggest that endothelial ET-1 
contributes to enhanced lipid biosynthesis and accelerates formation of atherosclerosis 
in the vascular wall. All these observations indicate that there may be a connection 
between ET-1, obesity and its associated cardiovascular diseases.   
 
1.8.5.3 Sympathetic nervous system pathway 
The sympathetic and parasympathetic systems are the two major components of the 
autonomic nervous system. There are two types of neurons involved in the 
transmission of sympathetic nervous system. The first type is the relatively short axons 
of preganglionic neurons which exit the spinal cord and synapse with post-
hocganglionic neurons. The second type is the long axons of postganglionic neurons 
which spread to innervate target organs, like blood vessels, kidney and heart. 
Acetylcholine is the main neurotransmitter which is produced from sympathetic 
preganglionic nerves. In contrast, the primary neurotransmitter of postganglionic 
sympathetic neurons is noradrenaline which activates adrenoceptors (mainly α1 
receptors in the vasculature), causing vasoconstriction (Rang et al., 2012). Today there 
are several different methods to measure the activity of the sympathetic nervous 
system, such as microneurography (a method to measure efferent multi-fibre traffic in 
sympathetic nerves), noradrenaline spillover (a measurement of noradrenaline release 
to plasma), variability in heart rate/blood pressure and arterial baroreflex sensitivity 
(Davy and Orr et al., 2009, Parati and Esler 2012). 
 
As mentioned above, one of the features of increased sympathetic nerve activity is the 
increased level of noradrenaline, which will elevate blood pressure. Plasma levels of 
noradrenaline are increased in the first hours following an acute ischemic or thrombotic 
cerebrovascular event (Thomas and Marks, 1978). Similarly, an elevation in plasma 
levels of noradrenaline has been reported in the advanced clinical phases of congestive 
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heart failure (Cohn et al., 1984). However, due to the limited reproducibility of plasma 
levels of noradrenaline as an indicator of sympathetic nerve activity, regional 
noradrenaline spillover has been developed (a measurement of organ-specific 
noradrenaline release to plasma).  
 
It is suggested that the sympathetic nervous system is constantly active at a basal level 
to maintain homeostasis (Brodal 2004), and plays a key role in the regulation of arterial 
blood pressure. However, over-active sympathetic nerves may have an important role 
in the development of hypertension and related cardiovascular disorders. It is 
suggested that the degree of sympathetic nerve activation is directly related to the 
severity of the high blood pressure state (Grassi 2009, Grassi 2010). The evidence for 
the concept that the sympathetic nervous system is activated in hypertension has been 
investigated long time ago. Elevated levels of sympathetic nerve activity are observed 
in young, middle-aged and elderly individuals (Anderson et al., 1989, Grassi et al., 1998, 
Grassi et al., 2000). In addition, Esler et al. reported that chronic sympathetic activation 
is observed in about 50% of patients with essential hypertension (Esler et al., 2010). In 
animal studies, adult spontaneously hypertensive rats (SHR) have demonstrated 
reduced cardiac parasympathetic nerve activity (Friberg et al., 1988) and elevated 
sympathetic nerve activity with elevated noradrenaline release (Judy and Farrell 1979, 
Lundin et al., 1984). In addition, experimental infusion of noradrenaline elicits vascular 
remodelling and increased aortic medial thickening (Friberg et al., 1988). Therefore, it is 
certain that sympathetic activation is a hallmark of the essential hypertensive state. 
 
What exactly triggers the increase in sympathetic nerve activity is still unknown. 
However, evidence indicates that a sedentary lifestyle can lead to mechanisms that 
trigger increases in sympathetic nerve activities, for example increased visceral 
abdominal fat mass is associated with increased muscle sympathetic nerve activity 
(Alvarez et al., 2002). In addition, Agapitov et al. demonstrated that muscle sympathetic 
nerve activity in upper and lower limbs was significantly higher in obese subjects when 
compared with lean normotensive subjects (Agapitov et al., 2008). Moreover, 
cardiovascular and metabolic diseases associated with hypertension are linked to 
increases in sympathetic nerve activity together with increased noradrenaline levels 
(Grassi et al.,1995, Vaz et al., 1997).  Overall, these data suggest an important link 
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between the sympathetic nervous system and obesity. Chronic activation of the 
noradrenergic system leading to increased noradrenaline levels has been shown to 
contribute to peripheral sympathetic nerve system activation in heart failure (Lambert et 
al., 1995) and essential hypertension (Ferrier et al., 1992).  
 
1.8.5.4 Obesity 
In adults, obesity is defined as a BMI ≥ 30kg/m2 while pre-obese is used to define 
adults with a BMI of 25-29.9. Overall, an adult is defined as overweight if they have a 
BMI ≥ 25 kg/m2 (Branca et al., 2007). The UK has one of the highest prevalences of 
obesity in adults, throughout the world. In addition, a survey of children indicated that in 
Wales the prevalence of overweight 13-15 year olds is 25% and obese category is 
even higher at 33% (Branca et al., 2007). According to a 2011 National Health Service 
survey in England, high blood pressure was recorded in 48% of men and 46% of 
women in the obese group, compared with 30% of those in the overweight and 15% of 
those in the normal weight category (NHS survey 2011). Obesity is associated with 
multiple comorbidities, including hypertension, diabetes, sleep apnea and 
hypercholesterolemia.  It has been suggested that 60% - 75% of hypertensive disease 
is caused by patients being overweight (Allender et al., 2006, Wofford and Hall 2004). 
However the exact mechanisms involved are controversial. 
 
Studies in humans suggest that both bolus oral ingestion and the intravenous infusion 
of fat result in a significant increase in systolic blood pressure, decreased endothelial 
function, increased oxidative stress markers and activation of the sympathetic nervous 
system, assessed by heart rate variability (Gosmanov et al., 2010). Indeed, there are 
many pathways associated with obesity-induced hypertension. An established pathway 
is increased renal sodium re-absorption with impaired pressure, natriuresis via 
activation of the RAS and sympathetic nervous systems, and altered intrarenal physical 
forces. Segura et al. (2007) claimed that obesity is a risk factor for developing 
hypertension because of the activation of RAS in adipose tissue and its link with insulin 
resistance. They demonstrated that blockade of the RAS with either an ACE inhibitor or 
ARBs substantially increased adiponectin levels and improved insulin sensitivity. 
Furthermore, a recent study in humans involved blocking systemic nerve activity with 
trimethaphan, Shibao et al. demonstrated that obesity-induced sympathetic nerve 
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activation is an important determinant of hypertension and its associated conditions 
(Shibao et al., 2007). This finding suggests an important role of the sympathetic 
nervous system in the development of obesity associated hypertension. Moreover, in 
obesity with insulin resistance, NO-mediated vasodilatation is impaired, whereas there 
is increased levels of endothelin-1, which increases the vasoconstriction (Kotsis et al., 
2010). This suggests the importance of functional endothelium and the balance 
between vasodilatators and vasoconstrictors in vascular wall.  
 
Finally the levels of functional hormones (such as insulin, leptin and adipokine) and 
adipose cell-released ROS play an essential role in the obesity-induced hypertension 
(Kotsis et al., 2010). In addition, pro-inflammatory molecules (such as IL-1β IL-6 and 
TNFα) also contribute to such an event (Kotsis et al., 2010). Obesity is also 
characterised as impaired glucose tolerance and insulin resistance. High levels of 
insulin have been shown to enhance sodium retention (Sechi & Leonardo, 1999) and 
have acute sympathoexcitatory action (Anderson et al., 1992). Moreover, adiponectin is 
the most common adipokine which has vasorelaxant effects on small arteries. Clinical 
studies demonstrated low levels of adiponectin in hypertensive patients but levels 
increased with anti-hypertensive treatment (Yilmaz et al., 2007). In addition, it has been 
shown that adiponectin can improve the endothelial dysfunction by increasing NO 
production in diet-induced obese rats (Deng et al., 2010). Furthermore, knocking out 
the adiponectin, an adipokine, caused severe diet-induced insulin resistance and 
atherogenesis. This data suggests that lack of adiponectin is one of the factors 
contributing to cardiovascular symptoms in obesity.  
 
Overall the exact mechanisms involved in the development of obesity-induced 
hypertension is in need of further research. The possible pathways discussed above 

























Fig 1.8 The complex pathophysiology of obesity-related hypertension RAS: renin-angiotensin 
system; SNS: sympathetic nervous system (Aghamohammadzadeh and. Heagerty, 2012). 
 
1.8.6  Experimental models of hypertension  
As the mechanisms involved in essential hypertension are complicated, a range of 
hypertensive models in animals have been developed to investigate new insights into 
the pathogenesis of hypertension. An ideal animal model of hypertension should be 
easy to perform and be highly reproducible. It has to be able to predict the potential 
agent with antihypertensive properties, require minimal quantities of compounds, be 
comparable to human hypertension and be feasible in a small animal. Several recent 
literature reviews have reported a range of different models using different animals with 
different techniques (Badyal, et al., 2003; Lerman et al., 2005; Nuyt 2008; Dornas and 
Silva 2011). Each model has its own advantages and disadvantages. As we know that 
hypertension is a complex disease, no model can be designed to answer all our 
questions. Therefore, for specific research purposes, different experimental designs 
and choices of animal models are applied. Generally, animal models of hypertension 


















designed to study hypertension by altering human and mouse genomes. By 
comparison, non-genetic models are those using surgery, drug treatments or metabolic 
disorders by diet feeding, to study the mechanisms involved in hypertension 
development. 
 
1.8.7 1.8.7 Genetic models: Phenotype-driven models 
Essential hypertension accounts for 90-95% of hypertension in humans, in which 
several genes contribute to the individual phenotype (Dickson et al., 2006). Therefore, 
in humans it is impossible that a single genetic defect can manifest the development of 
essential hypertension. The understanding of human and mouse genomes has 
promoted the development of transgenic or gene-targeted animal models to study more 
about hypertension. Phenotype-driven models are believed to be the most abundant 
tools for studying hypertension and the potential for exploration of hypertension caused 
by more than one gene mutation. In general, homozygous hypertensive rat strains are 
developed by selectively breeding of animals with the desired phenotype for several 
generations. Once the feature is determined, breeding of relative rats is required for 
another 20 generations to obtain genetic homogeneity. With this method, the first SHR 
was introduced in 1963 by Okamoto and Aoki (1963). These SHR rats can become 
hypertensive at age 4-6 weeks with no physiological, pharmacological or surgical 
intervention (Zicha and Kunne 1999). This model is not only benefiicial for studying the 
pathogenesis and therapy for essential hypertension, but also is useful in terms of 
researching the prevention of the development of essential hypertension and its relative 
complications. There are other phenotype-driven models such as SHR-stroke prone, 
Dahl salt-sensitive rat, milan SHR and obesity-related models.  
 
1.8.8 Genetic models: Genotype-driven model 
Studies of the molecular basis of hypertension have made significant progress and 
have revealed several disease susceptible genes. Researchers now know that 
disruption of certain genes that manage peptides or receptors linked to regulating blood 
pressure are involved in the pathogenesis of hypertension. The most studied models 
involve overexpression or deletion of selected genes which are normally involved in 
regulating vascular tone, renal physiology, and/or electrolyte and fluid homeostasis 
(Cvetkovic and Sigmund, 2000). This has allowed specific mouse models to be 
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developed, such as targeting at renin, nitric oxide and ET. For example, selective 
overexpression of the rat angiotensinogen gene in mice, with accompanying 
overexpression of rat renin, results in high blood pressure (Ohkubo et al., 1990). 
Moreover, the ET-1 gene is linked to blood pressure in obese patients. Similarly, the ET 
receptors are also suggested to be related to essential hypertension (discussed 
previously). Therefore, the ET-1 gene and ET receptor genes have also been targeted. 
In this thesis, two different transgenic mice have been used. The first one is smooth 
muscle cell-targeted RAMP2 (an AM1 receptor component) over-expressing mice. As 
discussed before, AM has shown a protective role in cardiovascular disease, but the 
influence of the AM1 receptor is unknown. The second mouse is the TRPV1 KO mouse. 
TRPV1 activation is associated with the release of vasodilator CGRP which is mainly 
known to be protective. 
 
1.8.9  Non- genetic model: Surgically-induced hypertension 
Several experimental non-genetic approaches have led to the development of useful 
models. These provide the possibility of inducing hypertension and end-organ damage 
in different species, thus providing a range of models, possibly comparable with the 
human pathology. These models are based on mechanisms of surgically-induced renal 
vascular or tissue injury. Goldblatt and co-workers developed the first animal model of 
hypertension in dogs by unilateral constriction of renal artery (Goldblatt et al., 1934). 
Since then, it became a very commonly used model for hypertension, including 
development for use in rats (Wilson and Byrom 1939), rabbits (Pickering and 
Prinzmetal 1937), dogs (Romero et al., 1981), pigs (Lerman et al., 1999), monkeys 
(Panek et al., 1991) and mice (Wiesel et al., 1997). Renovascular hypertension can 
also be achieved by coarctation of aorta, reduction of renal mass and external 
compression of renal parenchyma (Badyal et al., 2003). 
 
1.8.10 Non- genetic model: Endocrine, metabolic and diet-induced hypertension 
Administration of a mineralocorticoid (Selye et al., 1942) is the most common endocrine 
method to evoke hypertension, particularly DOCA. Increased DOCA-induces re-
absorption of salt and water resulting in increased blood volume and, thus, increased 
blood pressure. In rats and dogs, both partial removal of a renal mass and high salt diet 
feeding are required for generation of hypertension (Selye et al., 1942). Administration 
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of glucocorticoids can also cause hypertension in both rats and mice (Dahl et al., 1965), 
possibly by activating the RAS. However, they are reported to be less effective than 
DOCA. Moreover, chronic infusion of components of the RAS (such as ATII) has also 
been shown to induce hypertension successfully (more details will be discussed later).  
 
As discussed before, inherited salt sensitivity is involved in the development of 
essential hypertension. Thus, an experimental model of hypertension with different 
dietary interventions was introduced by increasing salt intake. A strain of salt-sensitive 
rats developed by Dahl (1972), was characterised by hypertension (even with a low-
sodium (0.5% NaCl) intake) and low heart rate with elevated sodium and water 
retention and plasma volume, renal parenchymal lesions as well as elevated activity of 
the sympathetic nervous system. More recently, dietary the intake of fats and 
carbohydrate has also been introduced. For example, the intake of simple sugars and 
the resultant effects of plasma insulin, adipokine and lipid concentrations may have an 
effect on cardiomyocyte size and function (Sharma et al., 2007). In addition, an 11-35% 
HFD in mice for 12-40 weeks to mimic the western diet-style of human food intake that 
leads to the development of hypertension has been utilised (more details will be 
discussed later). 
 
1.9 ATII induced hypertension 
ATII, an important mediator of the RAS, plays an essential physiological role in 
cardiovascular homeostasis. Moreover, ATII is suggested to play a key role in the 
physiological mediation of vascular tone and BP as well as in pathological conditions 
such as hypertension and heart failure. ATII is a potent vasoconstrictor of the peripheral 
vasculature and stimulates the proliferation of smooth muscle cells of blood vessels 
and in the heart (Itoh et al. 1993). Therefore, infusion of ATII induces hypertension and 
this is a common hypertensive model, which has been used since the agonist became 
available in pure form. The ATII infusion rate normally does not cause an instant 
increase in systemic BP but it rather results in a slow development of hypertension over 
a period of 6–10 days. It is suggested that the gradual development of hypertension by 
infusion of ATII is to mimic the human high renin (ATII) hypertension (Li and Wang 
2005). Such ATII-induced hypertension has a sympathetic component, at least to some 
extent, even though ATII is a direct constrictor agent. For example, it has been 
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suggested that different doses of ATII induce distinct degrees of hypertension, which 
leads to a presumably baroreflex-mediated sympatho-inhibition corresponding to the 
increased blood pressure (McBryde et al. 2007). The ATII-induced hypertension model 
is now commonly used; however the mechanisms by which ATII chronically leads to 
hypertension and its associated effects remain unclear. 
 
The primary advantage of the ATII-induced hypertension model is that infusion of ATII 
results in profound increases in blood pressure, becoming statistically significant within 
7-9 days when compared to the vehicle controls (Widder et al., 2009). With the same 
volume of the pumps, the dose of ATII depends on the concentration of ATII and the 
rate of the mini-pump. Currently there are a range of doses (from 0.3-1.44 mg/kg/day) 
of ATII used by different research groups (Qin, 2008). Depending on the required end-
points of the model, the above doses are administered for different periods, from 
between 7 to 28 days. The ATII-induced hypertension model established within our 
group involves the implantation of an osmotic mini-pump under the skin in the scapular 
region. In 2009 we demonstrated that with a dose of 0.9mg/kg/day and infusion for 13 
days, a significant increase in blood pressure is observed, together with vascular 
inflammation (Liang et al., 2009). Also, within our group, a dose of 1.1mg/kg/day has 
been used and showed a significant increase in blood pressure in addition to vascular 
inflammation and remodelling in WT and CGRP KO mice (Smillie, 2012).  
 
1.10 Obesity-induced hypertension  
As discussed previously, the incidence of obesity and its associated conditions, such as 
hypertension, are growing worldwide, which makes it essential that animal models 
sharing characteristics of human obesity and its co-morbidities are developed for novel 
prevention and treatment. Today, there are many different kinds of obesity models 
being used by research groups, such as using db/db mouse (Senador et al., 2009) and 
the Zucker rat (Alonso-Galicia et al., 1996). A HFD-induced hypertension model is used 
in this thesis. HFDs have been used to model obesity and insulin resistance in rodents 
for many decades (Lemonnier et al., 1975, Grundleger & Thenen, 1982, Friedman & 
Halaas, 1998; Reimer & Ahren, 2002). It is clear that exposure of animals to a HFD 
often results in the development of obesity. Feeding mice a HFD over a period of 12-15 
weeks to induce obesity is thought to mimic the development of human obesity in the 
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Western world and leads to obesity-induced hypertension (Friedman & Halaas, 1998; 
Reimer & Ahren, 2002). Long-term feeding of mice with HFD (35% fat diet) increased 
body weight compared to standard chow-fed controls (Lei et al., 2007). In addition, in 
our group, we have demonstrated that feeding mice with 35% fat (lard) causes a 
significant increase in body weight and blood pressure, in addition to vascular 
hypertrophy (Marshall et al., 2012). 
 
Compared to the ATII-induced hypertension model, this model results in a moderate 
increase (less extreme than that induced by ATII) in blood pressure in obese animals 
(approximately 108mmHg to 118mmHg in obese WT animals, Rao et al., 2007), which 
is similar to human obesity-induced hypertension. Obesity-induced hypertension 
models have become a common model to study hypertension development. In a rat 
model of obesity-induced hypertension, it was demonstrated that increased oxidative 
stress and then decreased NO bioavailability did contribute to the development of 
hypertension induced by HFD (Dobrian et al., 2001). In addition, mice fed with HFD 
beginning at age 3 weeks for 10 weeks, developed hypertension, increased oxidative 
stress and enhanced vasoconstriction (Smith et al., 2006). Interestingly, their results 
suggest that these effects induced by HFD feeding are not associated with the RAS 
(Smith et al., 2006). However, a recent study in which rats were fed on a HFD for 4, 8 
and 17 weeks, the rats exhibited increased plasma levels of aldosterone and/or 
increased renin activity (Northcott et al., 2012). However, they did not investigate the 
precise mechanisms involved.  
 
A HFD induces endothelial dysfunction which represents an important link between 
obesity and cardiovascular events. Kobayasi et al. demonstrated that HFD feeding in 
female Swiss mice caused a significant increase in both systolic and diastolic blood 
pressure and endothelial dysfunction (Kobayasi et al., 2010). Their results suggested 
that decreased anti-oxidant defence mechanisms partially contribute to the impairment 
of endothelium-dependent relaxation in aorta from obese mice (Kobayasi et al., 2010). 
Furthermore, Wang et al. revealed that diet induced obesity is associated with 
perivascular adipose tissue inflammation (macrophage content and vascular oxidative 
stress) and endothelial dysfunction in mesenteric arteries, which can be prevented by 
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deletion of P-selectin glycoprotein ligand-1 (Wang et al., 2012). This research suggests 
that obesity-induced hypertension has a complex aetiology.  
 
1.11 Aim and Hypothesis  
As discussed previously, in recent years many different mechanisms underlying 
hypertension have been suggested. However, considering the rates of obesity in both 
developed and developing countries, further research is still required in order to provide 
novel therapeutic targets. Therefore the hypothesis of my PhD project is that both the 
AM (via upregulating AM1 receptor component RAMP2) and TRPV1 (via release of 
CGRP) mediate protective roles in models of hypertension as well as hypertension 
associated vascular hypertrophy induced by either ATII or obesity. The aims of my PhD 
project are: 
 
1. Investigating the role of the AM1 receptor component RAMP2 in model of ATII-
induced hypertension and vascular hypertrophy.  
2. Studying the role of TRPV1 in the hypertension model of ATII and its associated 
vascular hypertrophy. 
3. Investigating the role of TPRV1 in the development of hypertension and 























All the procedures were performed under the UK Animals (Scientific Procedures) Act, 
1986. The RAMP2 TG mice were received from the Research Laboratory for Calcium 
Metabolism in University of Zurich, Switzerland. The RAMP2 TG mice were 
characterised in 2006 and bred on site. Mice of both sexes were used for these studies 
and transgenic mice were sex and age-matched with their respective WT controls. 
Blood pressure results were analysed for gender differences and as no difference were 
observed, results were pooled from both sexes. WT and TRPV1 KO mice were gifted 
from Merck, Sharpe and Dohme and also bred in-house. Mice were maintained in a 
climatically controlled environment with free access to food and water. Mixed gender 
mice were used for blood glucose tolerance test. Only male mice were used for all the 
other experiments in TRPV1 projects. In order to keep the experimenter blinded during 
the studies, mice were put together and labelled as number such as 1,2,3, and so on. 
Details were kept in the lab books so we could trace back when needed for analysis.  
 
2.2 Generation and genotyping of RAMP2 TG mice 
 
Both WT and RAMP2 TG mice, aged 4-7 months and weighing 25 to 35g, were used.  
The transgene consisted of an α-actin promoter fused to DNA encoding the CD33 
signal sequence, a Mycepitope-tag (Myc) and mouse RAMP2 without the 
corresponding signal sequence (mRAMP2). 
 
 
Fig 2.1 The RAMP2 transgene. The RAMP2 transgene consists of a mouse α-actin promoter 
fragment (1074bp), fused to DNA encoding the signal sequence CD33 (SigCD33), a Myc tag 
(Myc) and mouse RAMP2 without the corresponding signal sequence (mRAMP2). The binding 
 Myc  mRAMP  
Sig  
CD33 Myc RA P2 
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position for the oligonucleotide primers used for PCR genotyping are shown as black horizontal 
arrows on the bottom line.    
 
The α-actin promoter is designed for the transgene targeting primarily to smooth 
muscle cells. The Myc tag, a human gene, is the target gene to identify the presence or 
absence of the transgene and the signal sequence CD33 targets the whole gene 
product to the membrane. To generate, the cDNA construct was inserted into a pSMP8 
plasmid using restriction enzymes BamHI at the 5‘ end and EcoRI at the 3‘ end, 
followed by the ligating enzyme T4-ligase. The transgene was microinjected into a male 
pronucleus which was mated with a female pronucleus. Finally the zygote was 
surgically injected into a female WT (C57BL6) mouse, which will generate 
heterozygous positive mice. Expression of myc-mRAMP2 was examined by Prof. 
Born‘s group (University of Zurich) in a range of smooth muscle cells, where myc-
mRAMP2 predominantly expresses (Fig 2.2).  
 
After obtaining the RAMP2 TG mice from Prof. Born‘s group, genotyping was carried 
out regularly. Genotypes were determined by end-point PCR analysis of ear biopsies. 
In order to create a similar level of up-regulation of RAMP2 in each mouse, a 
heterozygous TG mouse is bred with a WT mouse to produce offspring that are 50% 
WT and 50% heterozygous positive for the transgene. The mice are not positive for the 




To genotype, ear samples were collected using metal ear clippers from mice under 2% 
isoflurane and 2% O2 (Abbott Laboratories, Kent, UK) anaesthesia. Genomic DNA was 
Fig 2.2: Myc-mRAMP2 expression (top) in mouse 
aorta (A), stomach (S), uterus (U), bladder (BL), 
liver (L), kidney (K) and brain (BR) from WT (-) 
and TG (+). Immunohistochemistry of cross-
sections of aorta with anti-myc antibodies reveal 
myc-mRAMP2 expression (arrowheads) in smooth 




extracted using the REDEXtract – N – AMP Tissue polymerase chain reaction (PCR) kit 
(Sigma, UK) and a PCR amplification of the target regions was performed on the 
genomic DNA using the following primers () : 
 
RAMP2 forward:  5‘AGC AAA AGC TCA TTT CTG AAG AGG 3‘ 
RAMP2 Reverse: 5‘ GTG GGA AGG ATG AGA GTA AGT GG 3‘ 
 
These RAMP2 primers are used to amplify the copies number of DNA that is present in 
the isolated genomic DNA, which will allow the visualization of absence and presence 
of the RAMP2 transgene. Details of the PCR mixture reagents are shown in table 2.1.  
 
Component  Volume/sample 
5x High fidelity PCR green GoTaq® buffer (600mM Tris-
SO4, pH8.5, 180mM ammonium sulphate and blue dye and 
yellow dye ) 
        4 μl 
dNTP mix (2.5mM)       0.8 μl  
RAMP2 Forward Primer (50M)       0.4 μl 
RAMP2 Reverse Primer (50M)       0.4 μl 
Mg2+ (50mM)       1.6 μl 
Platinum Taq DNA polymerase (Invitrogen)       0.2 μl 
DEPC H2O       10 μl 
Total/sample       16.6 μl 
Table 2.1: The PCR mixture for RAMP2 genotyping 
 
Amplification of the DNA was carried out in a thermal cycler (Techne, Cambridge, UK) 
using the conditions listed in table 2.2: 
 
No. Cycles Temperature Time Phase 
1 95°C 5 mins Initial melting the DNA 
30 cycles 
95°C 1 min Melting the DNA 
56°C 1 min Annealing of primers 
72°C 2 min Elongation 
1 72°C 7 mins Final elongation 
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Table 2.2 PCR programme for RAMP2 genotyping 
Following the final elongation, the samples were stored at 4ºC until use. The PCR 
products were visualised using gel electrophoresis on a 1.8% agarose gel in running 
buffer (0.5% tris-borate-EDTA buffer) with 4µl ethidium bromide (to get final 
concentration 0.5 ug/ml). The gel was covered in running buffer and 10µl of the PCR 
product mixing with 5µl loading buffer (0.1% bromphenol blue, 15% w/v Ficoll in running 
buffer) and 5µl of DNA ladder (Sigma, UK) were loaded into the wells. The gel was run 
at 90V for 20 minutes and the DNA was visualised under UV light to allow identification 
of WT and RAMP2 transgene bands.  
 









2.3  Generation and genotyping of TRPV1 KO mice 
TRPV1 KO mice were generated by replacing an exon encoding part of the fifth and 
entire sixth transmembrane domains of the channel, including the interconnecting pore-
loop, with a pGK-neo (phosphoglycerine kinase-neomycin) casette as described by 
Caterina and colleagues (Caterina et al., 2000). This genetic alteration was shown to 
render the channel unable to conduct ions and respond to selective agonists (Cateriba 
et al., 2000). Heterozygote TRPV1 mice were mated to produce homozygous WT, KO 
and heterozygote offsprings. After five generations, following genotyping, homozygous 
breeding pairs were set up to give homozygous WT and TRPV1 KO offspring. 
Subsequent generations of the WT and TRPV1 KO breeding colonies were genotyped 
to confirm the presence or absence of the functional TRPV1 receptor gene. An ear 
biopsy was collected under 2% isoflurane and 2% O2 anaesthesia from mice. Genomic 
DNA was extracted using the REDEXtract – N – AMP Tissue polymerase chain 
710bp
488bp
I     II     III
Fig 2.3: Representative image of gel with PCR    
products. (I) = DNA size maker; (II) = negative 
for the transgene; (III) = positive for the 
transgene; bp=base pairs. In the molecular maker, 
the gap between the uppermost (710bp long) and 
the band beneath (488bp long) indicates the gene 




reaction (PCR) kit (Sigma, UK) and a PCR amplification of the target regions was 
performed on the genomic DNA using the following primers: 
TRPV1 - Forward  5‘ CGA GGA TGG GAA GAA TAA CTC ACT G 3‘ 
TRPV1 – Reverse 5‘ GGA TGA TGA AGA CAG CCT TGA AGT C 3‘  
NEO – Forward 5‘ TTT TGT CAA GAC CGA CCT GTC C 3‘ 
NEO – Reverse 5‘ CCC TCA GAA GAA CTC GTC AAG AAG 3‘ 
The TRPV1 WT primers were used to amplify a PCR product of approximately 188 
base pairs that confirmed the presence of the WT TRPV1 receptor gene. The neomycin 
primers were used to amplify a PCR product of approximately 700 base pairs that 
corresponded to the neomycin construct found in the disrupted gene in the KO mice. 
The PCR reaction mixture was composed of the materials listed in table 2.3 
    Volume (µl) 
REDEXtract – N – AMP PCR Reaction Mix    10 
TRPV1 – 1 (5pmol/µl)    2 
TRPV1 – 2 (5mol/µl)    2 
NEO - 1 (5pmol/µl)    2 
NEO – 2 (5pmol/µl)    2 
Genomic DNA sample    5 
Total volume    25 
Table 2.3 The PCR mixture for TRPV1 genotyping 
 
Amplification of the DNA was carried out in a thermal cycler (Techne, Cambridge, UK) 
using the conditions listed in table 2.4. 
 
No. Cycles Temperature Time Phase 
1 95°C 14.5 mins Initial melting the DNA 
35 cycles 
95°C 45 sec Melting the DNA 
60°C 60 sec Annealing of primers 
72°C 60 sec Elongation 
1 72°C 60 sec Final elongation 
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Table 2.4 PCR programme for TRPV1 genotyping 
 




2.4. Mini-pump Implantation 
Sex and age matched mice were used for these experiments. Experimental 
hypertension was introduced using osmotic minipumps (Model 1002, Alzet, USA) 
containing angiotensin II (ATII; infusion rate 0.9 mg/kg/day, Sigma, UK) or vehicle 
(0.01% 10 mmol/l acetic acid in saline) were implanted into the mid-scapular region of 
WT and RAMP2 TG mice (25-35 g, 12 – 16 weeks old, matched for age and sex). The 
body weight of each individual mouse was obtained on the same day of the surgery. 
Calculations for the amount of ATII were based on the body weight and the pumping 
rate, and then osmotic mini-pumps were filled carefully. Surgical procedure was carried 
out using aseptic techniques under isoflurane anaesthesia (2.5%, Abbott Laboratories, 
UK, in 3L/minute O2) following administration of buprenorphine hydrochloride (Reckitt 
Benckiser, UK, 50 g/kg) intramuscular for post-hoc-operative pain relief. The outer 
incision was sealed with absorbable sutures (4.0, Ethicon, Johnson and Johnson) in a 
discontinuous pattern. Then mice were kept under a heating lamp to provide warmth 
until recovery. Mice were singly housed. Thorough daily checking was provided post-
hoc-surgery until termination.  
 
2.5 High Fat Diet induced hypertension model  
Age and sex matched male and female TRPV1 WT and KO mice (3-4 weeks old) were 
either fed with a HFD, 35% of fat from lard, 58.4% Kcal from fat, custom diet ref: 
TD03584, was bought from Harlan Teklad, USA). The 35% fat was comprised of 





Figure 2.4: Representative image of gel 
with PCR products under UV light (I) = 
DNA size maker; (II) and (III) TRPV1 
heterozygote; (IV) TRPV1 WT (product 
size=188bp); (V) TRPV1 KO (product 
size=700bp). 
 
          I          II         III         IV         V 
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polyunsaturated fat. It also contained sodium level: 0.15% and potassium level: 0.5%. 
The normal diet consisted of 4% fat (mainly from fatty acids but also from plant or grain 
sources) with 6.8% Kcal from fat with the sodium level: 0.25% and potassium level: 
0.67%, Rodent Diet RM 1E, SDS, Essex, England) for 12 weeks. Paired mice were 
also matched by body weight at the beginning of the study to reduce variability. Mice 
were housed in groups of 2-3 until termination or telemetry surgery. Body weight and 
food intake for individual mice was monitored twice weekly. When the mice were singly 
housed, a box maze and wooden bars were provided to reduce stress.    
 
The relative components of these two diets are detailed in fig 2.5.  
 
Figure 2.5: Relative components of the normal diet (4% fat diet) and the high fat diet (35% fat 
diet). The high fat diet contains much less carbohydrates and bulking agents when compared to 
the normal diet. For human, nutritionists advise us that a maximum of 35% of our calorie intake 
should come from fats, with only 10% derived from saturated fats. 
 
2.6 Blood Pressure Measurement Methods 
Blood pressure was monitored either using tail cuff plethysmography (CODA6 System, 
Kent Scientific, USA) in conscious restrained mice or through telemetry probe (PA-C10, 
DSI, NL)) in conscious unrestrained mice.  Mice were handled as gently as possible to 
reduce any stress.  
 
2.6.1 Tail cuff plethysmography 
Tail cuff plethysmography is a well established method in our group (Clark et al., 2007; 
Liang L et al., 2009) using the CODA 6 non-invasive BP acquisition technique system 
for mice (Kent Scientific, Torrington, CT, USA). Briefly, this system uses volume-
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pressure recording to measure blood pressure. Mice are restrained in the specially 
designed tubes. An occlusion cuff is placed at the base of the tail followed by a v-cuff. 
The occlusion cuff halts the blood flow into the tail where it is slowly deflated, and the v-
cuff that is contacted to a pressure sensor measuring the returning blood flow. Return 
of blood causes the tail to swell which is when the systolic blood pressure is measured. 
Once the tail has completely ceased swelling the diastolic blood pressure is calculated. 
Then the mean arterial blood pressure is calculated based on systolic and diastolic 
measurements.  
 
For this study, mice were trained for the tail cuff method for two weeks during which 
mice were acclimatized to the procedure. All the measurements were carried out in a 
25ºC, semi-dark, quiet room. For each measurement session, five acclimatization 
cycles were performed before collecting data. Any cycles with animal moving disruption 
or with an inadequate waveform were discarded. At least five good cycles were 
collected for each mouse every day.  
 
For mice used in the mini-pump implantation experiments, blood pressure was 
measured before the implantation as baseline and at day 3, 6, 9 and 13. For the HFD 
study, different sets of studies were carried out. For one set of study, blood pressure 
was measured on the last week of the feeding study, to determine the blood pressure 
change after 12 weeks of HFD compared to normal diet. In a separate study, blood 
pressure was measured for the last four weeks of the study to investigate when the 
blood pressure changes began.  
 
2.6.2 Telemetry 
Blood pressure was also measured using a telemetry probe (PA-C10, DSI, NL). 
Together with the blood pressure, telemetry also provides data on the heart rate and 
spontaneous activity. The implantation surgery procedure was carried out using aseptic 
techniques under isoflurane anaesthesia (2.5%, Abbott Laboratories, UK, in 3L/minute 
O2) followed by intramuscular administration of buprenorphine hydrochloride (Reckitt 
Benckiser, UK, 50 g/kg) for post-hoc-operative pain relief. A catheter tip was inserted 
into the left carotid artery and advanced towards the aortic arch. The catheter was 
secured to the carotid artery using non-absorbable surgical braided silk sutures (5.0, 
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waxed, Pearsalls sutures, Pearsalls Ltd) and the transmitter body was implanted 
subcutaneously into the right flank. The outer wound was closed with absorbable 
sutures (4.0, Ethicon, Johnson and Johnson) in a discontinuous pattern. The mice were 
kept under a heating light until fully recovered. Mice were singly housed and special 
care was provided post-hoc-surgery until termination. Mice were allowed to fully 
recover for two weeks before mini-pump implantation or collection of the data. Data 
was recorded every 15 min for 30 seconds.  
 
For ATII treated mice, baseline data was collected following day 13 post-hoc- mini-
pump implantation for 4 days. Then blood pressure was collected on day 3 and 6 
onwards until termination at day 13. For the HFD model, telemetry surgery was carried 
out following 8 weeks feeding, when the normal diet fed mice were big enough while 
the HFD mice were not too fat for the surgery. Data was collected at week 13. All 
collected data was calculated by the DSI software (DSI Dataquest A.R.T.) and 
analysed in Microsoft Excel and GraphPad Prism 5.   
 
2.7 Methodology of other physiological parameters measured in vivo 
2.7.1 Body Weight and food intake  
Body weight was recorded twice per week throughout the study where mice were 
handled as gently as possible. Food intake was measured for a few mice twice a week. 
During this recording period the HFD was changed for fresh after each measurement 
point.  
 
2.7.2 Glucose tolerance test 
A glucose tolerance test was carried out the day prior to termination, after measuring 
blood pressure in the morning. Mice were fasted for 6 hours followed by a bolus 
glucose (2mg/kg, Sigma) i.p injection. Blood samples were taken prior to glucose 
administration as baseline and then every 15 mins for 135 mins post-hoc-injection. 
Blood samples (approximately 3μl) were obtained by creating a small incision in the tail 
of conscious mice using a needle allowing measurement of blood glucose. The blood 





2.8 Experimental procedures performed in vitro following termination 
2.8.1 Preparation of plasma samples 
On the day of termination, under isoflurane anaesthesia (2.5%, Abbott Laboratories, UK, 
in 3L/minute O2), blood sample was collected by cardiac puncture, using a 25G needle 
(Therumo Coperation) and 1ml syringe (BD Plastipak, UK) washed with heparin (500 
I.U/ml heparin sodium, LEO Pharma, UK) to prevent coagulation. The blood sample 
was then centrifuged at 2000rpm at 4ºC for 20 min. Plasma (the supernatant) was 
collected, aliquoted and stored at -80ºC for further analysis.  
 
2.8.2 Homogenisation of kidney samples 
One of the two kidneys was frozen in liquid nitrogen whilst the other was protected by 
RNAlater (Ambion) in the fridge overnight and then stored at -80ºC, until use for RT-
qPCR. To prepare for endothelin-1 ELISA and CGRP ELISA, the frozen kidney 
samples were homogenized. Appoximately 50mg of kidney was homogenised in 5ml/g 
lysis buffer (10 mM Tris, pH 7.4) using a Qiagen TissueLyser®LT (at 30Hz for 2 mins, 
Qiagen, UK). Following centrifugation (1,600 g for 15 min at 4°C) the supernatants 
were collected and used for peptide extraction. To homogenise the kidney samples for 
noradrenaline ELISA, 50mg of kidney sample was placed in 900μl RIPA buffer (Sigma) 
containing protease inhibitor cocktail (one tablet in 50ml of buffer, Roche diagnostics), 
followed by mixing for two hours on an orbital shaker. Finally, the homogenates were 
centrifuged at 13000rpm for 10 min at 4ºC and the supernatant was collected for 
extraction.  
 
2.8.3 Endothelin-1 & CGRP ELISA 
Peptide extraction from plasma or homogenised tissue supernatant is required before 
measurement using ELISA. This CGRP (rat and mouse) ELISA kit measures both the α 
and β isoforms (Phoenix Pharmaceuticals Inc, USA). The antibody also has 78.6% 
cross-reactivity with rat CGRP II, 0.01% cross-link with rat amylin and 0% link with rat 
calcitonin. The endothelin-1 ELISA was also purchased from Phoenix Pharmaceuticals 
Inc. 
 
The plasma or supernatant was acidified with an equal amount of buffer A (TFA, 1% 
trifluoroacetic acid, Phoenix Europe GmbH, Europe), mixed well and centrifuged at 
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10,000 rpm for 20 min at 4ºC. The SEP-COLUMN containing 200mg of C18 was 
equilibrated by washing with 1ml of buffer B (60% acetonitrile in 1% of TFA, Phoenix 
Europe GmbH, Europe), followed by washing three times with 1ml buffer A. The 
acidified plasma or supernatant was loaded onto the pre-equilibrated C-18 SEP-
Column (Phoenix Europe GmbH, Europe), where it was washed with 3ml of buffer A (3 
times). Eluant was collected following addition of 3ml of buffer B. Eluant was dried 
overnight for 24h in a freeze dryer. 
 
Plasma endothelin 1 and CGRP, and endothelin-1 from kidney homogenates were 
assayed following peptide extraction.  Extracted peptide powders were resuspended in 
250µl of 1xassay buffer (Phoenix Europe GmbH, Europe). Standards were also 
prepared using 1xassay buffer to provide concentrations ranging from 0.04–25ng/ml for 
endothelin-1 and 0.01–100ng/ml for CGRP. The immunoplate is pre-coated with 
secondary antibody and nonspecific binding sites are pre-blocked. The secondary 
antibody can bind to the Fc fragment of primary antibody (CGRP antibody or 
endothelin-1 antibody) whose Fab fragment will be competed for by the biotinylated 
peptide, and then by peptide standard or the targeted peptide in the samples. The 
biotinylated peptide interacts with streptavidin-horseradish peroxidase (SA-HRP) which 
catalyses the substrate solution, producing a yellow colour. The intensity is directly 
proportional to the amount of biotinylated peptide-SA-HRP complex but inversely 
proportional to the amount of the peptide in the standard solutions or samples. The 
reaction was terminated using 100µl/well of 2N HCL and the plate was read in a 
microtiter plate reader (SpectraMAX 190, Meso Scale Discovery, Maryland, USA; used 
with SOFTmaxPRO software, version 3.13 ©1999, Molecular Devices Corporation, 
California, USA) at 450nm.  
 
2.8.4 Noradrenaline ELISA 
Supernatants from kidney homogenates were purified according to the manufacturer‘s 
instructions (IBL international GMBH, Germany). Briefly, 20µl of each standard, positive 
control, negative control or the supernatant samples were pipetted into respective wells 
of the extraction plate (provided with the ELISA kit) which is coated with boronate 
affinity gel. Samples were extracted with the extraction buffer containing an acylation 
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reagent. The release buffer (0.1M HCL and colour indicator) was added and the 
extracted samples were immediately quantified using the ELISA.  
 
The standard concentration ranges from 0ng/ml to 500ng/ml. The wells of the plate 
were coated with a goat anti-rabbit antibody. The added liquid antibody, directed 
towards an epitope of an antigen molecule binds to the plate within the incubation time. 
The antigen of the sample is incubated in the well coated with enzyme conjugated 
second antibody, directed towards a different region of the antigen molecule. After the 
substrate reaction, the intensity of the developed colour is proportional to the amount of 
the antigen. At the end of the experiment, the plate was read in a microtiter plate reader 
(SpectraMAX 190, used with SOFTmaxPRO software, version 3.13 ©1999, Molecular 
Devices Corporation, California, USA) at 405nm. Results of samples were determined 
directly using the standard curve.  
 
2.8.5 Protein assay 
The bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, USA) was used. To 
determine the protein content in cells, 10l of BSA protein standards (0.1-1.2 mg/ml 
BSA in distilled water) were added in duplicate into wells in a 96-well plate and 50l 
/well of 0.5M NaOH added to these. 10l of MilliQ water was added to the 50l of lysed 
cell samples to maintain a consistent volume in all the wells. The ‗blank‘ was measured 
in duplicate where it consisted of 10l of MilliQ water and 50l of 0.5M NaOH. 200μl of 
BCA reagent was added which comprised of reagent A (sodium carbonate, sodium 
bicarbonate BCA detection reagent and sodium tartrate in 0.1N NaOH) and reagent B 
(4% copper sulphate) in a ratio of 50:1, respectively. The plate was covered and 
incubated for 30min (37oC) before the absorbance was read using a plate reader 
(SpectraMAX 190, used with SOFTmaxPRO software, version 3.13 ©1999, Molecular 
Devices Corporation, California) at 562nm. Protein assay did not carried out for the 
ELISA experiment in chapter 4. 
 
To determine the protein content of tissue homogenates or plasma, 10μl of standards 
(0.1-2mg/ml) or homogenate/plasma samples were added into their respective wells. 
200μl of BCA reagent was added to each well which consisted of reagent A (sodium 
carbonate, sodium bicarbonate BCA detection reagent and sodium tartrate in 0.1N 
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NaOH) and B (4% copper sulphate) in a ratio of 50:1, respectively. The plate was 
covered and incubated for 30min (37oC) and read at 562nm.  
 
 
2.8.6 Smooth muscle cell culture 
Primary culture of vascular smooth muscle cells (VSMCs) was obtained from mouse 
aorta explants of WT and RAMP2 TG mice. Mouse aorta was quickly collected under 
isoflurane anaesthesia (2.5%, Abbott Laboratories, UK, in 3L/minute O2) and was 
stored in ice-cold sterilized-PBS. In a cell culture hood, the aorta was opened 
longitudinally, cut into 2-mm cubes and placed on the surface of a 25-cm2 culture flask 
(BD Biosciences). The whole procedure was carried out under sterile conditions. Tissue 
was incubated in high glucose Dulbecco‘s modified Eagle‘s medium (DMEM; Sigma) 
containing 20% foetal calf serum (FCS; Sigma) and 1% of (100 U penicillin / 0.1 mg/ml 
streptomycin) in a 37⁰C, 5% CO2 incubator. The flask was placed upright for two hours 
then was laid down slowly to make sure that the medium was covering all the tissue 
cubes. When the VSMCs started growing and reached 80% of a confluent monolayer in 
the flask, they were sub-cultured into a 75-cm flask The VSMC were cultured to third 
passage before experiments. 
 
To study the proliferation, the VSMCs were trypsinised and placed into 24-well plates at 
a density of 104 cells/well. The cells were kept undisturbed for 24h and the baseline 
was obtained before addition of drugs by cell counting. Cell counts were performed 
using haemocytometer. The cells were treated with PBS as control, ATII (10-7 M) or 
ATII (10-7 M) with or without AM22-52 (10
-7 M) in DMEM containing 5% FCS for 24, 48 or 
72 hours. Cells were trypsinised and cell counts performed for each treatment group.  
 
2.8.7 Tissue processing for histology 
Aortic tssues, mesenteric tissues or adipose tissue were fixed in 10% 
paraformaldehyde (Sigma) for 24 hours to prevent autolysis and necrosis, and to 
preserve the antigenicity of the tissue. Tissues were processed overnight using a 
Tissue-Tek VIP Vacuum Infiltration processor (Sakura Tissue Tek VIP 1000), 
dehydrated using graded alcohol, cleared with xylene (100%) and then infiltrated the 
tissue with paraffin. Aortic tissue (standing longitudinally upright) and mesenteric tissue 
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were put into a mould and was embedded with paraffin. It was then set onto a cold 
panel until the blocks were removed from the mould, approximately 10-15 min later. 
Paraffin blocks were then stored at room temperature until further use. To prepare 
slides for staining, 4 μm thick transverse sections were cut from the paraffin blocks 
using a microtome (Reichert-Jung 2030 Biocut microtome). APE (3-
aminopropyletriethoxysilane) -coated slides were mounted with four 4 μm thick sections. 
The mounted slides were then dried for a minimum of 18h. Slides were stained for 
haematoxylin and eosin (H&E) and Masson‘s trichrome. 
 
2.8.8 Haematoxylin and eosin (H & E) staining 
The H&E stain: This standard stain uses two separate dyes, hematoxylin (dark purple) 
staining the nucleus and eosin (orange-pink) staining the cytoplasm and connective 
tissue. The slices were taken through changes of xylene, alcohol and distilled water to 
de-paraffinize and re-hydrate sections (table 2.5). The slices were then stained with 
hematoxylin and rinsed, then placed in water and differentiated in acid alcohol (0.5%, 
HCL in 70% ethanol), and then placed in the eosin (1% eosin in ethanol). After 
haematoxylin and eosin staining, slices were dehydrated with alcohol, cleared in xylene 
and finally covered with a cover-slip using DPX as mounting media, then dried 
overnight in a fume hood.  
 
Deparaffinize & rehydrate    Hematoxylin stain    Eosin stain 
 






 Eosin 3 mins 
Xylene 2 2 mins  Rinse   Ethanol 1 2 mins 
Ethanol 1 2 mins  Tap water 1 2 mins  Ethanol 2 2 mins 
Ethanol 2 2 mins  Tap water 2 2 mins  Ethanol 3 2 mins 
Ethanol 3 2 mins  Acid ethanol 10 fast 
dips 
 Xylene 1 2 mins 
Ethanol 4 2 mins  Tap water 3 2 mins  Xylene 2 2 mins 
Distill water 2 mins  Blot excess water    
Blot excess water       
 Table 2.5: Procedures of H&E stain 
 
The sections were analysed for aortic wall width, aortic wall area, aortic minimum wall 
width, arteriolar diameter and arteriolar wall width. To quantify the aortic wall thickness, 
radial lines were drawn to determine the distance from internal to external elastic 
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lamina at 8 sites which were chosen to be 45° apart around the circumference of each 
aortic section and a mean value and a minimum wall width were obtained (three aortic 
sections per mouse). To determine the aortic cross-sectional wall area, the perimeters 
of the internal and external elastic laminas were traced of each section. The area inside 
each respective perimeter was determined and the difference between these two areas 
was defined as the aortic wall area (mean of six aortic sections per mouse). To assess 
the arteriolar diameter from mesenteric tissue, the perimeter of each vessel was traced 
and the diameter was determined (average of 9 measurements per mouse). To quantify 
the arteriolar wall width from mesenteric tissue, radial lines were drawn to determine 
the distance from internal to external elastic lamina at 4 symmetrical sites and a mean 
value was obtained (average of 9 measurements per mouse). To measure the size of 
the adipocytes, after H&E staining, 3 pictures were randomly taken from each mouse. 
Three different people randomly measured 100 cells from each slide (different people 
started from different corner of each picture). The mean of the measurements from 
these three people are presented in this thesis.    
 
2.8.9 Masson‘s trichrome staining  
In order to further differentiate between collagen and smooth muscle, Masson‘s 
trichrome staining was used. Masson‘s Trichrome stain uses three dyes selectively: 
haematoxylin stains the nucleus, beibrich scarlet (Sigma) stains the cytoplasm and 
muscle and aniline blue stains collagen/fibrin. After the sections were de-paraffinised in 
xylene and re-hydrated in alcohol, sections were placed in Bouin‘s solution (a 
compound fixative, Sigma) at 65ºC to intensify the final coloration of the tissue, and 
then washed in running tap water and rinsed in distilled water (table 2.6). After that, 
sections were stained with haematoxylin (Sigma) and rinsed, then placed in Phospho 
solution (phosphomolybdic/phosphotungstic acid solution; volume ratio: 
phosphomolybdic: phosphotungstic: distilled water = 1:1:2, Sigma), followed by aniline 
blue staining and rinsed in distilled water. The sections were then placed in 1% acetic 
acid and dehydrated in ethanol (VWR BDH Prolab International Ltd) and cleared in 
xylene (VWR BDH Prolab International Ltd). Slides were covered with a coverslip using 









Deparaffinize & rehydrate     Masson trichrom stain  
Xylene 1 10 mins   Bouins solution  15 mins 
Xylene 2 2 mins   cool and wash out the yellow color in water 
Ethanol 1 2 mins  Hematoxylin  5 mins 
Ethanol 2 2 mins  wash in the water for 5 mins and rinse in 
distill water Ethanol 3 2 mins  Biebrich scarlet  5 mins 
Ethanol 4 2 mins  Rinse in distill water 
Distill water  2 mins  Phospho solution 5 mins 
Blot excess water  Aniline blue 5 mins 
   Ethanol acid 2 mins 
   Ethanol 5 mins 
   Xylene 5 mins 
Table 2.6: Procedures of Masson Trichrome stain 
 
With the Masson‘s trichrome stain, the medial thickness and perivascular fibrosis 
thickness were measured. To assess the medial thickness and the perivascular fibrosis 
thickness, the perimeters of lumen, the boundary between media and fibrosis (between 
the red and blue) and the vessel were traced. The diameter of every respective 
perimeter was obtained and the different distance between the lumen and the media 
was reported as the medial thickness while the difference between the media and the 
fibrosis was defined as the perivascular fibrosis thickness (average of six 
measurements per mouse). 
 
2.8.10 Immunohistochemistry 
The principle of immunohistochemical staining uses a primary antibody raised against 
the antigen of the protein being investigated, and a biotinylated second labeled 
antibody raised against the primary antibody. The biotinylated secondary antibody is 
coupled with steptavidin horseradish peroxidase, which reacts with 3, 3‘ 





The presence of vascular cell adhesion molecule-1 (VCAM-1) and monocyte 
chemotactic protein-1 (MCP-1) was examined by immunohistochemistry in thoracic 
aorta. For VCAM-1 staining, isolated aortic samples were immersed in OCT compound 
(Cryo-M-Bed, Bright, UK) snapped frozen in liquid nitrogen and stored at -80ºC until 
further analysis. A cryostat cut frozen aortic cross 10 µm sections where they were 
fixed in acetone for 10 min before staining or storage at -20ºC. On the staining day, 
slides were warmed and dried at room temperature before applying blocking serum 
(3% of goat serum, from the same species in which the secondary antibody is made, 
Dako, UK) followed by incubation with a rabbit anti-human VCAM-1 antibody at room 
temperature for one hour (1:50 dilution; sc-8304, Santa Cruz Biotechnology, USA) and 
visualised with Envision plus System-HRP (DAB; Dako Cytomatic, Denmark). A 
negative control was also used in all the staining procedures to verify the specificity of 
the labeling of the target antigen by the primary antibody. The absence of specific 
staining in the negative control tissue confirmed the lack of antibody cross-reactivity to 
the cells/cellular components. Staining was stopped by immersing the slides in running 
tap water for 5 minutes. In order to counterstain the sections, slides were immersed in 
haematoxylin (Sigma) for 1 minute followed by washing in running tap water for a 
further 5 minutes. Slides were then rehydrated through a series of ethanol and xylene 
washes before mounted with pertex xylene based mountant (Sigma). Slides were 
covered with a coverslip.  
 
For MCP-1 expression, paraffin aortic sections (5µm) were cut and dried before 
staining. Antigen unmasking was achieved by incubating the slides in Tris-EDTA 
(pH7.5) and microwaving for 5 min at 500W. Slides were allowed to cool down after 
which they were immunostained with goat anti-MCP-1 antibody (1:50, sc-1785, Santa 
Cruz Biotechnology, USA). The MCP-1 staining was amplified using the VECTASTAIN 
Elite ABC kit (pk-6105, Vector Laboratories) and visualised by DAB staining. Then 
slides were counterstained and dehydrated as above.  
 
The percentage of the overall area of brown stained sites representing VCAM-1 or 
MCP-1 compared to the total area of the field of vision was quantified by Image Pro 
Plus software or Cell^P Olympus software. The mean area percentages were 
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calculated for each section by measuring three sites.  This was done on two tothree 
sections from each group. 
 
 
2.8.11 Myography  
First-order mesenteric artery branches (approximately 100-200μm diameter) were 
isolated in a modified ice cold Krebs‘-Henseleit (118mM NaCl, 24mM NaHCO3, 1mM 
MgSO4, 4mM KCl, 0.5mM NaH2PO4, 5.5mM glucose, and 2.5mM CaCl2, all salts from 
Sigma, UK). They were cleaned of fatty tissue, mounted and normalized to normal 
peripheral arterial tension (13.3kPa) on a wire myograph (DMT 610M or 620, Danish 
Myo Technology, Denmark) using 25µm tungsten wire. Vessels were maintained 
throughout the experiment in 37°C Krebs‘ solution gassed with air/5% CO2. The 
maximum contraction was assessed using 2 minute incubations in ‗high (80mM) K‘ 
solution (38mM NaCl, 24mM NaHCO3, 1mM MgSO4, 80mM KCl, 0.5mM NaH2PO4, 
5.5mM glucose, and 2.5mM CaCl2). Endothelial function was assessed using carbachol 
(10µM diluted in water, Sigma, UK), where a relaxation of >60% over 2 minutes was 
regarded as an endothelial-intact tissue. For contraction studies, tissues were 
contracted with accumulative doses of phenlyephrine (10nM, Sigma, UK) For relaxation 
studies, tissues were sub-maximally pre-constricted with phenylephrine then given 
accumulative concentrations of CGRP (cambridge bioscience, UK) and carbachol 
with % relaxation at 3 minute intervals were determined. Time and vehicle controls 
were collected for all vessels to ensure comparative functioning. Results from multiple 
vessels per mouse were averaged to produce each n. The pEC50 was calculated for 
each mouse using curve fitting software (GraphPad Prism 5).  
 
2.8.12 Real-Time Quantative Polymerase Chain Reaction (RT-PCR) 
RT-qPCR is a technique to quantitatively detect gene expression through creation of 
cDNA transcripts from mRNA. Total RNA was extracted from approximately 30mg of 
aorta samples (collected immediately after termination and stored in RNAlater (Ambion)) 
using a commercial kit, where tissue was disrupted by the phenol-based reagent 
QIAzol (Qiagen RNeasy Microarray tissue mini Kit, Qiagen, USA) and mechanically 
lysed (Qiagen‘s TissueLyser LT). The homogenate was then treated with chloroform 
(Sigma) before being centrifuged, purified and eluted using a spin column based 
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procedure. RNA quality was then assessed using a Nanodrop Spectrophotometer 
which provides a ratio of A260/A280 indicating whether there is any ethanol and phenol 
contamination; a ratio between 1.8 and 2.2 was considered as good purity. 500ng of 
extracted RNA was used for the reverse transcription to create cDNA. This was 
performed using the high capacity RNA to cDNA, reverse transcription enzyme kit with 
RNAase inhibitor (Applied Biosciences) on a thermal cycler (Applied Biosystems) set to 
temperatures recommended in the manufacturer‘s instructions. 
 
To perform the RT-qPCR, stock cDNA was diluted 1:5 in RNAse/DNAse free water 
(Fisher, UK). PCR was conducted in 10μl reactions using SYBR-green based PCR mix 
(Sensi-Mix, SYBR-green No ROX, Bioline), together with 1μl cDNA, 0.4μl of each 
primer (10μM) and 3.6μl RNAse/DNAse free water. This was added to 100 well gene 
discs (Qiagen) by an automated robot (CAS1200, Corbett Robotics). Discs underwent 
PCR (hold: 10 minute at 95oC; cycling: 45 cycles: 10s at 95oC, 15s at 57oC and 5s at 
72oC; melt: 68-90oC) in a Corbett Rotorgene 6000. Data was collected as copies/μl and 
standardised against B2M and HPRT1 expression using a normalisation factor 




















Table 2.7: primers of each gene and amplicon size (base pairs) used for Q-PCR. 
 
2. 9 Data interpretation and statistical analysis 
Results are shown as mean ± standard error of the mean (SEM) except for histology 
(as mentioned in the section 2.8.8).  Statistical analysis was undertaken with one way 
and two way ANOVA + Bonferroni‘s post-hoc t test, the unpaired Student t test of mean 
area under curve as appropriate, using Graph Pad Prism version 5.02 (Graph Pad 
Software, USA). A significant difference from the null hypothesis was accepted when 











Gene Forward Primer Reverse primer Amplicon 
Size 
CGRP AGCAGGAGGAAGAGCAGGA CAGATTCCCACACCGCTTAG 71 
TRPV1 CAACAAGAAGGGGCTTACACC TCTGGAGAATGTAGGCCAAGAC 77 
SOD CTGGACAAACCTGAGCCCTA GATAGCCTCCAGCAACTCTCC 61 
HO-1 GGTCAGGTGTCCAGAGAAGG CTTCCAGGGCCGTGTAGATA 70 
eNOS GACCCTCACCGCTACAACAT GTCCTGGTGTCCAGATCCAT 62 
ET-1 GTGTCTACTTCTGCCACCTGGACAT GGGCTCGCACTATATAAGGGATGAC 474 
VCAM-1 TGGTGAAATGGAATCTGAACC CCCAGATGGTGGTTTCCTT 86 
Nox 2 TGCCAACTTCCTCAGCTACA GTGCACAGCAAAGTGTTGG 73 
HPRT1 TCCTCCTCAGACCGCTTTT CCTGGTTCATCATCGCTAATC 90 
B2M CCTGCAGAGTTAAGCATGCC GATGCTTGATCACATGTCTCG 74 
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CHAPTER 3: THE PROTECTIVE ROLE OF SMOOTH-MUSCLE TARGETED RAMP2 
TG MICE IN ATII INFUSION MODEL. 
 
3.1 Introduction 
As discussed in the introduction, AM is a member of the CGRP family of peptides 
(Brain et al., 2004). AM is a potent vasodilator peptide which is expressed in 
cardiovascular tissue, including vascular wall and heart (see general introduction for 
details). Levels are elevated in patients with different cardiovascular conditions 
(Ishimitsu et al., 1994, Kato et al., 1996, Suzuki et al., 2004 and Oyar et al., 2011). 
Therefore, it is believed to be a predictor of future cardiovascular events (Nishida et al., 
2008). Despite this, studies in AM transgenic and heterozygous knockout (partially 
knocking out 50% of the AM gene, in this chapter, AM KO mice refer to this 
heterozygous knockout mice unless stated) mice have demonstrated a protective role 
of AM (Kato et al; 2005, Bell et al., 2010). Thus increased attention has been focused 
on AM and its importance in cardiovascular events. However, little is known about the 
involvement of its receptor components. 
 
AM acts via a unique family of GPCRs, composed of CLR and RAMP1, RAMP2 or 
RAMP3. Heterodimerization of the CLR with RAMP1, RAMP2 and RAMP3 produces 
CGRP, AM1 or AM2 receptors, respectively (McLatchie et al., 1998). AM can act on 
CGRP, AM1 and AM2 receptors, whilst CGRP primarily activates the CGRP receptor. 
However, CLR together with RAMP2 forms the functional receptor AM1, which is 
primary target of AM and can be antagonised by the AM peptide fragment AM22-52.  It 
should be noted that the AM-related peptide intermedin also is an agonist at all the 
receptors complexes. Receptors for CGRP and AM are widely distributed but the 
RAMP2 is expressed to a greater degree than RAMP1, producing functional AM1 
receptors (Hay et al., 2006). Indeed RAMP2 is found to be expressed in most tissue 
types, such as rat lung, liver, spleen by northern blot analysis, and also be expressed in 
human aortic smooth cells, human aortic endothelial cells determined by qPCR (Hay et 
al., 2006). RAMP2 expression has been studied not only in healthy individuals, but also 
in patients with a range of cardiovascular conditions. For instance, increased gene 
expression of RAMP2 is reported in left ventricular hypertrophy and even to a higher 
level in heart failure (Nishikimi et al., 2003). Therefore, the levels of RAMP2 expression, 
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as a consequence of functional AM1 receptor may be related to the development and 
progression of some cardiovascular diseases. However receptor activities and 
signalling are different depending on the vascular cell type and beds (Brain and Grant, 
2004). As a consequence, little is known regarding the cardiovascular relevance of the 
functional AM1 receptors in vivo.  
 
Previously in our group, we have developed and investigated smooth muscle cell 
specific, overexpressing RAMP2 TG mice (Tam et al., 2006). It was the first time, to our 
knowledge, the AM1 receptor rather than the peptide itself, has been targeted for in 
vivo study. In our previous findings, the RAMP2 TG mice showed similar profiles in 
baseline blood pressure and heart rate, recorded by tail cuff in conscious mice or by 
carotid artery cannulation of anaesthetised mice. Interestingly the RAMP2 TG mice 
showed increased sensitivity to AM and subsequently an increase in functional AM1 
receptor was shown, as i.v. administration of AM induced a greater hypotensive 
response in RAMP2 TG mice. Furthermore studies with isolated aortic vessels and 
mesenteric microvessels showed increased responses to AM in RAMP2 TG compared 
with WT tissue, while both RAMP2 TG and WT mice displayed similar responses to 
CGRP. The combined in vivo and in vitro data indicates the potentially important role of 
RAMP2 in the sensitivity of AM-induced hypotensive responses via the selective up-
regulation of the functional AM1 receptor. This implies that the potency of the anti-















3.2 Hypothesis and aims 
 
3.2.1 Hypothesis  
RAMP2 TG mice will be protected against hypertension and vascular hypertrophy 
induced by ATII. 
 
3.2.2 Aims 
The aims of this chapter were:  
 Investigate WT and RAMP2 TG mice in the ATII-induced hypertensive model 
 To measure blood pressure by tail cuff plethysmography 
 To measure vascular hypertrophy in the aorta by histology 
 To investigate vascular inflammation by immunohistochemistry 
























3.3.1 Effect of ATII on body weight, blood pressure and cardiac hypertrophy in WT and 
RAMP2 TG mice 
 
Both WT and RAMP2 TG mice (25-35 g, 12-16 weeks old, matched for age and sex) 
were treated with ATII (0.9mg/kg/day) or vehicle (0.01% 10mM acetic acid in saline) for 
13 days by mini-pump infusion. Body weight was monitored on day 0, 3, 6, 9 and 13.  
Figure 3.1 shows that the body weight remains stable for both WT and RAMP2 TG 
mice throughout the entire period (n=9-12).  
 
Figure 3.2 demonstrates blood pressure measured by tail cuff plethysmography before 
surgery (taken as baseline) and day 3, 6, 9 & 13 post-hoc mini-pump implantation. Fig 
3.2a indicates both WT and TG have similar systolic blood pressure when they were 
treated with vehicle. However ATII (0.9mg/kg/day) increased the systolic blood 
pressure in a similar manner in both WT and RAMP2 TG mice, and became 
significantly different on day 13 when compared to vehicle-treated mice. Fig 3.2b 
demonstrates diastolic blood pressure and exhibited the same trend as systolic blood 
pressure. Basal blood pressure did not differ between WT (117.8±3.2mmHg) and 
RAMP2 TG mice (119.7±4.2mmHg; n=8-16), as previously reported. Again, ATII (0.9 
mg/kg/day) increased mean arterial blood pressure over 13 days in both WT and 
RAMP2 TG mice (Fig 3.2c).  
 
Fig 3.3 displays that ATII (0.9mg/kg/day for 13 days) also induced significant and 
similar left cardiac and ventricular hypertrophy in both WT and RAMP2 TG mice when 































Figure 3.1.  The body weight of WT and RAMP2 TG mice over the 13 days implantation peroid. 












Figure 3.2. Effect of ATII (0.9 mg/kg/day for 13 days) on blood pressure in WT and RAMP2 
TG mice. A. Systolic blood pressure, B. Diastolic blood pressure and C. Mean arterial pressure 
measured in conscious mice by tail cuff plethysmography, n=8-16.  Data are presented as mean 
± SEM. * p<0.05 WT and TG mice after ATII treatment compared to their vehicle-treated mice 













































































































































































Figure 3.3. Effect of ATII (0.9 mg/kg/day for 13 days) on cardiac hypertrophy in WT and 
RAMP2 TG mice. (A) Heart to body weight (BW) ratio, (B) Mouse left ventricle (LV) to body 
weight (BW) ratio, n=10-12. Data are presented as mean ± SEM. * p<0.05 and *** p<0.001 
when WT and TG mice after ATII treatment were compared to their vehicle-treated mice 
























3.3.2 Effect of ATII on vascular hypertrophy in WT and RAMP2 TG mice 
 
Aortic sections were collected from both WT and RAMP2 TG mice after 13 days 
infusion either with ATII (0.9mg/kg/day) or vehicle (0.01% of 10mM acetic acid in 
saline). Aorta tissues were then processed into paraffin blocks. 5m of aortic sections 
were used for haemotoxylin and eosin (H&E) staining and Masson‘s Trichrome staining. 
Vascular hypertrophy was determined by histological assessment using both staining 
methods.  
 
Fig 3.4 displays representative H&E staining images of aortic wall at 20X and 100X 
magnification. In the images, haematoxylin stains the nuclei as blue while the eosin Y 
stains the other components as pink/red. Although, both WT and RAMP2 TG mice 
demonstrated similar hypertension when compared to the vehicle-treated mice, the WT 
ATII-treated mice did show an increase in aortic wall width when compared to WT 
vehicle-treated mice. Such differences were not seen between ATII-treated and 
vehicle-treated RAMP2 TG mice.  Indeed, Fig 3.5a and 3.5b indicate that ATII caused 
hypertrophy of the aorta in WT mice, this was not observed in RAMP2 TG mice. 
Analysis of H&E-stained cross-sections revealed a significant increase in thickness of 
aortic wall of ATII-treated WT mice as compared to the vehicle-treated WT mice; such a 
difference was not seen in the RAMP2 TG mice. Furthermore, ATII also induced a 1.5-
fold increase in aortic wall area when compared to the vehicle-treated WT mice (p<0.01; 
n=8-9 sections from 3 mice in each case); again ATII-treated RAMP2 TG mice 
displayed no significant difference from vehicle-treated RAMP2 TG mice regarding the 
aortic wall area.  
 
Fig 3.6 demonstrates the representative images for Masson‘s trichrome staining with 
aortic wall at 20X and 100X magnification. Masson‘s trichrome staining is a three-colour 
staining protocol to reveal the muscle fibers as red (cytoplasm as light red or pink), the 
collagen/fibrin and bone as blue, and cell nuclei as purple. With Masson‘s Trichome 
staining, it displays more convincingly that the smooth muscle layer in the ATII-treated 
WT mice is much thicker than the vehicle-treated WT mice. Such a difference is not 
seen between ATII-treated RAMP2 TG mice and vehicle-treated RAMP2 TG mice. Fig 
3.7 indicates the ATII caused no significant difference in fibrosis/collagen thickness 
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between different treatment groups (Fig 3.7a). However, significant differences were 
observed in medial thickness between the ATII-treated WT and vehicle-treated WT 
mice, between ATII-treated WT mice with ATII-treated RAMP2 TG mice (Fig. 3.7b). 
Furthermore, significant increases were also obtained in aortic wall area when 
comparing ATII-treated WT with vehicle-treated WT mice, and comparing ATII-treated 
WT mice with ATII-treated RAMP2 TG mice (Fig 3.7c). 
 
Due to such a significant differences being detected with the aortic tissue, it was of 
interest to investigate if there was an effect in much smaller vessels, such as 
mesenteric arteries. Therefore, mesenteric tissues were stained with H&E and 
analysed as above. Fig 3.8 demonstrates that ATII caused no significant difference in 
mesenteric arteriolar vessels between ATII-treated and vehicle-treated mice for both 
















Figure 3.4: Effect of ATII (0.9 mg/kg/day for 13 days) compared with vehicle (0.01% 10 mM 
acetic acid in saline) on vascular hypertrophy in WT and RAMP2 TG mice.  Representative 










































Figure 3.5: Effect of ATII (0.9 mg/kg/day for 13 days) compared with vehicle (0.01% 10 mM 
acetic acid in saline) on vascular hypertrophy in WT and RAMP2 TG mice. (A) aortic wall 
width (n=7-9 sections from 3 mice in each case) and (B) aortic wall area (n=7-9 sections from 3 
mice in each case). Data are presented as mean ± SEM. *p<0.05 and **p<0.01 when WT ATII-


























































Figure 3. 6: Effect of ATII (0.9 mg/kg/day for 13 days) compared with vehicle (0.01% 10 mM 
acetic acid in saline) on vascular hypertrophy in WT and RAMP2 TG mice. Representative 
Masson’s Trichrome staining of thoracic aorta wall at 20x and 100x magnification as indicated. 
Dark pink shows the staining of muscle, the blue shows collagen fibers & fibrin, while the 

















































Figure 3.7: Effect of ATII (0.9 mg/kg/day for 13 days) compared with vehicle (0.01% 10 mM 
acetic acid in saline) on vascular hypertrophy in WT and RAMP2 TG mice. (A) Thickness of 
collagen, (B) medial thickness in the aortic wall right; and (C) aortic wall area. n=8-9 sections 
from 3 mice in each case. Data are presented as mean ± SEM. ** p<0.01 when the RAMP2 TG 
ATII-treated mice were compared with the WT ATII-treated mice. ***p<0.001 when WT ATII-
treated mice were compared with the WT vehicle-treated mice. Statistics by two-way ANOVA 
with Bonferroni post-hoc-tests 
 
 



























































































Figure 3.8: Effect of ATII (0.9 mg/kg/day for 13 days) compared with vehicle (0.01% 10 mM 
acetic acid in saline) on mesenteric arteriolar wall width (A) and arteriolar diameter (B). The 
whole mesenteric tissue was embedded into a paraffin block and cross sections of the whole 
block were collected. Therefore the mesenteric arteriole can be from any order. Data are 
























































































3.3.3 Effect of ATII on vascular inflammation in WT and RAMP2 TG mice 
 
To examine the expression of vascular inflammatory markers on the aortic wall, 
immunohistochemical staining of VCAM-1 and MCP-1 was performed. 
  
For VCAM-1 staining, fresh isolated aortic sections (10µm) were stained with rabbit 
anti-human VCAM-1 antibody (1:50) and positive staining was visible as brown. Fig 
3.9a reveals the representative images for VCAM-1 staining by immunohistochemistry 
on aortic wall at 20x and 650x magnification.  A negative control was carried out using 
the same staining protocol but with no primary antibody incubation. The pictures were 
taken at 20x magnification.  Staining was quantified by comparing the area of the brown 
staining to the area of the whole aortic area. As indicated in Fig 3.9b, ATII significantly 
(p<0.001) increased the VCAM-1 expression on the aorta in the WT mice when 
compared to the vehicle-treated WT mice. It was also significantly increased in the WT 
mice after ATII treatment when compared with the RAMP2 TG.  
 
For MCP-1 expression, paraffin aortic sections (5µm) were immunostained with goat 
anti-MCP-1 antibody (1:50) and positive staining was also shown as brown. Fig 3.10a 
reveals the representative images for MCP-1 staining by immunohistochemistry of the 
aortic wall at 100X and 400X magnification. The negative control (same method as 
VCAM-1 negative control, where aortic sections were stained as others but without 
incubating with primary antibody) was also displayed at 100x magnification. As in the 
image of the aortic section from ATII-treated WT mice, the red arrow shows the positive 
staining on the endothelial cells. Following the assessment of the quantification showed 
in Fig 3.10b, ATII significantly (p<0.001) increased the MCP-1 expression on the aorta 
in the WT mice when compared to the vehicle-treated WT mice. In contrast, no 
difference is seen in the RAMP2 TG mice between ATII and vehicle treatment. Thus, a 
significant difference is observed when the WT mice were compared with the RAMP2 


































































Figure 3.9: Effect of ATII (0.9 mg/kg/day for 13 
days) on the vascular inflammatory marker VCAM-
1 expression in aortic wall in WT and RAMP2 TG 
mice. (A) Representative immunohistochemical 
staining at 20x and 650x, and negative control (B) 
Percentage area of VCAM-1 (n=3-6) expression 
compared with total area of the aorta. Data are 
presented as mean ± SEM. *** p<0.001 WT ATII-
treated mice were compared with WT vehicle-
treated mice. ### p<0.001 WT ATII-treated mice 
were compared with TG ATII-treated mice.  






















Figure 3.10: Effect of ATII (0.9 mg/kg/day for 13 
days) on MCP-1 expression in aortic wall (red 
arrow: positive MCP staining on the endothelial 
cell) in WT and RAMP2 TG mice. (A) 
Representative staining at 100x and 400x, and 
negative control (c). (B) Percentage area of MCP-1 
(n=8-9 section from 3 mice for each group) 
expression to total area of the aorta. Data are 
presented as mean ± SEM. *** p<0.001 WT ATII-
treated mice were compared with WT vehicle-
treated mice. ### p<0.001 compared WT ATII-
treated with TG ATII-treated mice.  Statistics by 
























































3.3.4 Effect of ATII and AM22-52 on WT and RAMP2 TG vascular smooth muscle cells  
To determine the effect of RAMP2 overexpression on cell proliferation, studies were 
carried out in cultured VSMCs from aortic explants in both WT and RAMP2 TG mice. 
Using the explant technique, VSMCs were cultured upto the third passage before the 
cells were used for experiments. Cell proliferation was assessed by cell counting using 
the haemocytometer after trypsinisation and placed into 24-well plates at a density of 
104 cells/well for 1 to 3 days. Fig 3.11 reveals that the VSMC from RAMP2 TG mice 
grew significantly slower than WT cells from as early as day 1.  
 
Then to investigate the effect of ATII on the VSMCs from WT and RAMP2 TG mice, 
VSMCs were stimulated with ATII (10-7 mol/L) for 1 to 3 days For this procedure, the 
cells were kept undisturbed for 24 hours prior to treatment Furthermore, the possible 
involvement of endogenous AM in VSMC growth was investigated using the AM1 
receptor antagonist AM22-52 (10
-7 mol/L). As indicated in Fig 3.12, ATII induced 
significant increases in the cell number in WT (Fig. 3.12a) as early as 24h, but not in 
TG cells (Fig 3.12b). Interestingly, the antagonist AM22-52 was found to significantly 
enhance the growth of RAMP2 TG cells in the presence of ATII, as shown in Fig 3.12b. 
But such enhancement induced by AM22-52 was not observed with WT cells (Fig 3.12a). 
Results are also depicted as a ratio of proliferation induced by ATII + AT22-52 alone, to 
that with ATII alone (Fig 3.12c). 
 
Initially, it was considered that protein content would match the cell proliferation results. 
Therefore we carried out the protein assay on day three of ATII treatment after 
determination of the cell numbers. Protein content together with cell number in both WT 
and RAMP2 TG mice (Fig 3.14) were determined after 3 days of treatment with ATII 
(10-7 mol/L). Fig 3.14a indicates that ATII significantly increases cell proliferation in WT 
cells when compared to vehicle-treated cells. But such a difference was not seen with 
RAMP2 TG cells. However, the protein content in ATII-treated WT cells is increased but 




Figure  3.11: Growth of VSMC of WT and TG mice in DMEM supplemented with 5% FCS. 
Each point presents the mean of three separate experiments run in triplicate on three separate 
cultures. Data are presented as mean ± SEM. *p<0.05 compared to the RAMP2 TG mice at the 












































































Figure 3.12: Effect of ATII in the present or absence of AM22-52 compared with PBS on the 
growth of VSMC cultured from WT and TG mice. Cell numbers were determined at 24, 48 and 
72 hours. (A) WT VSMC were treated with PBS or ATII (10-7 mol/L) ± AM22-52 (10-7 mol/L); 
(B) TG VSMC were treated with PBS or ATII (10-7 mol/L) ± AM22-52 (10-7 mol/L); (C) Ratio 
of proliferation induced by ATII + AM22-52 compared to ATII. Each point presents the mean of 
three separate experiments run in triplicate on three separate cultures. Data are presented as 
mean ± SEM.  In Fig A **p<0.05 and *** p<0.001 WT veh cells were compared with WT 
ATII-treated cells. In Fig B, *** p<0.001 TG ATII cells were compared with TG ATII + AM22-
52 cells. In Fig C, *p<0.05 VSMC from WT mcie  were compared with those from TG mice. 









































































































































Figure 3.13: Effect of ATII on the growth of VSMC cultured from WT and TG mice. Cell 
numbers were determined at 72 hours post-hoc treatment. (A) total cell number and (B) Protein 
content after treatment either with ATII or PBS for 72 hours. Each point presents the mean of 
three separate experiments run in triplicate on three separate cultures. Data are presented as 
mean ± SEM. **p<0.01 when compared WT ATII with WT veh, ## p<0.01 when compared WT 









































































































































3.4 Summary  
 
 ATII (0.9mg/kg/day) caused no change in body weight in either WT or RAMP2 
TG mice.  
 
 Tail cuff plesythmography indicated that both WT and RAMP2 TG mice showed 
similar basal blood pressure and increase in BP following ATII treatment. 
 
 13 days ATII infusion produced cardiac hypertrophy in both WT and RAMP2 TG 
mice when compared to the vehicle-treated mice.   
 
 WT ATII-treated mice demonstrated vascular hypertrophy when compared to 
their vehicle-treated mice. However the RAMP2 TG mice were protected against the 
vascular hypertrophy. 
 
 Mesenteric arterioles were investigated for evidence of vascular hypertrophy but 
no significant difference was found between ATII- or vehicle-treated groups. 
 
 Consistent with the vascular hypertrophy, following ATII treatment WT mice had 
increased expression of inflammatory markers (VCAM-1 and MCP-1) on aortic tissue 
when either compared to the vehicle-treated mice or compared with the ATII-treated 
RAMP2 TG mice.  
 
 Primary VSMCs were prepared from WT and RAMP2 TG mice for cell 
proliferation study. We have demonstrated that VSMCs from RAMP2 TG mice 
proliferated slower compared to WT VSMCs in the presence or absence of ATII. 
Furthermore, the AM1 receptor antagonist AM22-52 was able to induce cell proliferation 
significantly in RAMP2 TG cells after ATII treatment, but such an effect was not seen in 









3.5.1 Use of RAMP2 TG mice and effect on blood pressure and vascular 
remodelling 
In this study, we have used smooth muscle cell-targeted RAMP2 overexpressing mice 
in order to investigate of the consequence of the increased function of the AM1 
receptor levels in tissue rich in vascular smooth muscle cells (Tam et al., 2006). To our 
knowledge, it is the first time that these mice have been used to investigate the role of 
the AM1 receptor in a model of hypertension and hypertrophy induced by ATII. In the 
present study, despite up-regulated RAMP2 level in smooth muscle cells, RAMP2 TG 
mice showed no significant difference in raised blood pressure and cardiac hypertrophy 
after 13 days infusion of ATII (0.9mg/kg/day). Our results were supported by those of 
Caron et al. (2007), who generated genetically controlled transgenic mice with levels of 
AM mRNA ranging from 50% (one copy of AM gene) -140% (4 copies of AM gene) 
compared to the WT. They demonstrated that those genetically controlled mice showed 
no difference in the basal blood pressure measured by tail cuff plesythmography. This 
also agreed with a previous study carried out in our group using the RAMP2 TG mice 
(Tam et al., 2006). Moreover, Caron and co-workers determined the affect of the down-
regulation of AM level in models of hypotension from pregnancy or septic shock. They 
revealed that genetic reduction of AM in mice had no affect on the early hypotension 
observed during induced septic shock (Caron et al., 2007). This also agreed with 
previous studies from our laboratory that investigated the possibility that RAMP2 is 
involved in LPS-induced endotoxic shock (Liang et al., 2009). Here it was demonstrated 
that vascular smooth muscle RAMP2 and subsequently the AM1 receptor are unlikely 
to affect the LPS-induced hypotensive response and associated inflammatory events. 
Conversly, by crossing AM knockdown mice (one copy of AM gene) with renin gene 
overexpressing mice, Caron et al. (2007) demonstrated that the AM level does not 
affect the blood pressure in a chronic hypertension condition with overexpression of 
renin transgene (Caron et al., 2007).  All the results from Caron et al., (2007) support 
our results that the RAMP2 TG mice show no difference in blood pressure after 13 days 




The results in our study using RAMP2 TG mice show a similar degree of hypertension 
compared to WT mice. This is supported by other research groups. Heterozygous AM 
gene KO mice (plasma and organ AM concentrations that are 50%) exhibited no 
difference in basal blood pressure compared to WT controls, as determined by tail cuff 
(Shimosawa et al., 2002). At the same time, both heterozygous AM gene KO and WT 
mice were treated with ATII (0.9mg/kg/day) combined with a high salt diet for 12 days. 
A significant reduction in the AM concentration in the hearts of heterozygous AM KO 
mice was observed. Additionally, the heterozygous AM gene KO mice exhibited a 
similar degree of hypertension compared to WT mice, although significantly increased 
damage to coronary arteries was observed in the AM KO mice. Such damage was 
suggested to be mediated by oxidative stress (Shimosawa et al., 2002). Furthermore, 
more recent studies showed that with human gene delivery of AM (by systemic 
administration via the tail vein into rat) no progression of hypertension induced by the 
chronic administration of the NO synthesis inhibitor L-NAME, when compared to the 
control rat, measured by tail cuff. However, ventricular cardiomyocytes from these rats 
were protected against L-NAME-induced hypertrophy, as determined by ventricular 
cardiomyocyte width and mRNA level of hypertropic marker gene (skeletal-α-actin). 
This group later demonstrated that this protection was associated with oxidative stress 
(Bell et al., 2010). Niu and his colleagues demonstrated that following high dose ATII 
(3.2 mg/kg/day) treatment for 14 days, the heterozygous AM KO mice had significantly 
increased blood pressure and cardiac hypertrophy when compared to the WT mice, 
However, it is noted that the significant increase in blood pressure may be due to the 
high dose of ATII administered (Niu et al., 2004). Moreover, our RAMP2 TG mice were 
not protected against the cardiac hypertrophy, which could be due to the tissue 
selection of the RAMP2 up-regulation. This suggests that the up-regulated RAMP2 
levels, and as a consequence, the functional AM1 receptor in the heart may not 
influence  the high blood pressure and ventricular hypertrophy induced by ATII.  
 
RAMP2 TG mice were protected against the vascular hypertrophy induced by ATII as a 
significant increase of aortic wall thickness and wall area was observed in the WT but 
not in the TG mice. This indicates that a local up-regulation of RAMP2 in aortic VSMCs 
is sufficient to protect against the vascular proliferation response in this hypertensive 
model. Our results were supported by Imai and his colleagues who established 
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transgenic mice with significant overexpression of AM (2-4 fold overexpression in major 
organs and 2-8 fold in aorta) in a vessel-selective manner (Imai et al., 2002). They 
examined the effect of AM on the formation of vascular lesions by using two different 
models - cuff placement (on the left femoral artery) induced or hypercholesterolemia-
induced fatty streak formation. With the cuff injury model, they demonstrated that AM 
up-regulated mice were protected against high blood pressure and vascular injury, but 
this protection was diminished following chronic L-NAME treatment suggesting that the 
protective action of AM is NO-dependent. Moreover, after treatment with hydralazine 
(which increases cGMP levels and decreases the phosphorylation of smooth muscle 
myosin light chains, resulting in blood vessel relaxation) the WT mice were protected 
against the high blood pressure but not the vascular injury when compared to the AM 
up-regulated mice. This indicated that the protective properties of AM are independent 
of blood pressure reduction. Furthermore, Imai and colleagues also demonstrated a 
protective role of AM in atherosclerosis by comparing AM overexpressing/ApoE KO-
crossed mice with ApoE KO mice. This protective effect is partially mediated by NO 
(Imai et al., 2002). These studies supported the current results in this dissertation. 
Upregulation of the AM1 receptor, and consequently the function of AM, is able protect 
against ATII induced vascular hypertrophy observed by a significant augmentation of 
the smooth muscle layer but not to the collagen layer, as determined and analysed 
using the standard method - Masson‘s Trichrome staining (as used similarly by others, 
Shimosawa et al., 2002, Zhan et al., 2005). However, the exact mechanism involved in 
our model requires further investigation.  
 
Vascular inflammation and remodelling accompanies several diseases, including 
atherosclerosis and hypertension. Therefore, the anti-inflammatory effect of AM via the 
AM1 receptor was also examined in this study by immunohistochemistry to locate 
whether two established inflammatory markers, VCAM1 and MCP1 were present and 
up-regulated with ATII. In the current study, VCAM-1 and MCP1 were found to be 
significantly upregulated in the aortic wall of the WT mice after infusion of ATII for 13 
days compared to the vehicle-treated group. However, this was not seen in the RAMP2 
TG mice. Therefore, our results indicate that the protective function of AM via 
upregulation of functional AM1 receptors is achieved by inhibiting the smooth muscle 
proliferation and development of vascular inflammation in response to hypertension 
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induced by chronic infusion of ATII. Indeed, data from a previous PhD student (2009-12) 
Sarah-Jane Smillie of our research group supports these results that ATII treatment for 
13 days significantly increases the protein and mRNA expression of VCAM-1 in the 
aorta, when compared to the vehicle-treated mice. She used immunohistochemistry 
techniques that trained by me and then extended them to also measure gene 
expression using RT-qPCR (Smillie, 2012). She also demonstrated increased levels of 
MCP-1 in the aorta by using RT-qPCR. Moreover, Zhan and colleagues have also 
revealed that levels of inflammatory markers (both VCAM-1 and MCP-1) are increased 
in the mouse aortic smooth muscle wall following chronic stimulation with 1.4mg/kg/day 
of ATII for 2 weeks (Zhan et al., 2005). The up-regulation of VCAM-1 and MCP-1 in 
these studies appears to correlate with vascular remodeling in the models and in 
cardiovascular diseases specifically (Smillie, 2012; Zhan et al., 2005).   
 
3.5.2. Study of VSMC and protective mechanisms in vitro 
I then wanted to learn more about the possible protective mechanism of RAMP2 in our 
model by observing proliferation of VSMCs in vitro. For this I developed the technique 
of isolation and culture of primary VSMCs from mouse aorta. This technique had not 
previously been used in our group. VSMCs from both WT and RAMP2 TG mice were 
extracted using aortic explants. For all the experiments, primary cells from passage 3 
were used. We have demonstrated that VSMCs overexpressing RAMP2 proliferated 
significantly slower than the WT VSMC, either with foetal calf serum (20%) or ATII 
stimulation. In addition, to investigate the involvement of AM1 receptor, the selective 
AM1 receptor antagonist, AM22-52, was able to elevate the ATII-induced proliferation 
significantly in the RAMP2 TG VSMC. These results indicate that AM can inhibit 
VSMCs proliferation induced by ATII via increasing the functional AM1 receptor 
signalling.  
 
In this study, the mechanisms involved were not studied. However, several 
mechanisms have been identified by other researchers that may explain such a 
protective function of AM.  Liu and co-workers revealed the protective effect of AM 
against ATII-induced proliferation of cultured rat aortic smooth muscle cells (ASMC), in 
which AM directly inhibits the intracellular reactive oxygen species production induced 
by ATII in a concentration-dependent manner. Activation of Src plays a major role in 
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growth signalling (Liu et al., 2006). Based on these findings, Liu et al. (2006) further 
demonstrated that ATII-enhanced COOH-terminal Src kinase (a key enzyme that 
inactivates Src) phosphorylation inhibits Src phosphorylation. The inhibitory role of AM 
in cell proliferation was shown by up-regulating the COOH-terminal Src kinase in 
ASMCs to inhibit Src activity (Liu et al., 2006). Furthermore, another report implicated 
AM in regulating human ASMC proliferation as a growth promoter under quiescent 
state via ERK1/2 activation (Rossi et al., 2006). This group also revealed that AM acts 
as potent inhibitor of a proliferative state where they demonstrated that AM inhibited the 
ATII-induced proliferation at a concentration of 100nM and greater showing a 
concentration-dependent effect. Such an inhibition was mainly via the cAMP/PKA 
pathway.  It is worth noting that the AM effects can be inhibited by the AM1 receptor 
antagonist AM22-52, and also blunted by CGRP8-37, which indicates the presence of 
specific AM receptors and some link with the CGRP receptor (Rossi et al., 2006). 
 
3.5.3. Relevance of findings with respect to the CGRP family of peptides  
As discussed previously, the results indicate that AM plays a protective role in 
cardiovascular events via a functional AM1 receptor. However, AM may also act via the 
CGRP receptor (Rossi et al., 2006). Moreover, in an L-NAME-induced hypertension 
model, the concentrations of both AM and the AM-related peptide, intermedin, have 
been shown to be increased, at protein and mRNA level. Interestingly, the anti-
hypertension drug, hydralazine/hydrochlorothiazide, abolished the up-regulation of AM 
and its receptor components but not intermedin or RAMP1 (Zhao et al., 2006). 
Furthermore, a recent report demonstrated that intermedin plays a protective role in an 
ischaemia-reperfusion injury model in cultured cells However, this protection was 
abolished following treatment with siRNA for CLR and RAMP2, but not RAMP1 and 
RAMP3, indicating that the protection is via an AM1 receptor-dependent pathway (Bell 
et al., 2012). All these reports indicate that the functional AM1 receptor activity may be 
influenced by more than one agonist. Indeed, in this dissertation the results of these 
studies may involve either adrenomedullin or intermedin as an agonist.  
 
In conclusion, for the current study, by using smooth muscle cell targeted RAMP2 
overexpressing mice with both in vivo and in vitro methods, we demonstrate a novel 
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and important role of vascular smooth muscle AM1 receptors in terms of protecting 






































We have shown in last chapter that local upregulation of the RAMP2 gene in smooth 
muscle cells protected mice from vascular hypertrophy and vascular inflammation 
induced by ATII (0.9mg/kg/day), that was not related to blood pressure changes. This 
supports the hypothesis that AM is protective in many cardiovascular diseases (see 
chapter 3 for details). As a member of the CGRP family of peptides, AM shares similar 
vascular activities with CGRP. Both AM and CGRP are vasodilators in vivo, although 
CGRP is 3-30 times more potent, depending on the tissue (Brain and Grant, 2004). 
Additionally, AM and CGRP share some components for their receptors (discussed in 
section 1.3.2). CGRP and its receptor are expressed at elevated levels in experimental 
models of hypertension (Deng and Li 2005). There is evidence to support CGRP also 
possesses protective attributes in hypertension (Deng et al., 2004; Li et al., 2009; 
Smillie, 2012). However, the study of CGRP in the model of ATII-induced hypertension 
in the mice has not been previously investigated. Furthermore, it is noted that the role 
of CGRP depends on the experimental model chosen. Therefore, in vivo studies are 
essential to learn more about the role of CGRP in cardiovascular regulation.  
 
Thus within our group, we aimed to determine whether CGRP is protective in ATII-
induced hypertension and hypertrophy in a similar manner to AM. The effect of CGRP 
in an ATII model was investigated using WT and global αCGRP KO mice. This study 
was carried out by S-J Smillie (Smillie, 2012), who administered ATII (1.1mg/kg/day) to 
both WT and αCGRP KO mice for 13 days by implantation of an osmotic mini-pump, 
using the same technique described in this thesis. Blood pressure was monitored by tail 
cuff plethysmography. Vascular hypertrophy and inflammation were investigated at the 
end of the study by histology and immunohistochemistry. She demonstrated that WT 
mice became hypertensive (Fig 4.1) where they exhibited vascular hypertrophy (Fig 4.2) 
after 13 days of infusion of ATII, when compared to the vehicle-treated mice. Moreover, 
αCGRP KO mice demonstrated significantly increased hypertension (Fig 4.1) and 
vascular hypertrophy (Fig 4.2) when compared to the WT ATII-treated mice, with 
enhanced expression of the inflammatory marker VCAM-1 in the aortic vascular wall 
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(Fig 4.3). These results strongly suggest a protective effect of CGRP, in addition to AM, 
in protecting against the hypertension and vascular remodeling in this ATII model 

















Fig 4.1. Mean arterial pressure (of mixed gender WT and αCGRP KO mice treated with either 
Vehicle (saline) or ATII infusion for 14 days, measured by tail cuff plethysmography Statistical 
evaluation of mean ± SEM where ##=p<0.1 and ###=p<0.01 when compared to WT ATII 
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Fig 4.2. Total and SMC (µm), measured from aortic sections taken from mixed gender WT and 
αCGRP KO mice treated with either Vehicle (saline) or ATII infusion for 14 days. (a) Total 
width (SMC + collagen) in WT and αCGRP KO mice. (b) Total SMC width (µm) in WT and  
αCGRP KO mice, (n=5-6) in WT and αCGRP KO mice.  Statistical evaluation of mean ± SEM 
by 2 way ANOVA and Bonferroni’s test, where *=p<0.05, **=p<0.01 and ***=p<0.001. 
##=p<0.01 and ###=p<0.001 when comparing the ATII treated groups (from SJ Smillie PhD 






Fig4.3 Effect of ATII (1.1 mg/kg/day for 14 days) compared with vehicle (saline) on VCAM-1 
protein and mRNA expression in WT and αCGRP KO mice.  Quantitative analysis of aortic 
VCAM protein expression (A) by immunohistochemistry and representative mRNA expression 
measured by RT-qPCR, expressed as copies/µl and normalised to SDHA, HPRT-1 and PLA2 
(g). **p<0.01 and ***p<0.001 compared to vehicle. ##p<0.01 and ###p<0.001 compared to WT 
ATII-treated animals (from SJ Smillie PhD thesis, Smillie, 2012). 
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Indeed, studies have been carried out to investigate the role of CGRP in other models 
of hypertension. Li and his colleagues performed studies in two different animal 
hypertensive models, SHR and 2K1C hypertensive rats (Li et al., 2009). Systolic blood 
pressure was significantly increased in both SHR and 2K1C, measured by tail cuff. 
Plasma CGRP levels were decreased dramatically in SHR, when compared to the 
controls. A similar phenomenon was also documented for human essential 
hypertension, performed by the same group. However, plasma levels of CGRP were 
significantly increased in 2K1C hypertensive rats. The mRNA levels of both αCGRP 
and βCGRP were also significantly decreased in the SHR but increased in 2K1C 
hypertensive rats (Li et al., 2009). By using the different models, this example shows 
how CGRP has the potential to play different roles depending on circumstance.  
 
Due to the diverse role of CGRP in hypertension, one of our primary considerations 
was to understand how the family of CGRP related peptides are endogenously 
released. There is a range of agents regulating the tissue levels of both AM and CGRP, 
such as cytokines and TNFα (Sugo et al., 1995, Schafers et al., 2003). However, we 
are unaware of any selective agents. ATII has been shown to directly affect the plasma 
levels of both AM and CGRP (Eto et al., 2003; Harada et al., 2009). At the same time, 
the ATII infusion model was established in our group (Liang et al., 2009).  
 
The TRPV1 receptor is a non-selective cation channel, composed of six putative 
transmembrane domains, including a pore region between the fifth and sixth 
transmembrane domain (Alexander et al., 2008). TRPV1 is expressed in a range of 
tissues, but primarily on the peripheral terminals of polymodal unmyelinated C-fibres 
(Alexander et al., 2008). TRPV1 is also thought to be expressed in some non-neuronal 
tissue, such as smooth muscle cells (Kark et al., 2008) and keratinocytes (van der Stelt 
and Di Marzo, 2004). It is well established that activation of TRPV1 on sensory neurons 
can trigger the release of neuropeptides, including CGRP and substance P (Brain 
1997). Therefore, together with the evidence that both AM and CGRP show certain 
protective roles in ATII-induced hypertension and hypertrophy, we investigated whether 




It has been suggested that rutaecarpine, a major quinazolinocarboline alkaloid isolated 
from a well-known Chinese medicine called Wu-Chu-Yu, depressed the phenol-induced 
hypertension by synthesis and release of CGRP from sensory nerves via the TRPV1 
receptor (Deng et al., 2004). Deng and colleagues injected 50µl of 10% phenol to 
induce hypertension. Fifteen days later rats were divided into different groups receiving 
different dose (3 or 6 mg/kg/day) of rutaecarpine, with or without capsaicin or 
capsazepine (Deng et al., 2004). Blood pressure was monitored by tail cuff and 
indicated that rutaecarphine did significantly reduce the high blood pressure induced by 
phenol. Interestingly, high doses of capsaicin, used to deplete CGRP from the sensory 
nerve, abolished the majority of the depressor effect of rutaecarphine. A similar effect 
was observed by injection of the TRPV1 antagonist, capsazepine (Deng et al., 2004). 
They also investigated the protein and gene expression of CGRP (both αCGRP and 
βCGRP) by radioimmunosssay and qPCR, from which they revealed that CGRP was 
upregulated in rutaecarpine-treated groups in a dose-dependent manner. But such up-
regulation was lost following treatment with high dose capsaicin or with capsazepine.  
Moreover, the same research group demonstrated that following surgery there was 
increased sensory nerve-mediated CGRP release in the 2K1C hypertensive model, 
where CGRP is possibly counteracting the increased blood pressure; pre-treatment 
with high dose capsaicin significantly decreased the expression of CGRP and 
increased the blood pressure (Deng et al., 2003). These reports indicate the protective 
potential of TRPV1 in hypertension models by up-regulating sensory nerve-mediated 
CGRP levels.  
 
After TRPV1 KO mice were generated, different phenotypes between WT and TRPV1 
KO mice have been investigated. TRPV1 KO mice exhibit normal responses to noxious 
mechanical stimuli, but impaired nociception to heat (Caterina et al., 2000). Moreover 
compared to the WT mice, TRPV1 KO mice also show less anxiety-related behaviour in 
the light-dark test but more anxiety-related behaviour in the plus maze (Marsch et al., 
2007). Interestingly  there is no difference in locomotion (Marsch et al., 2007). However 
a recent study has shown that compared to the WT mice, TRPV1 KO mice have higher 
locomotor activity when they are young, but lower locomotor activity and overweight 
when they are old (Wanner et al., 2011). Furthermove in term of autonomic regulation, 
125 
 
TRPV1 KO mice show hypometabolic and hypervasoconstricted effects, when 
compared to WT mice (Garami et al., 2011).  
 
I wanted to investigate the role of TRPV1 in hypertension. Therefore in my studies, I 
utilised the TRPV1 KO mice previously characterized by our group by the studies of Dr 
Anna Starr who applied capsaicin in ethanol on the ear in WT mice to show significantly 
increased blood flow when compared to the ethanol-treated ear. The capsaicin-
increased blood flow was not observed in the TRPV1 KO mice (Starr et al., 2008). 
Further characterisation of these mice was performed by Dr Jeelie Keeble who induced 
Freund‘s complete adjuvant (CFA)-induced inflammation by intra-articular injection to 
both WT and TRPV1 KO mice. Knee swelling and hyper-permeability were assessed in 
this study where it was demonstrated that TRPV1 KO mice were protected against the 
CFA-induced joint inflammation with significantly swelling and thermal hyperalgesic 
sensitivity compared to the WT mice (Keeble et al., 2005).   
 
Here we used these TRPV1 KO mice to investigate the role of TRPV1 in the ATII-
induced hypertension model as developed by myself that is now a well established 


















4.2 Hypothesis and aims 
 
4.2.1 Hypothesis  




The aims of this chapter were:  
 Investigate WT and TRPV1 KO mice in the ATII-induced hypertensive model 
 To measure blood pressure by use of the tail cuff technique and telemetry 
 To measure vascular hypertrophy in the aorta by histology 


























4.3.1 Effect of ATII (1.1mg/kg/day) on body weight and blood pressure on WT and 
TRPV1 KO mice 
 
Both WT and TRPV1 KO mice (25-35 g, 12 – 16 weeks old, male) were treated with 
ATII (1.1mg/kg/day) or saline as vehicle for 13 days by mini-pump infusion. Body 
weight was monitored on day 13 (the last day of the study before termination). Figure 
4.4 shows that ATII (1.1mg/kg/day) caused no change in body weight for both WT and 
TRPV1 KO mice compared to the vehicle-treated mice (n=6-7). 
 
For this study blood pressure was measured by two methods; tail cuff plethysmography 
and radiotelemetry. For the first set of studies, blood pressure was measured by tail 
cuff where two weeks of training was provided to the mice prior to mini-pump surgery.  
Blood pressure was taken before surgery (and used as baseline) and also on day 3, 6, 
9 and 13 post-hoc mini-pump implantation as showed in Fig 4.5 A. In this figure systolic, 
diastolic and mean arterial blood pressure measurements are shown. Both WT and 
TRPV1 KO mice show similar baseline blood pressure. There is no significant 
difference between ATII and vehicle treated WT mice in systolic blood pressure (Fig 
4.5A) but statistical significance was detected from day 3 in both diastolic and mean 
arterial blood pressure results (Fig 4.5B and C). Such differences were not seen 
between ATII and vehicle-treated TRPV1 KO mice. Again in Fig 4.6, blood pressure on 
day 13 (the last day of study) shows that there was no significant difference in the blood 
pressure (systolic, diastolic and mean blood pressure) between WT and TRPV1 KO 
vehicle mice (Fig 4.6A, B and C). In summary, the WT mice showed a significantly 
enhanced systolic blood pressure and mean arterial pressure compared to the KO mice 
following ATII treatment.  
 
To further investigate the blood pressure, telemetry was introduced into this study. This 
is suggested to be a more sensitive measurement system and it allows measurement in 
the conscious-unrestrained mouse as discussed in the general introduction. In this 
study, no vehicle treatment was used; blood pressure before mini-pump implantation 
was taken as baseline. Telemetry surgery was carried out two weeks before mini-pump 
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surgery to ensure recovery from the telemetry surgery and provide sufficient time to  
collect baseline blood pressure. Fig 4.7 shows the blood pressure trace (A: systolic, B: 
diastolic and C: mean arterial pressure) recorded by telemetry. No significant difference 
in basal blood pressure between WT and TRPV1 KO mice, whether measured during 
the day or night, supporting the tail cuff data. Fig 4.8 shows daily systolic, diastolic and 
mean blood pressure differences between WT and TRPV1 KO mice on day 3 and from 
day 6 to day 13 post-hoc-administration of the ATII-containing mini-pump. It shows that 
the WT mice developed higher blood pressure than TRPV1 KO mice after ATII, 
although no significant difference was observed. This may due to a low n number in this 
study. But when the data was analysed from the last day (day 13 after ATII infusion) of 
the study as shown in Fig 4.9, both WT and TRPV1 KO displayed similar baseline 
blood pressure. However, ATII-treated WT mice displayed significantly higher systolic, 
diastolic and mean blood pressure compared to their baseline. Conversely, TRPV1 KO 
mice were protected against the increase induced by ATII (1.1mg/kg/day), as the 
TRPV1 KO mice displayed significantly lower systolic and mean arterial blood pressure 














































Figure 4.4.  The body weight of WT and TRPV1 KO mice after infusion with ATII by mini-
pump for 13 days. No significant difference was observed before and after ATII treatment 



















Figure 4.5: Effect of ATII (1.1mg/kg/day) on blood pressure in TRPV1 WT and TRPV1 KO 
mice, measured by tail cuff on day 3,6,9 and 13 post-hoc mini-pump implantation. A, systolic; B 
diastolic and C mean blood pressure. *=p<0.05 and **=p<0.01 when the WT ATII-treated mice 
were compared to the WT veh mice. #=p<0.05 and ##=p<0.01 the WT ATII-treated mice were 












































































































































Figure 4.6: Effect of ATII (1.1mg/kg/day) on blood pressure in WT and TRPV1 KO mice, on 
day 13 post-hoc mini-pump implantation, measured by tail cuff. A, systolic; B diastolic and C 
mean blood pressure. *=p<0.05 and ***=p<0.001 when the WT ATII-treated mice were 
compared to the WT veh mice. **=p<0.01 when compared the WT ATII-treated mice were 






























































































































































































Figure 4.7: Blood pressure trace from telemetry recording. Results from WT and TRPV1 KO 
















































































































































Figure 4.8: Effect of ATII (1.1mg/kg/day) on blood pressure in TRPV1 WT and TRPV1 KO 
mice, measured by telemetry for the baseline before the surgery and from day 3 to day 13 post-
hoc mini-pump implantation. A, systolic; B diastolic and C mean blood pressure. *=p<0.05 
when the WT mcie were compared to the TRPV1KO mice. N=3-4. Statistics by two-way 


































































































































Figure 4.9: Effect of ATII (1.1mg/kg/day) on blood pressure in WT and TRPV1KO mice on day 
13 post-hoc mini-pump implantation measured by telemetry. A. systolic; B. diastolic and C. 
mean blood pressure. **=p<0.01 and ***=p<0.001 when the WT ATII-treated mice were 
compared to the WT vehicle (VEH) mice. *=p<0.05 when the WT ATII-treated mice were 
compared to the TRPV1 KO ATII mice. #=p<0.05 when the TRPV1KO veh mcie were 
compared with the TRPV1 ATII-treated mice. Statistics by two-way ANOVA with Bonferroni 




















































































































































 WT   WT    TG    TG 




 WT   WT    TG    TG 




 WT   WT    TG    G 









4.3.2 Effect of ATII (1.1mg/kg/day) on heart to tibia ratio and vascular hypertrophy 
on WT and TRPV1 KO mice 
 
Thirteen days of treatment with ATII (1.1mg/kg/day) did not cause significant 
differences in heart to tibia ratio between WT and TRPV1 KO mice (Fig 4.10) 
suggesting there is no difference between WT and TRPV1 KO mice in terms of 
developing cardiac hypertrophy. To investigate the vascular hypertrophy induced by 
ATII, aortic sections were collected from both WT and TRPV1 KO mice after 13 days 
infusion either with ATII or vehicle (saline). The aorta was then processed into paraffin 
blocks (please see the section 2 for further details). Aortic sections (5m thickness) 
were used for H&E staining and Masson‘s trichrome staining. Vascular hypertrophy 
was determined based on histological assessment from using both staining methods   
 
Fig 4.11 displays the representative H&E staining images of aortic wall at 100X and 
400X magnifications. Measurements based on H&E staining are shown in Fig 4.12. 
Measurements show that in vehicle-treated groups, mice deleted of TRPV1 developed 
thicker aortic wall thickness when compared to the WT mice. However, after ATII 
(1.1mg/kg/day) treatment, WT mice showed significant increases in aortic wall width 
when compared to their vehicle-treated mice. But such a difference was not seen in the 
TRPV1 KO mice. Moreover, the WT ATII-treated mice displayed significantly thicker 
aortic wall width than the TRPV1 KO ATII-treated mice.  
 
Fig 4.13 demonstrates the representative images for Masson‘s trichrome staining with 
aortic wall at 100X and 400X magnifications. With Masson‘s trichrome staining, 
measurements of smooth muscle layer and collagen thickness were performed 
separately. Fig 4.14A indicates that ATII caused a significant increase in collagen area 
in both WT and TRPV1 KO mice compared to their vehicle-treated mice respectively. 
However, ATII did increase medial thickness (Fig 4.14B) and aortic wall area to 
perimeter ratio (Fig 4.14C) significantly in WT ATII treated mice when compared to the 





























Figure 4.10: Effect of ATII (1.1mg/kg/day for 13 day) in WT and TRPV1 KO mice 13 days 
after mini-pump implantation. A. raw data of body weight, heart weight and tibia length. B. 





 The raw data of body weight, heart weight and tibia length of the ATII treated 
TRPV1WT and TRPV1KO mice 
Mouse 
number 
1(KO) 2(KO) 3(WT) 4(WT) 5(KO) 6(WT) 
Body 
Weight(g) 
25.9 23.2 26.8 23.8 25.2 26.4 
Heart 
weight(g) 
0.14 0.14 0.155 0.15 0.18 0.15 
Tibia 
length(mm) 












































Figure 4.11: Effect of ATII (1.1 mg/kg/day for 13 days) on vascular hypertrophy in WT and 
TRPV1 KO mice. Representative H&E staining of thoracic aorta wall at indicated magnification. 























Figure 4.12: Effect of ATII (1.1 mg/kg/day for 13 days) on vascular hypertrophy in WT and 
TRPV1 KO mice aortic wall width (n=9-18 sections from 3-6 mice in each case).  Data are 
presented as mean ± SEM. *=p<0.05 and **p<0.01. Statistic was done by two-way ANOVA 
























































Figure 4.13: Effect of ATII (1.1 mg/kg/day for 13 days) on vascular hypertrophy in WT and 
TRPV1 KO mice. Representative Masson’s Trichrome staining of thoracic aorta wall at 
indicated magnification.  Dark pink shows the staining of muscle, the blue shows collagen fibers 

















































Figure 4.14: Effect of ATII (1.1 mg/kg/day for 13 days) on vascular hypertrophy in WT and 
TRPV1 KO mice, measured from Masson’s Trichrome staining.  A. collagen layer area, B. 
Smooth muscle wall width (medial thickness), and C. Smooth muscle wall width to perimeter 
(PRM) (n=9-18 sections from 3-6 mice in each case).  Data are presented as mean ± SEM. 
**=p<0.01 when the WT ATII-treated mice were compared to the WT vehicle (VEH) mice. 
***=p<0.001 when the TRPV1KO ATII-treated mice were compared to the TRPV1 KO veh 












































































































































































4.3.3 Effect of ATII (1.1mg/kg/day) on plasma and tissue levels of CGRP on WT 
and TRPV1 KO mice 
 
Plasma and tissue levels of CGRP were also investigated by rat and mouse enzyme 
immunoassay. Both plasma and tissue homogenized supernatant were extracted 
before quantifying CGRP levels using ELISA. As it was noticed that TRPV1 KO were 
protected from ATII-induced hypertension and partially protected against the vascular 
hypertrophy, we were interested in measuring plasma and kidney CGRP levels to see 
whether the protection in TRPV1 KOs was due to a possible compensatory up-
regulation of CGRP. The analysis of the samples was not straightforward, due to 
technical problems with the freeze dryer. However, we were able to show that plasma 
CGRP levels were similar between groups despite the different treatments (Fig 4.15, 
n=2-4). Interestingly, the kidney CGRP tissue levels were elevated in the WT ATII-
treated mice, albeit non-significantly possibly due to the small n number and high 





















































Figure 4.15: Effect of ATII (1.1 mg/kg/day for 13 days) on plasma CGRP levels in WT and 








































Figure 4.16: Effect of ATII (1.1 mg/kg/day for 13 days) on kidney levels of CGRP in WT and 







4.4 Summary  
 
 ATII (1.1mg/kg/day) had no effect on the body weight when WT and TRPV1 KO 
mice were compared.  
 
 Tail cuff plesthymography indicated that both WT and TRPV1 KO mice had similar 
basal blood pressure. ATII treatment (1.1mg/kg/day for 13 days) increased blood 
pressure significantly in the WT compared to the control, but this increase was reduced 
in the TRPV1 KO mice.  
 
 Radio-telemetry was used to record blood pressure also. The data collected 
through this method supported those from tail cuff plesthymography, indicating that the 
TRPV1 KO mice were protected against the hypertension induced by ATII but not the 
WT mice.  
 
 WT ATII-treated mice demonstrated vascular hypertrophy when compared to their 
vehicle-treated mice. However the TRPV1 KO mice were significantly protected against 
the vascular hypertrophy induced by ATII to a certain extent.  
 
 Plasma CGRP levels and kidney tissue CGRP levels between the ATII-treated WT 
and TRPV1 KO groups were investigated but a conclusion can not be drawn due to the 














4.5 Discussion  
 
In this study, we have used WT and TRPV1 KO mice to investigate the role of TRPV1 
in mediating hypertension and hypertrophy induced by ATII (1.1mg/kg/day). As 
expected, the WT mice developed hypertension but the TRPV1 KO mice were 
protected against the hypertension induced by 13 days infusion of ATII. Thus, the 
original hypothesis was incorrect. The degree of hypertension in the WT mice was 
substantial where the systolic blood pressure was significantly more elevated than 
compared to TRPV1 KO mice. The results were determined by two different blood 
pressure recording methods, tail cuff and telemetry, where both showed the same 
result. This was accompanied by vascular hypertrophy in the ATII-treated WT mice but 
not the ATII-treated TRPV1 KO mice. Previously the plasma CGRP levels had been 
investigated, which showed no difference between control rat (35.3 ± 3.4 pg/ml) and 
treatment rat ( 37.6 ± 2.2 pg/ml) after infusuin of ATII with 144mg/kg/day for 10 days (Li 
and Wang, 2005). In humans, ACE activities can increase CGRP plasma levels from 
13.4±4.4pg/ml to 27.0±20.4pg/ml but no significant difference was found (Fusayasu et 
al., 2007). In my study, in order to understand more about the mechanisms involved, 
we also measured the plasma and kidney levels of CGRP. The result from my study 
shown the mean value of the plasma levels of CGRP was higher than those from above 
publications, which may due to one really high reading from each group. That may due 
to the measurement of the majority of the samples was affected by equipment 
malfunction and no further samples were available for analysis. The preliminary results 
suggested the involvement of CGRP was not sufficient to protect against a role for 
TRPV1 in ATII-mediated hypertension.  
 
TRPV1 when activated leads to the release of neuropeptides that include CGRP in 
sensory neurones (Brain and Grant, 2004). CGRP is a potent vasodilator where it 
would be expected to combat the increased blood pressure. Indeed, as discussed in 
the introduction (section 1), Dr Sarah Smillie (Smillie, 2012) has shown that ATII-CGRP 
KOs exhibit a greater hypertensive phenotype than the ATII-WT mouse. In addition, 
CGRP gene expression is increased in ATII-treated WT mice in the present study. 
Therefore, I hypothesised that TRPV1 may play a protective role in regulating the 
hypertension. TRPV1 has been shown to be protective in regulating blood pressure in 
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hypertensive models by releasing CGRP. As discussed in the introduction (section 1), 
ruteacarpine was shown to play a protective role in a rat model of phenol-induced 
hypertension by activating TRPV1 and releasing CGRP (Deng et al., 2004). 
 
Moreover, in order to investigate whether spinal CGRP in afferent renal nerves affects 
the development of one-kidney renal wrap (1K-WRAP) hypertension, Burg and his 
colleagues applied the technique of selective long-term partial depletion of spinal 
CGRP within small primary afferents nerve fibres by intrathecal administration of high 
dose capsaicin (Burg et al., 1994). Interestingly, they revealed that systolic arterial 
pressure was greater in 1K-WRAP rats after depleting CGRP than in vehicle-treated 
1K-WRAP rats (Burg et al., 1994). This shows the expected protective effect of CGRP 
following TRPV1 activation.  
 
A separate study provided evidence for a protective effect of CGRP downstream of 
TRPV1 activation. In this study, baseline arterial blood pressure was significantly 
increased after feeding with high salt (4% by weight) diet for 3 weeks when compared 
to the normal sodium diet intake (0.4% by weight), measured following cannulation of 
carotid artery in anaesthetized rats. These authors then proceeded to measure blood 
pressure in conscious and un-restrained rats when capsazepine (3mg/kg), a selective 
TRPV1 antagonist, was administrated by i.v. injection. They demonstrated that 
capsazepine significantly increased the mean arterial pressure in the high salt fed but 
not in the normal salt fed rats. Plasma levels of CGRP were significantly increased in 
the high salt fed rats when compared to the normal salt fed rats. The results indicated 
that the TRPV1 channels were activated to release CGRP during the high salt intake, 
where CGRP counteracted the salt-induced elevation of blood pressure presumably 
through the vasodilator action of CGRP (Wang et al., 2007).  
 
All these studies contrast with the findings we report that TRPV1 deletion was 
associated with a lower blood pressure than in the TRPV1 WT mice. These results 
suggest that TRPV1 may be able to release CGRP, but that the CGRP was not able to 
protect against ATII-induced hypertension. The exact reasons for this are presently 
unknown and require further investigation. Possible mechanisms may include the 




First of all, substance P is known as a vasodilator as it has been reported to induce 
relaxation through the production of NO via tachykinin NK1 receptors in man (Bossaller 
et al., 1992). However in non-contracted rabbit intrapulmonary arteries, substance P 
mediated constrictor effects via different receptors depending on its concentrations 
(NK1 receptors at low concentrations and NK2 receptors at higher concentrations 
(Shirahase et al., 1995). Moreover it is reported that myogenic constriction is mediated 
by activation of TRPV1 and consequent action of substance P, which acts on NK1 
receptors on vascular smooth muscle, causes constriction (Scotland et al., 2004). In 
vitro, elevation of intraluminal transmural pressure of mesenteric small arteries caused 
a myogenic response. This could be inhibited by 73% with capsaicin desensitisation. 
Moreover, activation of C-fiber nerve terminals by pressure ending myogenic 
constriction was due to stimulation of TRPV1, which was inhibited by capsazepine 
(Scotland et al., 2004). By blocking the tachykinin NK1 receptors, they also 
demonstrated that the myogenic constriction was due to neuropeptide substance P 
release (Scotland et al., 2004). Thus activation of TRPV1 and, release of substance P, 
could contribute the myogenic constriction.  
 
Secondly, there is growing evidence that vascular tissue contains non-neuronal TRPV1 
receptors associated with vasoconstriction (Keeble et al., 2006; Kark et al., 2008 and 
Czikora et al., 2012). TRPV1-mediated vasoconstriction has been observed in the WT 
mouse knee joint, but not in TRPV1 KOs (Keeble et al., 2006). Using an isolated rat 
hind limb preparation, Kark et al (2008) demonstrated increased vascular resistance 
together with decreased skeletal muscle perfusion in response to capsaicin. Such an 
effect was unaffected by surgical sensory denervation (Kark et al., 2008). Furthermore, 
in isolated rat skeletal muscle arterioles, which are devoid of sensory innervation, high 
concentrations of capsaicin (0.1 – 1 µM) displayed endothelium-independent 
vasoconstriction (Kark et al., 2008). More recently Czikora et al (2012)., also 
demonstrated capsaicin evoked a constrictor response in isolated arteries similar to the 
effect mediated by noradrenaline. However, such constriction was absent in the arteries 
from TRPV1 KO mice and competitively inhibited by TRPV1 antagonist AMG9810 
(Czikora et al., 2012). Therefore, it is possible that the reduced magnitude of 
hypertension in TRPV1 KO mice in the present study may be due to the loss of function 
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of the non-neuronal TRPV1 and could be due to the adaptive phenotype of the TRPV1 
KO mice. 
 
In conclusion, these results lead to the proposal that TRPV1 deletion (and potentially 
blockade) may be beneficial in ATII-induced hypertension and vascular hypertrophy. 
However the exact mechanisms of observed protection in TRPV1 KO mice are 





























CHAPTER 5: A ROLE OF TRPV1 IN OBESITY-INDUCED CARDIOVASCULAR 
DISEASE 
 
5.1 Introduction  
Results in the previous study with WT and TRPV1 KO mice in an ATII-induced 
hypertension model (chapter 4), demonstrated that TRPV1 KO mice were protected 
from hypertension and partially from the vascular hypertrophy induced by ATII 
(1.1mg/kg/day). We had hypothesised that TRPV1 was protective in hypertension, due 
to release of CGRP, but it was apparent that this was not correct. Even with low N 
number, the CGRP levels in the kidney showed a trend towards increasing CGRP 
levels in the WT ATII treated mice but not in the TRPV1 KO mice. Overall, the results 
indicated that global deletion of TRPV1 is beneficial in the model of ATII-induced 
hypertension. The mechanisms are unknown, however, possibly CGRP levels can be 
up-regulated in tissues following TRPV1 activation (as CGRP kidney levels in the ATII-
WT mice were increased, but not in the TRPV1 KO mouse). Nevertheless, the 
increased hypertension observed in TRPV1 WT mice indicates a novel mechanism that 
requires further investigation. We therefore sought a second model to investigate the 
role of TRPV1 in hypertension.  
 
Recently, attention has been drawn to investigating the role of TRPV1 in regulating the 
development of obesity and type 2 diabetes (T2D). In 2007, it was demonstrated that 
when compared with lean counterparts, visceral adipose tissue from obese mice and 
humans displayed a reduced TRPV1 expression associated with reduced capsaicin-
induced calcium influx (Zhang et al., 2007) Moreover, activation of TRPV1 by oral 
administration of capsaicin for 120 days prevented obesity in WT mice but not in 
TRPV1 KO mice (Zhang et al., 2007). This led to an understanding that TRPV1 is 
protective in obesity. 
 
It is thought that approximately 60% to 70% (World Health Organisation 2003; Wofford 
& Hall 2004) of hypertensive disease is caused by the patient being overweight. Even 
though the relationship between obesity and hypertension has been well documented, 
the exact mechanisms remain uncertain. However, it is likely to be due to a 
combination of factors promoting sodium retention and vasoconstriction via the RAS 
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(Montani et al., 2002). We therefore thought that this high fat model may suit our 
studies as obesity-induced hypertension (Fellmann L. et al., 2012) may allow us to 
learn more about the role of TRPV1. The HFD model is less acute and less extreme in 
terms of the hypertension observed than the ATII model (Erdos B et al., 2009; Liang L. 































5.2 Hypothesis and aims 
 
5.2.1 Hypothesis  
TRPV1 plays a protective role in HFD-induced obesity and its associated hypertension  
 
5.2.2 Aims 
The aims of this chapter were:  
• Investigate WT and TRPV1 KO mice in the HFD-induced hypertensive model 
• To monitor blood pressure by both the tail cuff technique and telemetry 
• To investigate the glucose tolerance state 
• To measure vascular hypertrophy in the aorta by histology 
• To assess the vascular inflammation in the aorta by immunohistochemistry 
• To investigate the resistance vessel in response to constrictor (phenylephrine) 
and vasodilators (carbachol and CGRP)  
• To measure the plasma CGRP levels and ET-1 levels by ELISA 
• To determine the mRNA expression of TRPV1, CGRP and other genes such as 





















5.3.1 Effect of HFD on body weight, cardiac hypertension and adipocyte size in 
WT and TRPV1 KO mice. 
 
Both WT and TRPV1 KO mice (3-4 weeks old, matched for bodyweight, age and sex) 
were fed with HFD (35% of fat from lard) or normal diet (4% of fat; control) for 12 weeks. 
Body weight was monitored weekly. There was no significant difference in the body 
weight between WT and TRPV1 KO mice when they were fed with the normal diet. The 
HFD caused similar weight gain between WT and TRPV1 KO mice (Fig 5.1). Heart to 
tibia ratio was examined where there was no significant difference between WT normal 
diet and TRPV1 normal diet fed mice. However, HFD fed for 12 weeks caused 
significant increases in both WT and TRPV1 KO mice in heart to tibia ratio when 
compared to their normal diet fed mice (Fig 5.2). This suggests that both WT and 
TRPV1 KO mice, after fed with HFD for 12 weeks, developed cardiac hypertrophy. 
Moreover, assessment of adipocyte size revealed that mesenteric adipose tissue from 
TRPV1 KO HFD fed mice contained a significantly higher percentage of small 
adipocytes (1-20 µm) than that from WT HFD fed mice (Fig 5.3). This assessment was 


















Figure 5.1.  Effect of HFD (35%) on WT and TRPV1 KO mice. Body weight from 3 to 15 
weeks. N=3-4 *=p<0.05, ** = p<0.01, ***=p<0.001, compared to respective normal diet control. 
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Figure 5.2: Heart to tibia ratio of WT and TRPV1 KO mice after feeding with HFD or normal 












Figure 5.3. Effect of HFD (35%) on WT and TRPV1 KO mice on the adipocytes. Percentage of 
adipocytes based on cell size (µm2), n=4-5. *=p<0.05 (student’s unpaired-test) when compared 
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5.3.2 Effect of HFD on blood pressure and vascular hypertrophy in WT and 
TRPV1 KO mice. 
 
For this study, blood pressure was determined by both tail cuff and radio-telemetry. 
Initially, blood pressure was assessed in the last week of the feeding over the last three 
days before termination. Data was presented as mean of the three days (Fig 5.4) of 
systolic (A), diastolic (B) blood pressure and mean arterial pressure (C). HFD induced a 
significant increase in blood pressure in WT mice when compared to their normal diet 
fed mice but not in TRPV1 KO mice. Based on these results and the fact that this was a 
long term study (12 weeks), I was interested in the development of the hypertension in 
the WT mice. Therefore, a second study was performed where measurement of the 
blood pressure was monitored from 9 weeks feeding by tail cuff. As shown in Fig 5.5, a 
significant increase in diastolic and mean arterial pressure occurred after 8 weeks HFD 
feeding and for systolic blood pressure after 10 weeks, where these increases 
continued until the experiment was terminated. Despite the low n, we have clearly 
demonstrated the trend of consistent hypertension in WT HFD-fed mice but not in 
TRPV1 HFD-fed mice. To further investigate the effect of the HFD on blood pressure, a 
third set of studies was carried out using radio-telemetry to measure the blood pressure.  
The telemetry probe was implanted after 8 weeks of feeding when the normal diet fed 
mice were large enough and the HFD fed mice were not completely obese to 
compromise the surgical procedure. Data was collected only on the last three days of 
the study. Blood pressure traces are shown in Fig 5.6 with n=3-4 for normal diet and 
n=6 for HFD fed mice. The mean value of those three days was plotted in graph form 
(A systolic, B diastolic and C mean arterial pressure, Fig 5.7) and showed a similar 
trend with those obtained in the tail cuff studies. The data from telemetry demonstrated 
that both WT and TRPV1 KO normal diet fed mice had similar blood pressure. However 
HFD significantly induced high blood pressure in the WT mice but not in the TRPV1 KO 
mice.  
 
Due to the interesting results for the blood pressure, I moved to investigate the aortic 
histology using Masson‘s trichome staining. Fig 5.8 shows the representative staining 
pictures of aortic section (5m thickness) under 40x or 400x of magnifications. This 
staining was done by a previous PhD student (Marshall) who worked with me on some 
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aspects of the HFD feeding study.  Assessment of vascular hypertrophy was performed 
and results are shown in Fig 5.9A (aortic wall width) and Fig 5.9B (fibrosis/collagen 
width). These assessments reveal that HFD significantly increased the aortic wall width 
and fibrosis/collagen width in the HFD WT mice when compared with WT normal diet 
fed mice. These differences were not seen in the TRPV1 KO mice between HFD and 
normal diet fed mice. On the other hand, the gene expression of collagen III in the 
aortic tissue showed no significant difference between different treatment groups (Fig 


















Figure 5.4: Effect of HFD (35%) on blood pressure measured by tail cuff after feeding with 
either HFD or normal diet for 12 weeks. Readings were taken in the week 12 of the feeding 
study.  A. systolic, B. diastolic and C mean blood pressure. **=p<0.01 and ***=p<0.001. N=3-4. 


























































































































































Figure 5.5: Effect of HFD (35%) on blood pressure measured by tail cuff for four weeks after 
feeding with either HFD or normal diet. A. systolic, B. diastolic and C mean blood pressure. 
**=p<0.01 and ***=p<0.001 when compared to the normal diet. #=p<0.05, ##=p<0.01 and 
###=p<0.001 when compared to the KO HFD mice. N=3-4. Statistics by two-way ANOVA with 



































































































































Figure 5.6: Effect of HFD (35%) on systolic blood pressure measured by telemetry for the last 
three days  in the week 12 of HFD feeding study. Blood pressure trace comparing WT normal 
diet mice with WT HFD mice (A), KO normal diet mice with KO HFD mice (B) and WT HFD 
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Figure 5.7: Effect of HFD (35%) on blood pressure measured by telemetry after feeding with 
either HFD or normal diet. Readings were taken in the last three days of the week 12 of the 
feeding study.A. systolic, B. diastolic and C mean blood pressure. *=p<0.05, **=p<0.01 and 
##=p<0.01. WT normal diet n=3, WT HFD n=6, KO normal diet n=4 and KO HFD n=6. 




























































































































































Figure 5.8. Effect of HFD (35%) on vascular hypertrophy after feeding with either normal diet 
or HFD for 12 weeks. Representative Masson’s Trichrome staining of thoracic aorta wall at 40x 
and 400x magnification as indicated. Dark pink indicates the staining of muscle; the blue 





















Figure 5.9. Effect of HFD (35%) on aorta remodelling after fed either normal diet or HFD for 12 
weeks. A. Aortic wall width; B. Fibrosis and collagen thickness; and C. collagen III gene 
expression by QPCR. Samples were measured from Masson’s trichrome stained sections ( n=10-
14 with 3-4 sections from 3-4 mice in each group).  **=p<0.01 and ***=p<0.001 WT HFD mcie 
were compared with WT  normal diet control mice. #=p<0.05 and ###=p<0.001 when WT HFD 
mice were compared with TRPV1KO HFD mice. Results are analysed by two-way ANOVA 





















































































































































5.3.3 Effect of HFD on blood glucose and vascular inflammation in WT and 
TRPV1 KO mice. 
 
The effect of HFD on glucose tolerance was also investigated in the final week of the 
experiment, before the termination. Baseline blood glucose was measured following a 6 
hours fasting period and bolus i.p. administration of a 2 mg/kg glucose. Both WT and 
TRPV1 KO displayed similar baseline blood glucose with or without HFD (Fig 5.10 and 
Fig 5.11A). Although it seemed that the mice with HFD showed higher baseline blood 
glucose than the normal diet fed mice, there was not a significant difference between 
the different diets. The blood glucose levels of WT and TRPV1 KO mice fed a normal 
diet increased and peaked at a similar level (Fig 5.10).  When glucose was 
administered to HFD fed WT and TRPV1 KO mice, blood glucose peaked rapidly 60 
minutes after, before returning close to baseline.  For both genotypes, the HFD resulted 
in significantly higher glucose levels, which indicates a reduction in glucose tolerance. 
However, the blood glucose of TRPV1 KO mice returned to baseline significantly 
quicker than WT mice suggesting that TRPV1 KO mice retained more glucose 
tolerance than WT when fed a HFD (Fig 5.10 and Fig 5.11B).  
 
Vascular inflammation (expression of VCAM-1 in aortic tissue) was also assessed in 
this study by immunohistochemical staining. Fig 5.12A shows the representative 
pictures of the VCAM-1 staining in frozen tissue at 200x magnification. Based on the 
staining, VCAM-1 expression was assessed as percentage of VCAM-1 in the aortic wall 
area (Fig 5.12 B). There is low expression of VCAM-1 on the aortic wall and there is no 
significant difference between different treatment groups. However the VCAM-1 mRNA 
expression on aorta tissue shows that the VCAM-1 gene expression was significantly 
lower in the WT HFD fed mice than their normal diet fed control mice (Fig 5.13). There 
was no difference between HFD fed and normal diet fed TRPV1 KO mice, normalized 






Figure 5.10: Effect of HFD (35%) on blood glucose levels of WT and TRPV1 KO mice after 
feeding with HFD or normal diet for 12 weeks, following a 2mg/kg glucose bolus (n=5-13).  
Results are analysed by comparison of mean area under curve with two-way ANOVA with 


































































Figure 5.11: Effect of HFD (35%) on blood glucose levels of WT and TRPV1 KO mice after 
feeding with HFD or normal diet for 12 weeks, A. baseline blood glucose and B. area under the 
curve of plasma glucose following a 2mg/kg glucose bolus. n=5-13.  #=p<0.05. Results are 
analysed by two-way ANOVA with Bonferroni post-hoc-tests for baseline and student t-test for 



































































































































Figure 5.12 Effect of high (35%) fat diet on expression of VCAM-1 on aortic wall. A) 
Representative immunohistochemical staining of VCAM-1 in the thoracic aorta wall at 200x 





























































Figure 5.13. Effect of high (35%) fat diet on expression of VCAM-1 on aortic tissue using qPCR. 
Two reference genes (HPRT1 and B2M) were used to analysed data. ***=p<0.001. N=6-7. 


































































5.3.4. Effect of HFD on resistance vessel responsiveness and eNOS mRNA 
expression in WT and TRPV1 KO mice. 
 
The vascular responsiveness was investigated in resistance vessel (first order 
mesenteric arterioles) determined by wire myography. Following cumulative addition of 
phenylephrine (0.1-10µM), no significant change was observed between different 
treatment groups (Fig 5.14 and Fig 5.15). We also investigated the vasodilatation ability 
of these mesenteric arterials using CGRP (0.33-33nM) and endothelium-dependent 
vasodilator carbachol (1nM-10µM) following preconstriction with 10µM phenylephrine. 
Interestingly, there was no significant change seen between different treatment groups. 
Data were presented into two different ways: as percentage of contraction/relaxation 
(Fig 5.14) or as force (Fig 5.15). These results indicate that the HFD caused no 
significant effect on resistance vessels from both WT and TRPV1 KO mice in terms of 
their responsiveness to either constrictor (phenylephrine) or vasodilators (CGRP and 
carbachol) when compared to the normal diet treated mice.  
 
In addition eNOS expression in aortic tissue was investigated by RT-qPCR (normalised 
by two reference genes: HPRT1 and B2M). Both WT and TRPV1 KO mice had similar 
levels of eNOS mRNA levels after feeding with normal diet. Moreover, HFD increased 
the eNOS expression in both WT and TRPV1 KO mice at a similar level. But such an 
increase was not significantly different when compared to their normal diet fed mice 














Figure 5.14. The effect of phenylephrine, CGRP and carbahol on ND-WT and ND-TRPV1 KO 
mouse and also HFD-WT and HFD-TRPV1 KO mouse mesenteric arteries, as determined by 
myograph and data was present as percentage of contraction or relaxation. (A) Effect of 
phenylephrine (0.1-10µM) and (B) CGRP (0.33-33nM) on mesenteric arteries (including 
endothelium intact and denuded).n = 5-7. (C) Effect of carbachol (1nM-10 µM) on endothelium 
intact mesenteric arteries. n=3-6. Dilator responses were examined in the presence of 






















































































Figure 5.15. The effect of phenylephrine, CGRP and carbachol on ND-WT and ND-TRPV1 KO 
mouse and also HFD-WT and HFD-TRPV1 KO mouse mesenteric arteries, as determined by 
myograph and data was present as force. (A) Effect of phenylephrine (0.1-10µM) and (B) CGRP 
(0.33-33nM) on mesenteric arteries (including endothelium intact and denuded). n = 5-7. (C) 
Effect of carbachol (1nM-10 µM) on endothelium intact mesenteric arteries. n=3-6. Dilator 
responses were examined in the presence of phenylephrine (10 M). Results are analysed by 










































































































































Figure 5.16. Effect of high (35%) fat diet on expression of eNos in aortic tissue samples using 
QPCR. Two house keeping genes were used to analyse data. N=6-7. Results are analysed by 














[5.3.5. Effect of HFD on expression of TRPV1, CGRP, ET-1, Oxidized Stress 
markers and noradrenaline in WT and TRPV1 KO mice. 
 
In order to understand more about possible mechanisms of the protection we have 
observed in the TRPV1 KO mice in this study, RT-qPCR was used to evaluate selected 
genes in aortic tissue and followed with assessment of protein expression, using ELISA 
assays, to determine potential mediators.  
 
TRPV1 mRNA showed no significant difference in the WT mice between HFD and 
normal diet fed mice (Fig 5.17A) and as expected there was no expression in the 
TRPV1 KO mice. HFD reduced levels of CGRP mRNA in the WT mice when compared 
to the normal diet fed mice but with no significant difference. Interestingly, both HFD 
and normal diet fed TRPV1 KO mice showed similar CGRP mRNA levels to the HFD 
fed WT mice (Fig 5.17B). Moreover, plasma levels of CGRP were determined by ELISA 
and normalised by protein content, showed that both normal fed WT and TRPV1 KO 
mice had similar levels of plasma CGRP. Furthermore, the HFD did not cause any 
significant change in the plasma CGRP levels between WT and TRPV1 KO mice (Fig 
5.17C).  
 
The measurement of both plasma and mRNA levels of ET-1 (endothelin 1) were 
assessed in this study. Plasma levels of ET-1 were determined by ELISA after peptide 
extraction and normalised by protein content. After HFD there was a non-significant 
trend towards increased plasma levels of ET-1 in the WT mice (16.0±2.7pg/mg of 
protein) when compared to the normal diet fed mice (15.1±2.4 pg/mg of protein). 
However, such an increase was not seen in the TRPV1 KO mice between HFD 
(14.7±2.0 pg/mg of protein) and normal diet fed mice (14.9 ±2.2 pg/mg of protein, Fig 
5.18A).  Interestingly, the mRNA levels of ET-1 in the aortic tissue was significantly 
increased following HFD when compared to the normal diet fed mice (Fig 5.18B). 
However, there was no such difference in the TRPV1 KO mice between HFD and 
normal diet fed mice. When comparing the WT and TRPV1 KO mice after the HFD, WT 




Superoxide dismutase (SOD) exists as three isoforms (SOD1, SOD2 and SOD3) where 
all are important for the antioxidant defense. In this study, I focused on SOD1 as it has 
been studied and proved to be involved in inflammatory conditions by both others 
(Segui et al., 2004 and Gongora et al., 2006) and within our group (Smillie, 2012). SOD 
mRNA expression was investigated by RT-qPCR, where both WT and TRPV1 KO 
normal diet fed mice had similar levels of SOD mRNA levels. However, HFD 
significantly increased the SOD mRNA levels in the WT mice but not in the TRPV1 KO 
mice when compared to their normal diet control mice (Fig 5.19A). Moreover, we also 
assessed the mRNA expression of NOX2 (a member of the NADPH family of enzymes 
which primarily produce ROS) and HO1 (heme oxygenase composed of two forms HO1 
and HO2, we focused on HO1 in this study). For NOX2 no significant difference was 
seen in expression in the aorta between either WT and TRPV1 KO mice, or between 
HFD and normal diet fed mice (Fig 5.19B). HO1 mRNA was expressed at a similar level 
between WT and TRPV1 normal diet fed mice. The HFD did not affect the expression 
of HO1 in the WT mice. However, an increased level of HO-1 was observed in the 
TRPV1 KO mice after being fed the HFD (Fig 5.19C).  
 
At the end of the study, we investigated the noradrenaline level in the kidney tissue via 
ELISA and then normalised by protein content. Interestingly, the HFD significantly 
increased the noradrenaline levels in the kidney in the WT mice when compared to the 
normal diet fed mice (Fig 5.20). All the TRPV1 KO mice (both HFD and normal diet fed 
mice) had low levels of noradrenaline level in the kidney when compared to the WT 
mice. The HFD WT mice showed significantly more noradrenaline levels than the HFD 







Figure 5.17. Effect of high (35%) fat diet on expression of TRPV1 (A) and CGRP (B) on aortic 
tissue using QPCR. Two reference genes (HRPT1 and B2M) were used to analysed data. N=6-7. 
C. plasma level of CGRP by CGRP ELISA (WT normal diet n=7, WT HFD n=8, KO normal 
diet n=5 and KO HFD n=8). Results were analysed by two-way ANOVA + Bonferroni’s post-















Figure 5.18.  The effect of a HFD on (A) plasma levels of endothelin-1 taken from WT and 
TRPV1 KO mice fed either a normal or HFD from 3-15 weeks of age  (WT normal diet n=7, 
WT HFD n=8, KO normal diet n=5 and KO HFD n=8) and (B) gene expression of ET1 on aortic 
tissue. *=p<0.05 and **=p<0.01. Results were analysed by two-way ANOVA + Bonferroni’s 













Figure 5.19. Effect of high (35%) fat diet on expression of oxidase stress markers (Nox2, SOD 
and HO1) on aortic tissue using QPCR. Two reference genes (HRPT1 and B2M)  were used to 
analysed data. *=p<0.05 and ***=p<0.001. N=6-7. Results are analysed by two-way ANOVA 






















































































































































































































Figure 5.20.  The effect of a HFD on noradrenaline levels in kidney tissue taken from WT and 
TRPV1 KO mice fed either a normal or HFD from 3-15 weeks of age. WT normal diet n=4, WT 
HFD n=4, KO normal diet n=4 and KO HFD n=8. Analysed by two-way ANOVA + 

















 There was a similar weight gain in both WT and TRPV1 KO mice after feeding 
with a normal diet. However HFD (35% of fat) for 12 weeks significantly induced obesity 
in both WT and TRPV1 KO mice when compared to their normal diet fed mice. There 
was no difference between HFD-WT and HFD-TRPV1 KO mice in terms of weight.  
  
 The HFD significantly increased heart to tibia ratio in both WT and TRPV1 KO 
mice, indicating cardiac hypertrophy when compared with mice on a normal diet. In 
addition, the HFD induced enlargement of the size of mesenteric adipocytes in the WT 
mice but not in the TRPV1 KO mice, indicating an effect on adipocyte differentiation.  
 
 Both tail cuff plesthymography and telemetry revealed the same trend that both 
WT and TRPV1 KO have similar blood pressure levels under normal conditions, but 
HFD induced a hypertensive phenotype in the WT mice but not in the TRPV1 KO mice.  
 
 It was also demonstrated that HFD significantly induced aortic vascular 
hypertrophy in the WT mice but not in the TRPV1 KO mice.  
 
 WT and TRPV1 KO mice had similar blood glucose levels after HFD for 12 
weeks, when compared to those on normal diet.  Both WT and TRPV1 KO mice, fed 
with HFD, resulted in significant glucose intolerance. However, the blood glucose of 
TRPV1 KO mice returned to baseline significantly faster than that of WT mice. This 
indicates that HFD-TRPV1 KO mice possess improved glucose tolerance when 
compared with HFD-WT mice.   
 
 Both immunohistochemistry and QPCR indicated that there was no significant 
difference in term of the expression of the inflammatory marker VCAM-1 between the 
different treatment groups.  
 
 Use of myograph to study resistance vessel reactivity demonstrated no 
significant difference between the treatment groups in terms of their responsiveness to 
a vasoconstrictor agent phenylephrine, and vasodilators carbachol and CGRP.  
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Moreover, no significant difference was observed in term of the eNOS mRNA 
expression between the different treatment groups.  
 
 Feeding with HFD for 12 weeks did not cause significant change in the mRNA 
expression of TRPV1, CGRP, NOX2 and HO-1. A significant increase in mRNA level of 
ET-1 in aortic tissues in HFD-WT mice were seen compared to both normal diet and 
HFD-TRPV1 KOs. Moreover, HFD induced greater SOD1 mRNA expression on aortic 
tissue compared to WT but not in the TRPV1 KO mice. Furthermore, HFD-WT mice 
demonstrated significantly higher levels of noradrenaline in the kidney when compared 
to the normal diet fed WT mice. Interestingly, the basal noradrenaline levels in the 



























This study was designed to investigate the role of TRPV1 in the obesity associated 
hypertension induced by 12 weeks of HFD feeding in WT and TRPV1 KO mice. The 
reason for this was to determine whether HFD-WT mice would be protected from 
hypertension due to endogenous release of CGRP in this model as it is considered to 
be less ‗aggressive‘ than the ATII model used in Chapter 4. Here we demonstrate that 
the HFD-WT mice displayed an enhanced metabolic syndrome, in terms of 
hypertension and glucose handling, when compared to the HFD TRPV1 KO mice. Thus, 
we did not observe a protective role for TRPV1.  
 
Our current results confirmed that WT and TRPV1 KO mice developed similar weight 
gain between ages 3 to 15 weeks after feeding with HFD containing 35% of fat from 
lard. However, other studies have suggested that TRPV1 does affect weight gain. 
There are several studies where it has been concluded that TRPV1 is associated with 
weight loss (Zhang et al., 2007; Gram et al., 2007). For example, capsaicin-treatment 
(doses of capsaicin at 20, 30 and 50mg/kg, administered over three days) of Zucker 
rats (a model of the metabolic syndrome and T2D) led to less weight gain than the 
vehicle-treated Zucker rats over a three week period following treatment. However, 
after 3 weeks of the treatments, the body weight of capsaicin-treated rats increased 
significantly more than those of the vehicle-treated rats (Gram et al., 2007). This 
treatment regime of capsaicin is likely to cause desensitisation of the TRPV1 channels 
on sensory nerves which may imply that loss of functional neuronal TRPV1 in rats 
leads to a greater increase in body weight than the vehicle-treated rats. Therefore, our 
current results agreed that depletion of TRPV1 did not protect mice from gaining weight 
with HFD feeding compared to the normal diet.  
 
Secondly, our results revealed that HFD caused no significant effect on heart weight to 
tibia ratio between WT and TRPV1 KO mice. However, there was significant difference 
between HFD and normal diet fed mice. These results indicate that both WT and 
TRPV1 KO mice developed cardiac hypertrophy compared to their normal diet-fed 
counterparts. However, this study did demonstrate that WT mice showed a greater 
percentage of hypertrophied adipocytes, which agrees with the concept that functional 
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TRPV1 is implicated in adipocyte differentiation (Zhang et al., 2007). In the current 
study, both WT and TRPV1 KO mice had similar adipose tissue weight but the WT 
mice possessed a higher percentage of larger adipocyte cell size, which indicated that 
the TRPV1 KO mice had more (albeit smaller) adipocytes than the WT mice. However 
the enlarged adipocytes in the WT mice could be problematic as hypertrophied 
adipocytes is one of the characteristics of dysfunctional adipose tissue in obesity (Hajer 
et al., 2008). Moreover, recently a study in humans has shown that enlarged adipocyte 
cell size is one of the characteristics of adipose tissue metabolic dysfunction in non-
obese individuals with low insulin sensitivity (Hammarstedt et al., 2012).  
 
Generally, this study provided surprising results as TRPV1 KO mice were protected 
against the HFD-induced increase in blood pressure compared to WT mice. In this 
study, blood pressure was measured by two methods. The tail cuff data suggested that 
hypertension had developed, while the telemetry data suggested that increased blood 
pressure was present at the end of the study, but had not reached the hypertensive 
threshold. It was discussed in chapter 4 that TRPV1 is believed to be protective by 
releasing vasodilator neuropeptides, such as CGRP, resulting in peripheral vasodilation 
(Fernandes et al., 2011). Therefore, I hypothesised that TRPV1 KOs would be lacking 
this protective vasodilator effect and suffer a worse hypertension after HFD. However 
this was not the case. The increase in HFD-induced blood pressure increase was 
mirrored by an effect of HFD on vascular hypertrophy in the WT mice but not in the 
TRPV1 KO mice. Moreover, the protein expression in the plasma and the mRNA 
expression in aorta showed that the CGRP was expressed similarly between HFD-WT 
and HFD-TRPV1 KO mice. These results indicated that the HFD-WT mice did not 
appear to have the TRPV1-CGRP protective pathway activated. These results led us to 
think about other mechanisms via which TRPV1 could be acting. Following on from the 
discussion of TRPV1 potentially mediating vascular constrictor activity (please see the 
discussion at Chapter 4), it is possible that this is one of the reasons for the increased 
blood pressure observed in HFD-WT but not TRPV1 KO mice. However, there are 
other possibilities. 
 
In this study, it was also revealed that mRNA levels of ET-1 were significantly increased 
in the aorta from the HFD-WT mice than the WT normal diet mice or HFD-KO mice. 
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This could be one of the mechanisms why the HFD -WT mice developed hypertension 
but not the TRPV1 KO mice. There is evidence from other studies that link ET-1 levels 
with hypertension. The endothelin pathway is suggested to become functionally 
significant at an early stage in spontaneously hypertensive rats in which insulin 
resistance leads to impaired NO production in the vascular endothelium and enhanced 
ET-1 secretion (Potenza et al., 2005). This may reflect one pathophysiological 
mechanism in vascular beds that contributes to elevated peripheral vascular resistance 
and hypertension. Moreover, a recent study has revealed a mechanism by which 
TRPV1 activation leads to upregulation of the endothelin/ETA-mediated pathway, which 
results in vasoconstriction leading to increased mean arterial pressure. Results showed 
that capsaicin increased mean arterial pressure in a dose-dependent manner (1 µg/kg: 
5.7±1.6, 10 µg/kg: 11.7±2.1, 20 µg/kg: 25.4±3.4, 100 µg/kg: 51.6±3.9%) in the WT mice 
when compared to the control mice, measured in anaesthetised mice following artery 
catheterization. This effect was not seen in the TRPV1 KO mice (Ohanyan et al., 2011).  
Inhibition of endothelin A receptors abolished the increase in blood pressure induced by 
capsaicin (Ohanyan et al., 2011). However in this chapter, the myography results 
revealed that constrictor and dilator responses to phenylephrine, CGRP and the 
endothelial-dependent dilator carbachol were similar, suggesting little vascular 
dysfunction at the mesenteric resistance vessel level at least. This was mirrored by the 
result of eNOS mRNA expression, which showed no significant difference between the 
treatment groups. However, when these experiments were being performed, I had yet 
to determine that ET-1 gene expression was affected by TRPV1 in our HFD model, 
where unfortunately I did not save tissue from the myography studies to determine the 
role of ET-1 directly. 
 
In this study, we also demonstrated that using the glucose tolerance test the HFD-
TRPV1 KO mice were able to reverse the high plasma glucose levels significantly 
quicker than the HFD WT mice (analysed by area under the curve). Our results are 
supported by those of Gram et al. who demonstrated that sensory nerve desensitisation 
by resiniferatoxin (a TRPV1 agonist, used at a concentration that causes 
desensitisation) improved oral glucose tolerance, which was accompanied by elevated 
plasma insulin levels (Gram et al., 2005). The same group showed that desensitisation 
with capsaicin maintained the non-fasting glucose levels and 24 hour blood glucose 
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profile in the physiological range. Furthermore, in an oral glucose tolerance study, the 
capsaicin-desensitised rats had lower fasting glucose levels but higher plasma insulin 
levels. Interestingly, such enhanced insulin secretion in capsaicin-treated rats was 
associated with reduced serum CGRP (Gram et al., 2007). Thus, they suggested that 
the loss of CGRP-containing sensory fibres could prevent the deterioration of glucose 
homeostasis, mainly by reducing CGRP-mediated inhibition of insulin secretion. These 
results are supported by this current study as they suggested that the presence of 
TRPV1 enhanced glucose levels, which implies that removing the TRPV1-CGRP 
pathway may be beneficial in term of glucose tolerance.  
 
We also investigated mRNA levels of oxidative stress markers (SOD, NOX2 and HO1) 
in the aorta. Significantly higher levels were found in HFD-WT extracts compared with 
HFD-TRPV1 KO mice in term of expression of SOD. Such an increase in SOD may be 
due to this anti-oxidant attempting to counteract oxidative stress which is known to 
increase blood pressure (Welch et al., 2006). 
 
Finally, I investigated the noradrenaline level within the kidney. We revealed that there 
was significantly higher level of noradrenaline in the HFD WT mice when compared to 
the WT normal diet mice. High levels of noradrenaline indicate high levels of 
sympathetic activity, which may contribute to the increased blood pressure in the WT 
mice. My results are partially supported by Moreira-Rodrigues et al. (2012) who 
demonstrated that mice fed with high fat high simple carbohydrate diet had insulin 
resistance and increased sympathetic tone with increased plasma noradrenaline levels 
(Moreira-Rodrigues et al., 2012).  Furthermore, recently Santoni et al. (2013) 
demonstrated a functional and structural cross-talk in cancer cells (PC3 cells) between 
α1d-adrenergic receptor and TRPV1 receptor via a functional assay with different 
antagonists and confocal microscopy (Santoni et al., abstract 2013). They 
demonstrated that noradrenaline stimulated proton release, calcium influx and cell 
proliferation in PC3 cells were completely reverted by the WS433 (α1d-adrenergic 
receptor antagonist) and capsazepine (TRPV1 antagonist) given combination. This 




In conclusion, these results lead to the proposal that TRPV1 deletion (and potentially 
blockade) is beneficial in obesity-induced hypertension and vascular hypertrophy. 
Although I originally hypothesised a protective role of TRPV1, this is not supported by 
my findings. The precise mechanisms of the pro-hypertensive mechanisms are 
unknown but may involve non-neuronal TRPV1 channels, endothelin-1 and 






























CHAPTER 6: GENERAL DISCUSSION   
 
6.1 Hypertension: the present situation  
Hypertension, as discussed in the introduction (chapter 1), remains a major public 
health problem and is a risk factor for many secondary cardiovascular diseases such as 
for atherosclerosis, one of the biggest killer in the western world (British Heart 
Foundation 2011). Therefore, it is important to understand the mechanisms 
underpinning the development of hypertension so that the underlying cause of the 
disease can be detected and treated more effectively than presently possible. Although 
there is no direct cause of essential hypertension, many factors lead to the increase in 
blood pressure. Obesity is one of the main factors where more than 85% of patients 
with hypertension also have body mass index greater than 25 (Aram et al., 2003). At 
present, several lines of evidence show that current blood pressure control methods 
are unsatisfactory in treated hypertensive patients. This is due to a variety of factors, for 
instance patients‘ poor compliance, insufficient use of combination drug treatment and 
real difficulties in achieving well controlled BP. Moreover, understanding the 
mechanisms involved in the development of hypertension is essential. Therefore, it is 
hoped that the investigation of mechanisms will allow a deeper insight and novel 
pharmacological approaches into the detection and treatment of hypertension. This 
thesis has hopefully provided more information into the development of hypertension 
and also suggested mechanisms by which we can protect against hypertension and 
vascular hypertrophy.  
 
6.2 Major novel findings from the studies in this thesis  
This thesis involved the study of vascular components of murine models of 
hypertension with two main topics. Firstly, the protective role of the CGRP-like peptide 
AM was investigated using smooth muscle selective RAMP2 (AM1 receptor component) 
up-regulated mice. Secondly, TRPV1 was studied, activation of which is known to 
release CGRP, using WT and TRPV1 KO mice.  
 
The data obtained in chapter 3 of this thesis has shown for the first time that RAMP2 
TG mice with up-regulation of the vascular smooth muscle RAMP2 levels, which 
correlates with raised levels of functional AM1 receptor, were protected against ATII 
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induced aortic vascular hypertrophy although the level of hypertension was similar to 
that in WT mice. The current study is novel also because in chapter 4 and 5 of this 
thesis I have demonstrated for the first time that the TRPV1 KO mice were protected 
against the hypertension and aortic vascular hypertrophy induced either by ATII or HFD 
feeding (which will be discussed in details in the later part of this discussion section). 
These findings provide evidence of new mechanisms involved in the pathophysiology of 
hypertension and of factors involving the CGRP like peptide AM and the sensory nerve 
receptor TRPV1 (that when activated releases CGRP).  
 
6.2.1 AM  
AM, a member of the CGRP family of peptides, is a vasodilator. This project provides 
an important insight in that the vascular smooth muscle AM1 receptor (CL/RAMP2) 
plays a key protective vascular role in vivo in the ATII-induced hypertension model. 
After infusion with ATII, the RAMP2 TG mice did not differ from WT mice in terms of the 
magnitude of the raised systemic blood pressure observed. However, the RAMP2 TG 
mice were protected against ATII–induced aortic vascular hypertrophy mainly via 
preventing smooth muscle cell proliferation. This finding was supported by the study of 
VSMCs in vitro. The cell proliferation study demonstrated that ATII significantly 
increased cell number in the WT VSMCs but not in RAMP2 TG cells, which provides 
evidence of an anti-proliferative function of AM by raising levels of functional AM1 
receptor. Moreover, the observed vascular hypertrophy in this part of the thesis was 
also accompanied by increased inflammatory markers (VCAM-1 and MCP-1). Overall 
this novel data provides evidence that up-regulation of RAMP2, and therefore raised 
levels of the AM1 receptor plays a novel protective role in ATII induced aortic vascular 
remodeling. 
 
6.2.2 Role of AM in hypertensive models induced by ATII 
The role of AM in ATII induced hypertensive models has been studied before using AM 
transgenic mice with lower endogenous AM levels (AM+/-) or with overexpressing AM 
level (Niu et al., 2003; Niu et al., 2004; Caron et al., 2007). Those studies illustrated 
that AM plays a protective role in ATII infusion induced diseases, such as 
cardiovascular hypertrophy, renal dysfunction, cardiac hypertrophy, and fibrosis without 
affecting the blood pressure. Here, in this thesis for the first time, by introducing smooth 
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muscle targeted RAMP2 overexpression we demonstrate the protective function of the 
AM1 receptor against aortic vascular hypertrophy and inflammation induced by ATII 
infusion. Thus, the current study has revealed the important role of the smooth muscle 
AM1 receptor, which may represent a useful new target for the treatment of 
cardiovascular diseases. 
  
6.2.3 Potential therapeutic role of AM 
AM is known as a vasodilator and plays a generally protective and beneficial role to the 
cells and tissues. Indeed, in in vitro experimental studies, AM suppressed the 
hypertrophy of cardiomyocytes and proliferation of fibroblasts (Tsurude et al., 1998; 
Tsurude et al., 1999). The current study demonstrated that AM inhibited VSMC 
proliferation in vitro induced by ATII mainly via upregulating RAMP2 and as a 
consequence raised functional AM1 receptor levels. In vivo experiments have also 
showed that the infusion of AM plays a protective role in left ventricular remodeling after 
ischemia (Nakamura et al., 2002; Okumura et al., 2003). These findings indicate that 
AM administration may benefit patients who have myocardial infarction. However, AM 
has a short half-life in the plasma that this limits the systemic infusion of AM as therapy. 
Therefore, the strategy of AM gene delivery hopefully will extend the beneficial actions 
of AM as discussed above using transgenic mice (Niu et al, 2003, 2004 and Caron et 
al., 2007). More studies are required in order to better utilise the protective role of AM 
for therapy.  
 
Although AM has an important therapeutic role, few studies have been able to 
associate with its RAMP receptor components in specific cell or tissue types. In this 
thesis, my data provided evidence that smooth muscle AM1 plays an important 
protective role against vascular hypertrophy caused during the development of 
hypertension, therefore providing evidence that the vascular AM1 receptor may be a 
potential and novel target for the treatment of vascular hypertrophy by tissue-specific 
targeting of the AM1 receptor via gene delivery or smooth muscle-specific means.  
 
6.2.4. CGRP in ATII-induced hypertension 
The role of CGRP (αCGRP), one of the CGRP family peptides like AM, in mediating the 
blood pressure under both normal physiological conditions and during the onset of 
189 
 
hypertension has been investigated extensively and is well documented (Smillie & 
Brain SD, 2011). In our group, the role of CGRP in the ATII-induced hypertension has 
been investigated (Smillie, 2012) using αCGRP KO mice. We, for the first time, 
demonstrated that αCGRP KO mice are more susceptible to the development and 
severity of hypertension induced by ATII infusion for 14 days. Such elevated increased 
blood pressure in the CGRP KO mice was also associated with an enhanced aortic 
inflammation and vascular remodeling. These results provide evidence for a protective 
role of αCGRP in the development of hypertension induced by ATII, which provides 
evidence for the potential development of new drugs for treatment of hypertension. 
 
6.2.5. The mechanisms of AM and CGRP in protecting against hypertension 
AM is 3-30 times less potent vasodilator than CGRP. The mechanisms involved in the 
vascular relaxation and anti-proliferation of AM against hypertension are different with 
regards to both species and vascular beds. Although they are not completely 
understood, it is suggested that it involves smooth muscle cell located CGRP receptors, 
in addition to AM receptors. As mentioned in the introduction (chapter 1), the CGRP 
receptor is composed of CL and RAMP1, while CL with RAMP2 produces the AM1 
receptor and CL with RAMP3 produce a CGRP/AM2 receptor. It was shown that AM 
can act via CGRP receptors located on vascular smooth muscle cells to cause 
vasodilatation. This would lead to increasing cAMP levels and activation of a protein 
kinase A-dependent pathway (Nakamura et al., 1995). Interestingly, this pathway is 
also thought to mediate AM1 receptor-mediated effects that lead to activation of the 
cAMP/protein kinase A–dependent pathway. Moreover, AM can also act via the 
phosphatidylinositol 3-kinase (PI3K)/Akt-NO synthase dependent pathway (Brain & 
Grant 2004, Ishimitsu et al., 2006). These AM responses could then be the 
mechanisms observed in my studies with vascular smooth muscle localised AM1 
receptors, rather than any effect of AM on CGRP receptors.  
 
CGRP is the most potent vasodilator to date (Smillie & Brain SD, 2011), with its 
vasodilator activity predominantly mediated by CGRP binding to its receptor on the 
membrane of both VSMCs and the endothelium of blood vessels. Such binding 
stimulates either endothelium dependent or independent mechanisms triggering a rise 
in cAMP thereby causing vasodilatation (Brain and Grant, 2004). It has been suggested 
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that CGRP suppresses the proliferation of VSMC together with an increase of the 
cAMP (Li et al., 1997). More recently CGRP has been shown to inhibit VSMC 
proliferation induced by ATII (Qin et al., 2004; Fang et al., 2011), which was believed to 
be blocking the MAPKs and NF-κB pathways. However the exact mechanism of CGRP 
regulating the proliferation of VSMCs remains unclear. Certainly from the studies 
carried out in this group with the ATII model, evidence was found for an effect of CGRP 
on blood pressure but not for AM acting via the AM1 receptor.  
 
Overall, there is similarity in the mechanisms of CGRP and AM induced relaxation and 
anti-proliferation. This may be because they all belong to CGRP family peptides and act 
via the same G protein-linked receptor (CL).  
 
6.2.6. Release of endogenous AM and CGRP  
AM is widely expressed in a range of organs and cell types (see the chapter 1 
introduction). The stimulation and release of AM has been examined in isolated and/or 
cultured endothelial cells, vascular smooth muscle cells and cardiomyocytes (Ishimitsu 
et al., 2006). AM production is up-regulated by several factors including oxidative stress, 
pro-inflammatory cytokines (such as IL-1 and TNFα), hypoxia, RAS and the 
sympathetic nervous systems (Beltowski and Jamroz 2004; Ishimitsu et al., 2006).  
However, there is not a clear single mechanism that primarily upregulates AM, all these 
factors are very general.  
 
CGRP is distributed widely throughout the central and peripheral nervous systems. In 
the periphery, it is primarily expressed within sensory neurons, specifically 
unmyelinated C-fibres and myelinated Aδ-fibres (Brain and Grant, 2004, Smillie & Brain  
SD, 2011). It is well charaterised that TRPV1 activation on sensory neurons leads to 
the downstream release of CGRP (Brain SD 1997).  
 
Therefore, it is difficult to selectively stimulate endogenous AM release in our models. 
However, activation of TRPV1 receptor provides the possibility of stimulation of the 
endogenous release of CGRP. It may be one of the reasons why there has been a 





Previous novel findings from first part of this thesis (protective role of AM1 receptor) 
and Smillie‘s PhD project (Smillie,  2012, protective role of αCGRP in ATII-induced 
hypertension) form my basis for the interest of the second part of my PhD – to 
investigate an endogenous mechanism via which either AM or CGRP may be released. 
An evaluation of these mechanisms lead me to consider that activation of TRPV1 may 
be the most direct mechanism to study, especially as WT and TRPV1 KO mice were 
available.  
 
6.3.1 TRPV1 activation and neuropeptides release 
As discussed in the general introduction (chapter 1), TRPV1 can be 
activated/sensitised by a number of different endogenous compounds, such as 
anandamide, protons (pH<6), nerve growth factor (NGF) tachykinins (Deng & Li 2005), 
lipoxygenase products also known as endovanilloids and other fatty acids (van der Stelt 
and Di Marzo, 2004). Activation of afferent neuronal TRPV1 causes the opening of the 
central pore which is permeable to the influx of extracellular cations and calcium. This 
results in the depolarization of the neuronal membrane and causes the subsequent 
release of sensory neuropeptides, including CGRP and substance P. As discussed 
previously, CGRP is a potent vasodilator and plays a protective role in several 
hypertension disease models (Smillie and Brain 2011). Therefore I believed that 
activation of TRPV1 leading to the release of CGRP would cause vasodilatation, and 
thus should protect in the hypertensive models.  
 
6.3.2 TRPV1 in hypertension 
The peripheral vascular system is widely innervated both by sympathetic and 
capsaicin-sensitive sensory nerves, which play an important role in mediating vascular 
tone via releasing vasoactive neurotransmitters. Among the vasodilators involved (e.g. 
nitric oxide and prostacyclin etc), CGRP released following TRPV1 activation may  
down-regulate the raised blood pressure in hypertensive models. Indeed it has been 
shown that rutaecarpine  (a well known Chinese herbal medicine Wu-Chu-Yu) was able 
to stimulate the release of CGRP by activation of TRPV1 to protect in phenol-induced 
or 2K1C hypertensive rats (Deng et al., 2004). Furthermore, in high salt diet fed rats, 
capsaicin induced a dose-dependent decrease in blood pressure (Wang and Wang 
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2006). The effect of capsaicin in this model has been supported by further studies 
which showed that i.v. infusion of capsazepine increases systolic blood pressure in 
those rats (Wang and Wang 2006). These observations suggest that in rats, TRPV1 
protects against the hypertension, probably through release of CGRP.  
 
The contribution of TRPV1 to the hypotensive effect in vivo is still equivocal especially 
as observed in studies using TRPV1 KO and WT mice. Hypotension was also observed 
with the administration of the proposed TRPV1 agonist anandamide, which were almost 
completely abolished in the presence of capsazepine (Wang et al., 2007). However 
Pacher et al. (2004) demonstrated that the predominant hypotensive effects of 
anandamide were similar in TRPV1 KO and TRPV1 WT mice, and were completely 
prevented by a CB1 receptor antagonist. These results suggest that the hypotensive 
effect of anandamide in vivo is regulated by the CB1 receptor but not by TRPV1. 
Moreover, in a separate study where TRPV1 KO and WT mice were made 
hypertensive with DOCA salt, no difference in blood pressure was seen between 
genotypes despite more extensive renal end organ damage in TRPV1 KO mice 
compared to WT counterparts (Wang et al., 2008b). Thus, the general hypothesis that 
TRPV1 activation results in the release of vasodilator CGRP and this is central in 
hypertension may be flawed, although this was my hypothesis for the studies designed 
to investigate models involving TRPV1 where endogenous CGRP may be involved.  
 
6.3.3 Role of TRPV1 in hypertensive models induced by ATII or HFD 
The investigation of the role of TRPV1 in hypertensive models induced by ATII or HFD 
in this thesis, using TRPV1 KO and WT mice, showed surprising and interesting results. 
My data showed that TRPV1 KO mice were partially protected against the hypertension 
and vascular hypertrophy induced by ATII. This ‗partial‘ effect may be due to the nature 
of the ATII model (extreme and aggressive). Data indicated up-regulation of kidney 
tissue levels of CGRP in the WT mice but we assume that it was not able to protect 
against such an aggressive increase in blood pressure in response to ATII.  
 
Therefore, we moved to a less extreme hypertensive model – obesity-induced 
hypertension.  Here we demonstrate that global knock out of TRPV1 indicated a 
beneficial phenotype against hypertension and vascular hypertrophy induced by HFD. 
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Such protection in the TRPV1 KO mice was accompanied by an observed protection in 
term of glucose tolerance.  
 
Overall the findings from this thesis were against my original hypothesis (TRPV1 
protects in hypertension) but provided evidence for a novel insight into the complex role 
of TRPV1. Further investigations are required in order to fully understand the 
mechanisms. However, these findings lead to a further insight as follows.   
 
6.3.4. Comparison of the finding with published literature. 
As previously mentioned, the results discussed in this thesis are novel. To our 
knowledge, no other group has yet published on the role of TRPV1 on ATII-induced or 
obesity-induced hypertension using TRPV1 KO mice. 
 
6.3.4.1. TRPV1 and ATII-induced hypertension 
It is well documented that because CGRP is a potent vasodilator, that activation of 
TRPV1 causes release of CGRP which should theoretically protect against the 
augmenting effects of the RAS system on blood pressure (Deng & Li et al, 2005, 
Szallasi et al., 2007). Indeed, a study had shown that rats with capsaicin-depleted 
sensory nerves exhibited a higher mean arterial pressure than control rats when ATII 
(0.216 mg/kg/day) was administered via chronic mini-pump infusion (Wu et al., 2000) 
for 14 days, which suggested a protective role of sensory nerves in attenuating the 
elevated blood pressure initiated by ATII. In our model, we observed that global TRPV1 
KO mice were protected against hypertension and vascular hypertrophy following ATII 
infusion for 14 days. We did observe an increase in kidney levels of CGRP in the WT 
mice after ATII infusion but apparently this was insufficient to mediate protection. 
Moreover, there is increasing evidence for the presence of non-neuronal TRPV1 and its 
constrictor properties. This may contribute to the increased blood pressure and 
compensate for CGRP-induced vasodilator activity in this model. However, the 
mechanism of how TRPV1 mediates the blood pressure in ATII model is still unclear. 






6.3.4.2 TRPV1 and obesity-induced hypertension 
Several studies have investigated the role of TRPV1 in obesity and/or diabetic 
conditions via long term treatment with capsaicin (Gram et al., 2007,Yang et al,., 2010), 
a TRPV1 antagonist (Tanaha et al., 2011) or TRPV1 KO mice (Motter et al., 2008, 
Yang et al,., 2010 Ma et al., 2011). However, we have data demonstrated novel data 
where TRPV1 deletion is associated with protection against obesity-induced 
hypertension and aortic vascular hypertrophy by HFD feeding. Our results on body 
weight gain agree with Motter et al. (2008) that both WT and TRPV1 KO mice had 
similar body weight gain after HFD feeding. Moreover, we showed that TRPV1 KO 
have improving glucose tolerance. This finding was supported by Gram et al.,(2007) 
and Tanaka et al., (2011) who applied capsaicin denervation in Zucker diabetic rat and 
TRPV1 antagonist in ob/ob diabetic mice respectively to show the anti-diabetic 
pharmacological effect of blocking TRPV1 signal. Yang et al (2010) showed that dietary 
capsaicin consumption can reduce blood pressure in normal conditions and such an 
effect was not seen in the TRPV1 deficient mice. However, it is noted that chronic 
dietary capsaicin will increase plasma levels of capsaicin and consequently result in 
strong agonism of all accessible nerve located TRPV1 receptors. There is also the 
complicating factor that chronic capsaicin pre-treatment can desensitise TRPV1 
receptors. Therefore, such an effect of reduced blood pressure may involve other 
neuronal TRPV1 co-located receptors such as arterial baroreceptors. Further studies 
are required to understand the multiple TRPV1 actions and their role in mediating blood 
pressure. Our study focused on the role of TRPV1 in obesity induced hypertension 
which is specific to the disorder of endocrinology system. Therefore it is very difficult to 
accurately compare results with Yang et al.,(2010).  
 
6.3.5. Possible mechanisms of TRPV1 in mediating increased blood pressure 
The findings from this thesis have led me to suggest possible mechanisms by which 
TRPV1 may be mediating increased blood pressure.  
 
The first possible mechanism could be via the non-neuronal TRPV1 pathway (Fig 6.1). 
There is increasing evidence showing the constriction function caused by non-neuronal 
TRPV1 (Keeble et al., 2006; Kark et al., 2008 and Czikora et al., 2012). As mentioned 
before, Keele et al. (2006) have demonstrated TRPV1-mediated vasoconstriction in the 
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WT mouse knee joint, but not in TRPV1 KOs. Moreover both Kark et al., (2008) and 
Czikora et al., (2012) demonstrated the exciting and constriction function of non-
neuronal TRPV1 using skeletal muscle with surgical sensory denervation on skeletal 
muscle arterioles obtained from WT or TRPV1 KO rats. Those studies support my 
findings that the observed increased blood pressure in the WT may be mediated by 
non-neuronal TRPV1. Therefore, the lost function of non-neuronal TRPV1 may be 
beneficial for the hypertension induced by HFD (please refer to the chapter 4 and 5 for 





Figure 6.1:  Proposed mechanism by which blood pressure is mediated via the non-neuronal 
TRPV1 pathway as compared with the neuronal pathway. 
 
The up-regulation of ET-1 mRNA levels in aorta suggest the second possible 
mechanism, which could be via the endothelin pathway (please refer to the discussion 
in chapter 5 for details). It was shown that endothelin potentiates TRPV1 via a protein 




























activation of TRPV1 by capsaicin caused increased blood pressure in anaesthetised 
mice following artery catheterization, which was abolished by antagonising the 
endothelin A receptor (Ohanyan et al., 2011). These findings were further supported 
when cultured endothelial cells exposed to capsaicin, it increased endothelin production, 
which was attenuated by inhibiting TRPV1 or endothelin-converting enzyme (Ohanyan 
et al., 2011). These findings support the proposal of the second possible mechanism 
that activation of TRPV1 may lead to release of endothelin from endothelial cells, which 




Figure 6.2:  Proposed mechanism by which blood pressure is mediated via the endothelin 
pathway. 
 
A third possible mechanism may involve the sympathetic system. Indeed in obese 
patients, total noradrenaline spillover is increased, which indicates elevated levels of 
sympathetic activity (Esler, 2011). Studies indicate that excess weight gain is 
associated with increased sympathetic nervous system activation (especially renal 
sympathetic activity) and that it contributes to the development of hypertension in 
obese humans and animal models of diet induced obesity (Davy et al., 2009, Hall et al., 
2000). Moreover Scott et al., (2000) demonstrated that blockage of the sympathetic 
nervous system with hexamethonium (ganglionic blocker) caused a significant 
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decrease in mean arterial pressure in obese zucker rats (Scott et al., 2000). This 
literature supports a proposed sympathetic pathway mechanism. My findings of low 
kidney noradrenaline levels in the TRPV1 KO mice indicate low renal sympathetic 
activities, which may help to prevent the increased blood pressure induced by obesity. 
 
In conclusion, obesity is the most common cause of human hypertension and it is a 
complex autoimmune mediated disease. Therefore the above suggested mechanisms 
may play a part but further investigations are required.  
 
6.3.6. Future work  
In order to better understand the exact mechanism behind the findings presented in this 
thesis, several experimental suggestions are now made. Firstly, as mRNA data 
indicates increased ET-1 levels in the aorta, investigation of protein expression of ET-1 
in the aorta and other organs like the kidney will provide more convincing evidence of 
its presence. The ETA antagonist can be applied to block the constrictive effect induced 
by ET-1, and to investigate whether ETA antagonist can reduce the evelated blood 
pressure and vascular inflammation induced by HFD feeding in the WT mice.  If ET-1 
does play a functional role in the hypertension induced by obesity, ETA antagonists 
should be able to prevent or attenuate the increased blood pressure in the WT mice 
with the HFD feeding. 
 
Secondly, it has been discussed before that the metabolic mechanisms are 
sympathetically driven. Therefore further investigation of the involvement of the 
sympathetic nervous system in the development of hypertension induced by HFD 
feeding is important. The activities of sympathetic nervous system can be investigated 
through study of noradrenaline levels in different organs such as heart and aorta. The 
involvement of the sympathetic nervous system can also be tested by applying blockers 
of the sympathetic nervous system to the WT mice to check whether the increased 
blood pressure in the WT can be prevented. If the sympathetic nervous system does 
contribute to the development of hypertension in the WT mice after HFD feeding, it 
indicates an important link between TRPV1 activities and sympathetic activaties. 
Therefore we may consider whether or not removing the TRPV1 activities can 
influence/control the activities of the sympathetic nervous system in metabolic 
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conditions, which may be novel and benefical for other metabolic-linked sympathetic 
drived diseases, such as renal failure in diabetic patients. 
 
 Thirdly and most importantly, it is important to test for involvement of non-neuronal 
TRPV1. I believe that the smooth muscle TRPV1 expression is likely to be responsible 
for the constriction, which contributes to the development of hypertension during the 
ATII infusion and HFD feeding. This hypothesis could be confirmed with conditional 
(tissue selective) TRPV1 KO mice. If the VSMC selective TRPV1 KO mice could be 
developed, then they can be characterised after HDF study. If my hypothesis is correct 
then those VSMC selected TRPV1 KO mice should show similar or maybe a better 
control of blood pressure when compared with the global TRPV1 KO mice. Moreover 
conditional TRPV1 antagonists which should exert the same effects as conditional 
TRPV1 KO mice, Potentially this may become a breakthrough in terms of the 
pharmacological prevention of obesity-induced metabolic syndrome with lower vascular 
inflammatory side effects than normally happens after a prolonged period of HFD 
feeding.  
 
6.3.7. Potential therapeutic role of TRPV1 
TRPV1 is an interesting therapeutic target due to its complex role in mediating diseases. 
There may be two directions for TRPV1 in drug development, namely TRPV1 agonists 
to activate and desensitise the channel, and inactivation using antagonists (Wong & 
Gavva 2009, Knotlkova et al., 2008). Agonists can block the whole nerve terminal, 
which may be more potent and beneficial for pain treatment (such as with capsaicin 
creams), while antagonists selectively block TRPV1 function. Indeed, choice of agonist 
or antagonist therapy may be disease dependent. Recently many TRPV1 antagoinsts 
are currently under investigation, especially for treatments for a range of painful 
conditions via blocking the TRPV1 activation. For example, A-995662, a potent and 
selective TRPV1 antagonist, shows its potential for treatment against osteoarthritic pain 
in rat by reduction of CGRP and glutamate production from spinal cord (Puttfarcken et 
al., 2010). In vivo experiements have demonstrated that JTS-653, a potent TRPV1 
antagonist, showed an antihyperalgesic effect but with transiently increased 
temperature in rat (Kitagawa et al., 2012). Indeed acute increase in body temperature 
(hyperthermia) had been known as adverse effects of TRPV1 antagonist (Gavva et al., 
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2007, Othman et al., 2011, Kitagawa et al., 2012). This suggests that TRPV1 plays an 
important role in the maintenance of body temperature. However some TRPV1 
antagonists did not show the hyperthermia effect in rats studies, such as AMG8562 
(Lehto et al., 2008) and AS1928370 (Watabiki et al., 2010). It suggests the possibility of 
selective TRPV1 antagonist may solve the hyperthermia problem. At the same time, the 
results presented within this thesis suggest that pharmacological down-regulation of 
non-neuronal TRPV1 receptor may be therapeutically useful. If my hypothesis is correct, 
antagonists to selectively block the TRPV1 receptor may be beneficial for controlling 
the increased blood pressure and vascular inflammation induced by obesity. Therefore 
the therapeutic potential of TRPV1 is high, but more investigations are needed to 
understand more about the role of TRPV1 in different conditions.  
 
6.4 Comparison with hypotheses  
As previously mentioned, my original hypothesis was that both AM1 (via smooth 
muscle cell selective up-regulation of RAMP2) and TRPV1 (via vasodilator action of 
released CGRP) would play protective roles in the ATII-induced hypertension model. 
Interestingly, I found that up-regulation of the AM1 receptor was able to protect mice 
from vascular hypertrophy but not hypertension induced by ATII. This finding is 
consistent with the current literature (see also the discussion in the chapter 3). However, 
TRPV1 was not able to protect in the ATII model with WT and TRPV1 KO mice. In 
contrast, deletion of TRPV1 revealed a beneficial effect. I also investigated the role of 
TRPV1 in a less extreme hypertension model (obesity-induced hypertension), where 
again TRPV1 KO mice but not the WT mice were protected against the hypertension 
and vascular hypertrophy induced by HFD. However, there are some indications in the 
literature that this may occur (see above), also that TRPV1 may have directly 
deleterious effects on blood pressure, independently of CGRP.   
 
6.5 Limitation of the study 
There are possible limitations of the studies in my thesis. My studies were based on 
using transgenic mice, either tissue selective upregulating RAMP2 or globally knocking 
out the TRPV1. Therefore if suitable agonists or antagonists could be also investigated 
to test the hypotheses, it will potentially help to draw the conclusion in this thesis. On 
another hand, there are some methodological limitations. Sample size was low in 
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certain analysis, such as the ELISA for CGRP. Therefore the increase of the sample 
size would have provided more convincing data.  
 
6.6 Conclusion 
In conclusion, this thesis provides interesting and novel findings about functional AM1 
and TRPV1 in hypertension models induced either by ATII or HFD. The findings reveal 
a protective role of functional smooth muscle AM1 receptor against the vascular 
inflammation and hypertrophy which occurs during the development of ATII induced 
hypertension. Moreover, the results of this thesis are novel in that they reveal a 
protective role of deletion of TRPV1 in the development of hypertension and vascular 
hypertrophy in ATII-induced hypertension or obesity-induced hypertension models, 
which is against my original hypothesis. Further experiments are required to elucidate 
the mechanisms behind each of these findings specifically as to why a potential 
protective effect of CGRP is not observed as a consequence of probable TRPV1 
activation. However, it is hoped that these findings have advanced our knowledge of 
both the AM1 receptor and TRPV1 receptor, and can be utilised in the development of 
fundamental knowledge with respect to mechanisms involved in hypertension and also 
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